date generated: 2021-04-20
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Here is the first few lines of the input profile.
## x
## A1BG -3.0045626
## A1BG-AS1 -0.6855588
## A1CF 0.3272035
## A2M 1.6308274
## A2M-AS1 1.0554888
## A2ML1 1.0055621
Here are some metrics about the input data profile:
| Profile metrics | |
|---|---|
| num_genesets | 2408 |
| num_genes_in_profile | 22124 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 8463 |
| num_profile_genes_not_in_sets | 13661 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt
| Gene sets metrics | |
|---|---|
| num_genesets | 2408 |
| num_genesets_excluded | 1041 |
| num_genesets_included | 1367 |
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
Top N= 100 gene sets
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| Peptide chain elongation | 88 | 6.36e-25 | -0.635 | 4.35e-22 |
| Eukaryotic Translation Elongation | 93 | 5.98e-26 | -0.631 | 8.18e-23 |
| Viral mRNA Translation | 88 | 1.04e-22 | -0.604 | 2.37e-20 |
| Eukaryotic Translation Termination | 92 | 5.46e-23 | -0.595 | 1.87e-20 |
| Selenocysteine synthesis | 92 | 8.98e-23 | -0.592 | 2.37e-20 |
| Formation of a pool of free 40S subunits | 100 | 1.32e-23 | -0.579 | 6.02e-21 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 94 | 1.41e-20 | -0.554 | 2.75e-18 |
| Incretin synthesis, secretion, and inactivation | 10 | 3.60e-03 | 0.532 | 4.06e-02 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 10 | 3.60e-03 | 0.532 | 4.06e-02 |
| NF-kB is activated and signals survival | 12 | 2.07e-03 | -0.513 | 2.81e-02 |
| WNT5A-dependent internalization of FZD4 | 13 | 1.53e-03 | -0.508 | 2.37e-02 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 110 | 5.78e-20 | -0.504 | 9.88e-18 |
| DNA methylation | 20 | 1.26e-04 | -0.495 | 2.88e-03 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 100 | 1.78e-17 | -0.492 | 2.02e-15 |
| VLDLR internalisation and degradation | 11 | 5.00e-03 | -0.489 | 5.10e-02 |
| tRNA processing in the mitochondrion | 32 | 1.71e-06 | -0.489 | 5.69e-05 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 111 | 6.92e-19 | -0.487 | 1.05e-16 |
| AKT phosphorylates targets in the nucleus | 10 | 8.21e-03 | -0.483 | 6.81e-02 |
| CDC6 association with the ORC:origin complex | 11 | 5.97e-03 | 0.479 | 5.62e-02 |
| Josephin domain DUBs | 10 | 8.89e-03 | -0.478 | 7.10e-02 |
| Cytosolic iron-sulfur cluster assembly | 13 | 3.62e-03 | -0.466 | 4.06e-02 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 114 | 4.58e-17 | -0.455 | 4.47e-15 |
| Nonsense-Mediated Decay (NMD) | 114 | 4.58e-17 | -0.455 | 4.47e-15 |
| Cap-dependent Translation Initiation | 118 | 1.45e-17 | -0.454 | 1.80e-15 |
| Eukaryotic Translation Initiation | 118 | 1.45e-17 | -0.454 | 1.80e-15 |
| Formation of the ternary complex, and subsequently, the 43S complex | 51 | 4.73e-08 | -0.442 | 2.31e-06 |
| GP1b-IX-V activation signalling | 10 | 1.56e-02 | -0.442 | 1.02e-01 |
| RNA Polymerase I Promoter Opening | 19 | 1.00e-03 | -0.436 | 1.67e-02 |
| Condensation of Prometaphase Chromosomes | 11 | 1.25e-02 | 0.435 | 8.83e-02 |
| Trafficking of GluR2-containing AMPA receptors | 12 | 9.31e-03 | -0.433 | 7.28e-02 |
| Regulation of FZD by ubiquitination | 16 | 2.72e-03 | -0.433 | 3.38e-02 |
| Presynaptic phase of homologous DNA pairing and strand exchange | 39 | 3.16e-06 | 0.431 | 9.81e-05 |
| SUMOylation of DNA methylation proteins | 16 | 3.05e-03 | -0.428 | 3.69e-02 |
| Selenoamino acid metabolism | 114 | 6.82e-15 | -0.422 | 6.22e-13 |
| Processing and activation of SUMO | 10 | 2.18e-02 | 0.419 | 1.32e-01 |
| SRP-dependent cotranslational protein targeting to membrane | 111 | 1.48e-13 | -0.406 | 1.13e-11 |
| Olfactory Signaling Pathway | 61 | 5.11e-08 | 0.403 | 2.41e-06 |
| Homologous DNA Pairing and Strand Exchange | 42 | 6.30e-06 | 0.403 | 1.91e-04 |
| FOXO-mediated transcription of cell death genes | 16 | 5.58e-03 | -0.400 | 5.34e-02 |
| A tetrasaccharide linker sequence is required for GAG synthesis | 18 | 3.39e-03 | -0.399 | 3.92e-02 |
| rRNA processing in the mitochondrion | 29 | 2.27e-04 | -0.395 | 4.68e-03 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 16 | 6.39e-03 | -0.394 | 5.83e-02 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 59 | 2.08e-07 | -0.391 | 8.61e-06 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 11 | 2.49e-02 | -0.391 | 1.47e-01 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 12 | 1.93e-02 | -0.390 | 1.21e-01 |
| Pexophagy | 11 | 2.51e-02 | -0.390 | 1.47e-01 |
| Translation initiation complex formation | 58 | 2.90e-07 | -0.389 | 1.17e-05 |
| Influenza Viral RNA Transcription and Replication | 135 | 9.54e-15 | -0.386 | 7.67e-13 |
| MET activates RAP1 and RAC1 | 10 | 3.51e-02 | 0.385 | 1.83e-01 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 26 | 7.29e-04 | 0.383 | 1.26e-02 |
| Signaling by Leptin | 10 | 3.70e-02 | -0.381 | 1.88e-01 |
| Ribosomal scanning and start codon recognition | 58 | 5.74e-07 | -0.379 | 2.12e-05 |
| Pausing and recovery of Tat-mediated HIV elongation | 30 | 3.24e-04 | -0.379 | 5.90e-03 |
| Tat-mediated HIV elongation arrest and recovery | 30 | 3.24e-04 | -0.379 | 5.90e-03 |
| HS-GAG degradation | 16 | 8.72e-03 | -0.379 | 7.10e-02 |
| Interleukin-2 signaling | 11 | 3.16e-02 | -0.374 | 1.73e-01 |
| p75NTR signals via NF-kB | 15 | 1.27e-02 | -0.372 | 8.87e-02 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 22 | 2.55e-03 | -0.372 | 3.29e-02 |
| Activation of Matrix Metalloproteinases | 24 | 1.64e-03 | -0.371 | 2.47e-02 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 12 | 2.71e-02 | -0.369 | 1.54e-01 |
| Diseases of hemostasis | 12 | 2.71e-02 | -0.369 | 1.54e-01 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 12 | 3.12e-02 | 0.359 | 1.72e-01 |
| Establishment of Sister Chromatid Cohesion | 11 | 3.99e-02 | 0.358 | 1.94e-01 |
| Pre-NOTCH Processing in Golgi | 18 | 9.04e-03 | -0.355 | 7.14e-02 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | 14 | 2.16e-02 | -0.355 | 1.31e-01 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | 14 | 2.16e-02 | -0.355 | 1.31e-01 |
| HDR through Single Strand Annealing (SSA) | 37 | 1.89e-04 | 0.355 | 4.03e-03 |
| p75NTR recruits signalling complexes | 12 | 3.54e-02 | -0.351 | 1.83e-01 |
| RMTs methylate histone arginines | 37 | 2.31e-04 | -0.350 | 4.68e-03 |
| Heparan sulfate/heparin (HS-GAG) metabolism | 38 | 2.32e-04 | -0.345 | 4.68e-03 |
| Regulation of IFNG signaling | 14 | 2.55e-02 | 0.345 | 1.47e-01 |
| Synthesis of PIPs at the late endosome membrane | 11 | 4.79e-02 | 0.344 | 2.19e-01 |
| Collagen chain trimerization | 27 | 1.98e-03 | -0.344 | 2.76e-02 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 22 | 5.33e-03 | -0.343 | 5.16e-02 |
| Plasma lipoprotein clearance | 29 | 1.47e-03 | -0.341 | 2.34e-02 |
| IRAK4 deficiency (TLR2/4) | 10 | 6.21e-02 | 0.341 | 2.56e-01 |
| MyD88 deficiency (TLR2/4) | 10 | 6.21e-02 | 0.341 | 2.56e-01 |
| Constitutive Signaling by AKT1 E17K in Cancer | 26 | 2.70e-03 | -0.340 | 3.38e-02 |
| Regulation of localization of FOXO transcription factors | 12 | 4.48e-02 | -0.335 | 2.10e-01 |
| Retrograde neurotrophin signalling | 12 | 4.65e-02 | -0.332 | 2.16e-01 |
| Lewis blood group biosynthesis | 13 | 3.89e-02 | -0.331 | 1.92e-01 |
| Cleavage of the damaged purine | 24 | 5.20e-03 | -0.329 | 5.12e-02 |
| Depurination | 24 | 5.20e-03 | -0.329 | 5.12e-02 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 24 | 5.20e-03 | -0.329 | 5.12e-02 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 23 | 6.29e-03 | -0.329 | 5.77e-02 |
| Biosynthesis of DHA-derived SPMs | 14 | 3.36e-02 | -0.328 | 1.79e-01 |
| Chondroitin sulfate/dermatan sulfate metabolism | 39 | 4.15e-04 | -0.327 | 7.37e-03 |
| Common Pathway of Fibrin Clot Formation | 14 | 3.59e-02 | -0.324 | 1.84e-01 |
| Packaging Of Telomere Ends | 20 | 1.22e-02 | -0.324 | 8.74e-02 |
| Downregulation of ERBB2:ERBB3 signaling | 12 | 5.33e-02 | -0.322 | 2.35e-01 |
| HIV elongation arrest and recovery | 32 | 1.64e-03 | -0.322 | 2.47e-02 |
| Pausing and recovery of HIV elongation | 32 | 1.64e-03 | -0.322 | 2.47e-02 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 20 | 1.33e-02 | -0.320 | 9.12e-02 |
| NGF-stimulated transcription | 33 | 1.49e-03 | -0.320 | 2.34e-02 |
| EGFR downregulation | 27 | 4.23e-03 | -0.318 | 4.63e-02 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 32 | 1.94e-03 | -0.317 | 2.73e-02 |
| Cyclin A/B1/B2 associated events during G2/M transition | 24 | 7.49e-03 | 0.315 | 6.40e-02 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 21 | 1.30e-02 | -0.313 | 8.95e-02 |
| Formation of ATP by chemiosmotic coupling | 18 | 2.16e-02 | -0.313 | 1.31e-01 |
| Influenza Infection | 154 | 2.27e-11 | -0.312 | 1.41e-09 |
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| Peptide chain elongation | 88 | 6.36e-25 | -0.635000 | 4.35e-22 |
| Eukaryotic Translation Elongation | 93 | 5.98e-26 | -0.631000 | 8.18e-23 |
| Viral mRNA Translation | 88 | 1.04e-22 | -0.604000 | 2.37e-20 |
| Eukaryotic Translation Termination | 92 | 5.46e-23 | -0.595000 | 1.87e-20 |
| Selenocysteine synthesis | 92 | 8.98e-23 | -0.592000 | 2.37e-20 |
| Formation of a pool of free 40S subunits | 100 | 1.32e-23 | -0.579000 | 6.02e-21 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 94 | 1.41e-20 | -0.554000 | 2.75e-18 |
| Incretin synthesis, secretion, and inactivation | 10 | 3.60e-03 | 0.532000 | 4.06e-02 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 10 | 3.60e-03 | 0.532000 | 4.06e-02 |
| NF-kB is activated and signals survival | 12 | 2.07e-03 | -0.513000 | 2.81e-02 |
| WNT5A-dependent internalization of FZD4 | 13 | 1.53e-03 | -0.508000 | 2.37e-02 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 110 | 5.78e-20 | -0.504000 | 9.88e-18 |
| DNA methylation | 20 | 1.26e-04 | -0.495000 | 2.88e-03 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 100 | 1.78e-17 | -0.492000 | 2.02e-15 |
| VLDLR internalisation and degradation | 11 | 5.00e-03 | -0.489000 | 5.10e-02 |
| tRNA processing in the mitochondrion | 32 | 1.71e-06 | -0.489000 | 5.69e-05 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 111 | 6.92e-19 | -0.487000 | 1.05e-16 |
| AKT phosphorylates targets in the nucleus | 10 | 8.21e-03 | -0.483000 | 6.81e-02 |
| CDC6 association with the ORC:origin complex | 11 | 5.97e-03 | 0.479000 | 5.62e-02 |
| Josephin domain DUBs | 10 | 8.89e-03 | -0.478000 | 7.10e-02 |
| Cytosolic iron-sulfur cluster assembly | 13 | 3.62e-03 | -0.466000 | 4.06e-02 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 114 | 4.58e-17 | -0.455000 | 4.47e-15 |
| Nonsense-Mediated Decay (NMD) | 114 | 4.58e-17 | -0.455000 | 4.47e-15 |
| Cap-dependent Translation Initiation | 118 | 1.45e-17 | -0.454000 | 1.80e-15 |
| Eukaryotic Translation Initiation | 118 | 1.45e-17 | -0.454000 | 1.80e-15 |
| Formation of the ternary complex, and subsequently, the 43S complex | 51 | 4.73e-08 | -0.442000 | 2.31e-06 |
| GP1b-IX-V activation signalling | 10 | 1.56e-02 | -0.442000 | 1.02e-01 |
| RNA Polymerase I Promoter Opening | 19 | 1.00e-03 | -0.436000 | 1.67e-02 |
| Condensation of Prometaphase Chromosomes | 11 | 1.25e-02 | 0.435000 | 8.83e-02 |
| Trafficking of GluR2-containing AMPA receptors | 12 | 9.31e-03 | -0.433000 | 7.28e-02 |
| Regulation of FZD by ubiquitination | 16 | 2.72e-03 | -0.433000 | 3.38e-02 |
| Presynaptic phase of homologous DNA pairing and strand exchange | 39 | 3.16e-06 | 0.431000 | 9.81e-05 |
| SUMOylation of DNA methylation proteins | 16 | 3.05e-03 | -0.428000 | 3.69e-02 |
| Selenoamino acid metabolism | 114 | 6.82e-15 | -0.422000 | 6.22e-13 |
| Processing and activation of SUMO | 10 | 2.18e-02 | 0.419000 | 1.32e-01 |
| SRP-dependent cotranslational protein targeting to membrane | 111 | 1.48e-13 | -0.406000 | 1.13e-11 |
| Olfactory Signaling Pathway | 61 | 5.11e-08 | 0.403000 | 2.41e-06 |
| Homologous DNA Pairing and Strand Exchange | 42 | 6.30e-06 | 0.403000 | 1.91e-04 |
| FOXO-mediated transcription of cell death genes | 16 | 5.58e-03 | -0.400000 | 5.34e-02 |
| A tetrasaccharide linker sequence is required for GAG synthesis | 18 | 3.39e-03 | -0.399000 | 3.92e-02 |
| rRNA processing in the mitochondrion | 29 | 2.27e-04 | -0.395000 | 4.68e-03 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 16 | 6.39e-03 | -0.394000 | 5.83e-02 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 59 | 2.08e-07 | -0.391000 | 8.61e-06 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 11 | 2.49e-02 | -0.391000 | 1.47e-01 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 12 | 1.93e-02 | -0.390000 | 1.21e-01 |
| Pexophagy | 11 | 2.51e-02 | -0.390000 | 1.47e-01 |
| Translation initiation complex formation | 58 | 2.90e-07 | -0.389000 | 1.17e-05 |
| Influenza Viral RNA Transcription and Replication | 135 | 9.54e-15 | -0.386000 | 7.67e-13 |
| MET activates RAP1 and RAC1 | 10 | 3.51e-02 | 0.385000 | 1.83e-01 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 26 | 7.29e-04 | 0.383000 | 1.26e-02 |
| Signaling by Leptin | 10 | 3.70e-02 | -0.381000 | 1.88e-01 |
| Ribosomal scanning and start codon recognition | 58 | 5.74e-07 | -0.379000 | 2.12e-05 |
| Pausing and recovery of Tat-mediated HIV elongation | 30 | 3.24e-04 | -0.379000 | 5.90e-03 |
| Tat-mediated HIV elongation arrest and recovery | 30 | 3.24e-04 | -0.379000 | 5.90e-03 |
| HS-GAG degradation | 16 | 8.72e-03 | -0.379000 | 7.10e-02 |
| Interleukin-2 signaling | 11 | 3.16e-02 | -0.374000 | 1.73e-01 |
| p75NTR signals via NF-kB | 15 | 1.27e-02 | -0.372000 | 8.87e-02 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 22 | 2.55e-03 | -0.372000 | 3.29e-02 |
| Activation of Matrix Metalloproteinases | 24 | 1.64e-03 | -0.371000 | 2.47e-02 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 12 | 2.71e-02 | -0.369000 | 1.54e-01 |
| Diseases of hemostasis | 12 | 2.71e-02 | -0.369000 | 1.54e-01 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 12 | 3.12e-02 | 0.359000 | 1.72e-01 |
| Establishment of Sister Chromatid Cohesion | 11 | 3.99e-02 | 0.358000 | 1.94e-01 |
| Pre-NOTCH Processing in Golgi | 18 | 9.04e-03 | -0.355000 | 7.14e-02 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | 14 | 2.16e-02 | -0.355000 | 1.31e-01 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | 14 | 2.16e-02 | -0.355000 | 1.31e-01 |
| HDR through Single Strand Annealing (SSA) | 37 | 1.89e-04 | 0.355000 | 4.03e-03 |
| p75NTR recruits signalling complexes | 12 | 3.54e-02 | -0.351000 | 1.83e-01 |
| RMTs methylate histone arginines | 37 | 2.31e-04 | -0.350000 | 4.68e-03 |
| Heparan sulfate/heparin (HS-GAG) metabolism | 38 | 2.32e-04 | -0.345000 | 4.68e-03 |
| Regulation of IFNG signaling | 14 | 2.55e-02 | 0.345000 | 1.47e-01 |
| Synthesis of PIPs at the late endosome membrane | 11 | 4.79e-02 | 0.344000 | 2.19e-01 |
| Collagen chain trimerization | 27 | 1.98e-03 | -0.344000 | 2.76e-02 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 22 | 5.33e-03 | -0.343000 | 5.16e-02 |
| Plasma lipoprotein clearance | 29 | 1.47e-03 | -0.341000 | 2.34e-02 |
| IRAK4 deficiency (TLR2/4) | 10 | 6.21e-02 | 0.341000 | 2.56e-01 |
| MyD88 deficiency (TLR2/4) | 10 | 6.21e-02 | 0.341000 | 2.56e-01 |
| Constitutive Signaling by AKT1 E17K in Cancer | 26 | 2.70e-03 | -0.340000 | 3.38e-02 |
| Regulation of localization of FOXO transcription factors | 12 | 4.48e-02 | -0.335000 | 2.10e-01 |
| Retrograde neurotrophin signalling | 12 | 4.65e-02 | -0.332000 | 2.16e-01 |
| Lewis blood group biosynthesis | 13 | 3.89e-02 | -0.331000 | 1.92e-01 |
| Cleavage of the damaged purine | 24 | 5.20e-03 | -0.329000 | 5.12e-02 |
| Depurination | 24 | 5.20e-03 | -0.329000 | 5.12e-02 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 24 | 5.20e-03 | -0.329000 | 5.12e-02 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 23 | 6.29e-03 | -0.329000 | 5.77e-02 |
| Biosynthesis of DHA-derived SPMs | 14 | 3.36e-02 | -0.328000 | 1.79e-01 |
| Chondroitin sulfate/dermatan sulfate metabolism | 39 | 4.15e-04 | -0.327000 | 7.37e-03 |
| Common Pathway of Fibrin Clot Formation | 14 | 3.59e-02 | -0.324000 | 1.84e-01 |
| Packaging Of Telomere Ends | 20 | 1.22e-02 | -0.324000 | 8.74e-02 |
| Downregulation of ERBB2:ERBB3 signaling | 12 | 5.33e-02 | -0.322000 | 2.35e-01 |
| HIV elongation arrest and recovery | 32 | 1.64e-03 | -0.322000 | 2.47e-02 |
| Pausing and recovery of HIV elongation | 32 | 1.64e-03 | -0.322000 | 2.47e-02 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 20 | 1.33e-02 | -0.320000 | 9.12e-02 |
| NGF-stimulated transcription | 33 | 1.49e-03 | -0.320000 | 2.34e-02 |
| EGFR downregulation | 27 | 4.23e-03 | -0.318000 | 4.63e-02 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 32 | 1.94e-03 | -0.317000 | 2.73e-02 |
| Cyclin A/B1/B2 associated events during G2/M transition | 24 | 7.49e-03 | 0.315000 | 6.40e-02 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 21 | 1.30e-02 | -0.313000 | 8.95e-02 |
| Formation of ATP by chemiosmotic coupling | 18 | 2.16e-02 | -0.313000 | 1.31e-01 |
| Influenza Infection | 154 | 2.27e-11 | -0.312000 | 1.41e-09 |
| E2F mediated regulation of DNA replication | 22 | 1.13e-02 | 0.312000 | 8.29e-02 |
| Regulation of expression of SLITs and ROBOs | 162 | 7.62e-12 | -0.312000 | 5.21e-10 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 9.92e-03 | -0.311000 | 7.59e-02 |
| Collagen biosynthesis and modifying enzymes | 46 | 2.92e-04 | -0.309000 | 5.46e-03 |
| Regulation of TP53 Activity through Association with Co-factors | 12 | 6.47e-02 | -0.308000 | 2.64e-01 |
| Glycogen storage diseases | 13 | 5.47e-02 | -0.308000 | 2.36e-01 |
| ATF6 (ATF6-alpha) activates chaperone genes | 10 | 9.26e-02 | 0.307000 | 3.33e-01 |
| Activated NOTCH1 Transmits Signal to the Nucleus | 27 | 6.01e-03 | -0.305000 | 5.62e-02 |
| Diseases of carbohydrate metabolism | 29 | 4.52e-03 | -0.305000 | 4.83e-02 |
| rRNA processing | 219 | 8.59e-15 | -0.304000 | 7.34e-13 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | 11 | 8.43e-02 | 0.301000 | 3.16e-01 |
| Glycogen synthesis | 13 | 6.35e-02 | -0.297000 | 2.60e-01 |
| N-Glycan antennae elongation | 13 | 6.35e-02 | -0.297000 | 2.60e-01 |
| PKA activation in glucagon signalling | 14 | 5.46e-02 | -0.297000 | 2.36e-01 |
| Synthesis of IP3 and IP4 in the cytosol | 22 | 1.60e-02 | -0.297000 | 1.05e-01 |
| Repression of WNT target genes | 14 | 5.51e-02 | -0.296000 | 2.36e-01 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | 29 | 6.06e-03 | -0.294000 | 5.64e-02 |
| Collagen formation | 64 | 4.87e-05 | -0.294000 | 1.26e-03 |
| GAB1 signalosome | 15 | 4.91e-02 | -0.293000 | 2.22e-01 |
| Nuclear Receptor transcription pathway | 41 | 1.19e-03 | -0.293000 | 1.94e-02 |
| Chondroitin sulfate biosynthesis | 13 | 6.81e-02 | -0.292000 | 2.74e-01 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 27 | 9.16e-03 | -0.290000 | 7.20e-02 |
| rRNA processing in the nucleus and cytosol | 190 | 6.12e-12 | -0.289000 | 4.40e-10 |
| CD28 dependent PI3K/Akt signaling | 22 | 1.89e-02 | -0.289000 | 1.20e-01 |
| Inhibition of DNA recombination at telomere | 35 | 3.14e-03 | -0.288000 | 3.71e-02 |
| PKA activation | 15 | 5.36e-02 | -0.288000 | 2.35e-01 |
| Major pathway of rRNA processing in the nucleolus and cytosol | 180 | 2.80e-11 | -0.287000 | 1.67e-09 |
| Antiviral mechanism by IFN-stimulated genes | 80 | 9.57e-06 | 0.286000 | 2.78e-04 |
| Defective B3GAT3 causes JDSSDHD | 12 | 8.64e-02 | -0.286000 | 3.21e-01 |
| Formation of Fibrin Clot (Clotting Cascade) | 26 | 1.20e-02 | -0.284000 | 8.67e-02 |
| EPH-ephrin mediated repulsion of cells | 40 | 2.04e-03 | -0.282000 | 2.81e-02 |
| Interferon alpha/beta signaling | 57 | 2.33e-04 | 0.282000 | 4.68e-03 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | 12 | 9.41e-02 | -0.279000 | 3.33e-01 |
| NS1 Mediated Effects on Host Pathways | 40 | 2.37e-03 | 0.278000 | 3.12e-02 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | 32 | 6.63e-03 | 0.277000 | 5.92e-02 |
| Spry regulation of FGF signaling | 16 | 5.56e-02 | -0.276000 | 2.38e-01 |
| Effects of PIP2 hydrolysis | 24 | 1.92e-02 | -0.276000 | 1.20e-01 |
| Defective B4GALT7 causes EDS, progeroid type | 12 | 1.01e-01 | -0.274000 | 3.43e-01 |
| Base-Excision Repair, AP Site Formation | 31 | 8.35e-03 | -0.274000 | 6.88e-02 |
| Regulation of TP53 Activity through Acetylation | 29 | 1.09e-02 | -0.273000 | 8.09e-02 |
| Regulation of TLR by endogenous ligand | 11 | 1.22e-01 | 0.269000 | 3.75e-01 |
| Negative regulation of FGFR4 signaling | 21 | 3.27e-02 | -0.269000 | 1.78e-01 |
| HSF1-dependent transactivation | 29 | 1.24e-02 | -0.268000 | 8.82e-02 |
| Collagen degradation | 29 | 1.24e-02 | -0.268000 | 8.82e-02 |
| Assembly of collagen fibrils and other multimeric structures | 42 | 2.66e-03 | -0.268000 | 3.38e-02 |
| Cytochrome c-mediated apoptotic response | 13 | 9.45e-02 | 0.268000 | 3.33e-01 |
| Downregulation of ERBB2 signaling | 24 | 2.38e-02 | -0.267000 | 1.43e-01 |
| Signaling by PDGFRA extracellular domain mutants | 12 | 1.13e-01 | 0.264000 | 3.62e-01 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 1.13e-01 | 0.264000 | 3.62e-01 |
| Biosynthesis of specialized proresolving mediators (SPMs) | 16 | 6.83e-02 | -0.263000 | 2.74e-01 |
| Formation of the beta-catenin:TCF transactivating complex | 46 | 2.09e-03 | -0.262000 | 2.81e-02 |
| Mucopolysaccharidoses | 11 | 1.34e-01 | -0.261000 | 3.91e-01 |
| Other semaphorin interactions | 16 | 7.10e-02 | -0.261000 | 2.81e-01 |
| Hyaluronan metabolism | 13 | 1.05e-01 | -0.260000 | 3.51e-01 |
| Gap junction trafficking | 14 | 9.23e-02 | -0.260000 | 3.33e-01 |
| Signal regulatory protein family interactions | 12 | 1.20e-01 | -0.259000 | 3.72e-01 |
| Acetylcholine Neurotransmitter Release Cycle | 11 | 1.36e-01 | -0.259000 | 3.92e-01 |
| NRIF signals cell death from the nucleus | 15 | 8.41e-02 | -0.258000 | 3.16e-01 |
| Elevation of cytosolic Ca2+ levels | 13 | 1.09e-01 | -0.257000 | 3.57e-01 |
| Deadenylation of mRNA | 22 | 3.81e-02 | 0.255000 | 1.89e-01 |
| Transport of the SLBP Dependant Mature mRNA | 36 | 8.17e-03 | 0.255000 | 6.81e-02 |
| Signaling by ROBO receptors | 202 | 4.30e-10 | -0.255000 | 2.26e-08 |
| Activation of ATR in response to replication stress | 36 | 8.52e-03 | 0.253000 | 6.98e-02 |
| The role of Nef in HIV-1 replication and disease pathogenesis | 28 | 2.06e-02 | -0.253000 | 1.27e-01 |
| Degradation of cysteine and homocysteine | 13 | 1.15e-01 | -0.252000 | 3.65e-01 |
| IRAK2 mediated activation of TAK1 complex | 10 | 1.68e-01 | -0.252000 | 4.46e-01 |
| Senescence-Associated Secretory Phenotype (SASP) | 66 | 4.07e-04 | -0.252000 | 7.32e-03 |
| Signaling by NODAL | 13 | 1.17e-01 | -0.251000 | 3.68e-01 |
| Resolution of D-Loop Structures | 33 | 1.29e-02 | 0.250000 | 8.95e-02 |
| ISG15 antiviral mechanism | 72 | 2.56e-04 | 0.249000 | 5.00e-03 |
| Resolution of Sister Chromatid Cohesion | 104 | 1.13e-05 | 0.249000 | 3.09e-04 |
| Signaling by NOTCH3 | 43 | 5.11e-03 | -0.247000 | 5.12e-02 |
| AKT phosphorylates targets in the cytosol | 14 | 1.11e-01 | -0.246000 | 3.59e-01 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 22 | 4.58e-02 | -0.246000 | 2.14e-01 |
| Transport of the SLBP independent Mature mRNA | 35 | 1.27e-02 | 0.243000 | 8.87e-02 |
| Response of EIF2AK1 (HRI) to heme deficiency | 14 | 1.15e-01 | 0.243000 | 3.65e-01 |
| NEP/NS2 Interacts with the Cellular Export Machinery | 32 | 1.79e-02 | 0.242000 | 1.15e-01 |
| Assembly Of The HIV Virion | 15 | 1.05e-01 | -0.242000 | 3.51e-01 |
| TRAF6 mediated IRF7 activation | 15 | 1.06e-01 | 0.241000 | 3.51e-01 |
| Negative regulation of FGFR3 signaling | 20 | 6.18e-02 | -0.241000 | 2.56e-01 |
| Neurexins and neuroligins | 38 | 1.04e-02 | -0.240000 | 7.79e-02 |
| Gluconeogenesis | 28 | 2.80e-02 | -0.240000 | 1.58e-01 |
| Cleavage of the damaged pyrimidine | 29 | 2.54e-02 | -0.240000 | 1.47e-01 |
| Depyrimidination | 29 | 2.54e-02 | -0.240000 | 1.47e-01 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 29 | 2.54e-02 | -0.240000 | 1.47e-01 |
| Glycogen metabolism | 23 | 4.69e-02 | -0.239000 | 2.16e-01 |
| Amyloid fiber formation | 51 | 3.17e-03 | -0.239000 | 3.71e-02 |
| Transport of Ribonucleoproteins into the Host Nucleus | 32 | 1.95e-02 | 0.238000 | 1.21e-01 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 53 | 2.68e-03 | -0.238000 | 3.38e-02 |
| Notch-HLH transcription pathway | 28 | 2.91e-02 | -0.238000 | 1.63e-01 |
| HDACs deacetylate histones | 47 | 5.00e-03 | -0.237000 | 5.10e-02 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 43 | 7.38e-03 | 0.236000 | 6.35e-02 |
| Pre-NOTCH Transcription and Translation | 49 | 4.34e-03 | -0.236000 | 4.71e-02 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 1.58e-01 | 0.235000 | 4.32e-01 |
| Platelet Aggregation (Plug Formation) | 28 | 3.28e-02 | -0.233000 | 1.78e-01 |
| TBC/RABGAPs | 45 | 6.96e-03 | -0.232000 | 6.10e-02 |
| Plasma lipoprotein assembly, remodeling, and clearance | 54 | 3.17e-03 | -0.232000 | 3.71e-02 |
| Glycosaminoglycan metabolism | 93 | 1.14e-04 | -0.232000 | 2.68e-03 |
| Translation of structural proteins | 28 | 3.47e-02 | -0.231000 | 1.82e-01 |
| Interleukin-7 signaling | 21 | 6.76e-02 | -0.230000 | 2.74e-01 |
| Nuclear Events (kinase and transcription factor activation) | 55 | 3.17e-03 | -0.230000 | 3.71e-02 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 91 | 1.50e-04 | 0.230000 | 3.30e-03 |
| Amplification of signal from the kinetochores | 91 | 1.50e-04 | 0.230000 | 3.30e-03 |
| MicroRNA (miRNA) biogenesis | 24 | 5.30e-02 | -0.228000 | 2.35e-01 |
| SUMOylation of ubiquitinylation proteins | 39 | 1.38e-02 | 0.228000 | 9.38e-02 |
| Transport of Mature mRNA Derived from an Intronless Transcript | 42 | 1.12e-02 | 0.226000 | 8.28e-02 |
| HS-GAG biosynthesis | 20 | 8.02e-02 | -0.226000 | 3.06e-01 |
| Pre-NOTCH Expression and Processing | 65 | 1.70e-03 | -0.225000 | 2.50e-02 |
| Cristae formation | 31 | 3.02e-02 | -0.225000 | 1.68e-01 |
| Basigin interactions | 23 | 6.24e-02 | -0.224000 | 2.57e-01 |
| Laminin interactions | 21 | 7.51e-02 | -0.224000 | 2.91e-01 |
| Gap junction trafficking and regulation | 16 | 1.21e-01 | -0.224000 | 3.74e-01 |
| HDR through MMEJ (alt-NHEJ) | 10 | 2.20e-01 | 0.224000 | 5.11e-01 |
| Termination of O-glycan biosynthesis | 16 | 1.23e-01 | -0.223000 | 3.76e-01 |
| Interferon Signaling | 177 | 3.30e-07 | 0.222000 | 1.29e-05 |
| NR1H2 and NR1H3-mediated signaling | 40 | 1.49e-02 | -0.222000 | 1.00e-01 |
| Mitotic Spindle Checkpoint | 108 | 6.77e-05 | 0.222000 | 1.65e-03 |
| Cohesin Loading onto Chromatin | 10 | 2.26e-01 | 0.221000 | 5.18e-01 |
| Processing of Intronless Pre-mRNAs | 19 | 9.60e-02 | 0.221000 | 3.34e-01 |
| Nuclear signaling by ERBB4 | 24 | 6.19e-02 | -0.220000 | 2.56e-01 |
| Norepinephrine Neurotransmitter Release Cycle | 13 | 1.71e-01 | -0.219000 | 4.50e-01 |
| Hyaluronan uptake and degradation | 10 | 2.30e-01 | -0.219000 | 5.24e-01 |
| Signaling by PDGFR in disease | 19 | 9.90e-02 | 0.219000 | 3.40e-01 |
| MASTL Facilitates Mitotic Progression | 10 | 2.32e-01 | 0.218000 | 5.27e-01 |
| Regulation of TP53 Activity through Methylation | 19 | 1.01e-01 | -0.217000 | 3.43e-01 |
| PKA-mediated phosphorylation of CREB | 17 | 1.21e-01 | -0.217000 | 3.74e-01 |
| Signaling by NOTCH2 | 30 | 3.97e-02 | -0.217000 | 1.94e-01 |
| Pyrimidine salvage | 10 | 2.35e-01 | -0.217000 | 5.28e-01 |
| Cell-extracellular matrix interactions | 14 | 1.61e-01 | -0.216000 | 4.37e-01 |
| EML4 and NUDC in mitotic spindle formation | 95 | 2.77e-04 | 0.216000 | 5.30e-03 |
| CaM pathway | 27 | 5.36e-02 | -0.215000 | 2.35e-01 |
| Calmodulin induced events | 27 | 5.36e-02 | -0.215000 | 2.35e-01 |
| Assembly of active LPL and LIPC lipase complexes | 11 | 2.19e-01 | -0.214000 | 5.10e-01 |
| Activation of HOX genes during differentiation | 71 | 1.82e-03 | -0.214000 | 2.61e-02 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | 71 | 1.82e-03 | -0.214000 | 2.61e-02 |
| Gamma carboxylation, hypusine formation and arylsulfatase activation | 34 | 3.08e-02 | -0.214000 | 1.71e-01 |
| Metabolism of fat-soluble vitamins | 28 | 5.07e-02 | -0.213000 | 2.27e-01 |
| NOTCH4 Intracellular Domain Regulates Transcription | 18 | 1.18e-01 | -0.213000 | 3.69e-01 |
| Activation of RAC1 | 11 | 2.21e-01 | 0.213000 | 5.13e-01 |
| Insulin processing | 20 | 9.95e-02 | 0.213000 | 3.41e-01 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 31 | 4.06e-02 | 0.213000 | 1.95e-01 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | 31 | 4.06e-02 | 0.213000 | 1.95e-01 |
| Nuclear Pore Complex (NPC) Disassembly | 36 | 2.76e-02 | 0.212000 | 1.56e-01 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 10 | 2.45e-01 | -0.212000 | 5.35e-01 |
| Defective EXT2 causes exostoses 2 | 10 | 2.45e-01 | -0.212000 | 5.35e-01 |
| Response of Mtb to phagocytosis | 22 | 8.68e-02 | -0.211000 | 3.21e-01 |
| Retinoid metabolism and transport | 24 | 7.37e-02 | -0.211000 | 2.88e-01 |
| Export of Viral Ribonucleoproteins from Nucleus | 33 | 3.60e-02 | 0.211000 | 1.84e-01 |
| N-glycan antennae elongation in the medial/trans-Golgi | 21 | 9.46e-02 | -0.211000 | 3.33e-01 |
| Signaling by EGFR | 46 | 1.39e-02 | -0.210000 | 9.38e-02 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | 15 | 1.60e-01 | -0.210000 | 4.34e-01 |
| NRAGE signals death through JNK | 52 | 9.45e-03 | -0.208000 | 7.30e-02 |
| PRC2 methylates histones and DNA | 29 | 5.30e-02 | -0.208000 | 2.35e-01 |
| SUMOylation of DNA replication proteins | 46 | 1.51e-02 | 0.207000 | 1.00e-01 |
| RHO GTPases Activate NADPH Oxidases | 21 | 1.02e-01 | -0.206000 | 3.44e-01 |
| Disorders of Developmental Biology | 12 | 2.18e-01 | -0.206000 | 5.08e-01 |
| Disorders of Nervous System Development | 12 | 2.18e-01 | -0.206000 | 5.08e-01 |
| Loss of function of MECP2 in Rett syndrome | 12 | 2.18e-01 | -0.206000 | 5.08e-01 |
| Pervasive developmental disorders | 12 | 2.18e-01 | -0.206000 | 5.08e-01 |
| Negative regulation of FGFR1 signaling | 24 | 8.17e-02 | -0.205000 | 3.09e-01 |
| Plasma lipoprotein assembly | 11 | 2.40e-01 | -0.205000 | 5.33e-01 |
| Metabolism of non-coding RNA | 53 | 1.01e-02 | 0.204000 | 7.64e-02 |
| snRNP Assembly | 53 | 1.01e-02 | 0.204000 | 7.64e-02 |
| Adenylate cyclase inhibitory pathway | 11 | 2.41e-01 | -0.204000 | 5.35e-01 |
| Acyl chain remodelling of PG | 11 | 2.41e-01 | 0.204000 | 5.35e-01 |
| SUMOylation of immune response proteins | 11 | 2.42e-01 | -0.204000 | 5.35e-01 |
| Extracellular matrix organization | 220 | 1.90e-07 | -0.204000 | 8.10e-06 |
| Pentose phosphate pathway | 13 | 2.04e-01 | -0.204000 | 4.93e-01 |
| G2/M DNA damage checkpoint | 67 | 4.09e-03 | 0.203000 | 4.51e-02 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 14 | 1.89e-01 | -0.203000 | 4.79e-01 |
| Metabolism of Angiotensinogen to Angiotensins | 11 | 2.46e-01 | -0.202000 | 5.35e-01 |
| Antimicrobial peptides | 34 | 4.20e-02 | -0.201000 | 2.00e-01 |
| Uptake and function of anthrax toxins | 10 | 2.72e-01 | -0.201000 | 5.67e-01 |
| CRMPs in Sema3A signaling | 14 | 1.94e-01 | -0.200000 | 4.84e-01 |
| Cytosolic tRNA aminoacylation | 24 | 9.08e-02 | 0.199000 | 3.31e-01 |
| Purine catabolism | 16 | 1.67e-01 | -0.199000 | 4.46e-01 |
| DAG and IP3 signaling | 33 | 4.75e-02 | -0.199000 | 2.18e-01 |
| Nef mediated downregulation of MHC class I complex cell surface expression | 10 | 2.75e-01 | -0.199000 | 5.70e-01 |
| HDR through Homologous Recombination (HRR) | 66 | 5.12e-03 | 0.199000 | 5.12e-02 |
| Phosphorylation of the APC/C | 20 | 1.24e-01 | 0.199000 | 3.78e-01 |
| Attenuation phase | 23 | 9.97e-02 | -0.198000 | 3.41e-01 |
| Other interleukin signaling | 18 | 1.46e-01 | -0.198000 | 4.08e-01 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 2.35e-01 | 0.198000 | 5.28e-01 |
| alpha-linolenic acid (ALA) metabolism | 12 | 2.35e-01 | 0.198000 | 5.28e-01 |
| PI3K/AKT Signaling in Cancer | 81 | 2.10e-03 | -0.198000 | 2.81e-02 |
| LDL clearance | 17 | 1.58e-01 | -0.198000 | 4.32e-01 |
| Complex I biogenesis | 55 | 1.14e-02 | -0.197000 | 8.33e-02 |
| Regulation of PTEN gene transcription | 59 | 8.92e-03 | -0.197000 | 7.10e-02 |
| Rap1 signalling | 13 | 2.19e-01 | 0.197000 | 5.11e-01 |
| tRNA processing in the nucleus | 59 | 8.94e-03 | 0.197000 | 7.10e-02 |
| Regulation of TP53 Activity through Phosphorylation | 89 | 1.35e-03 | 0.197000 | 2.16e-02 |
| Leading Strand Synthesis | 14 | 2.03e-01 | 0.197000 | 4.93e-01 |
| Polymerase switching | 14 | 2.03e-01 | 0.197000 | 4.93e-01 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 4.26e-02 | -0.195000 | 2.02e-01 |
| Blood group systems biosynthesis | 17 | 1.64e-01 | -0.195000 | 4.40e-01 |
| Nuclear import of Rev protein | 34 | 4.95e-02 | 0.195000 | 2.23e-01 |
| Maturation of nucleoprotein | 10 | 2.87e-01 | 0.194000 | 5.74e-01 |
| Endosomal/Vacuolar pathway | 12 | 2.45e-01 | -0.194000 | 5.35e-01 |
| Membrane binding and targetting of GAG proteins | 13 | 2.26e-01 | -0.194000 | 5.18e-01 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | 13 | 2.26e-01 | -0.194000 | 5.18e-01 |
| RORA activates gene expression | 18 | 1.54e-01 | -0.194000 | 4.26e-01 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 49 | 1.90e-02 | 0.194000 | 1.20e-01 |
| Metabolism of porphyrins | 22 | 1.17e-01 | -0.193000 | 3.68e-01 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 1.26e-01 | 0.193000 | 3.81e-01 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 1.26e-01 | 0.193000 | 3.81e-01 |
| ATF6 (ATF6-alpha) activates chaperones | 12 | 2.51e-01 | 0.192000 | 5.41e-01 |
| Synthesis of PC | 23 | 1.12e-01 | 0.191000 | 3.61e-01 |
| Defects in cobalamin (B12) metabolism | 13 | 2.33e-01 | 0.191000 | 5.27e-01 |
| Activation of G protein gated Potassium channels | 20 | 1.41e-01 | 0.190000 | 3.99e-01 |
| G protein gated Potassium channels | 20 | 1.41e-01 | 0.190000 | 3.99e-01 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 20 | 1.41e-01 | 0.190000 | 3.99e-01 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 1.41e-01 | 0.190000 | 3.99e-01 |
| SIRT1 negatively regulates rRNA expression | 24 | 1.07e-01 | -0.190000 | 3.54e-01 |
| Diseases associated with glycosaminoglycan metabolism | 27 | 8.81e-02 | -0.190000 | 3.23e-01 |
| Regulation of innate immune responses to cytosolic DNA | 14 | 2.22e-01 | -0.189000 | 5.13e-01 |
| Cell Cycle Checkpoints | 259 | 1.77e-07 | 0.188000 | 8.06e-06 |
| Chemokine receptors bind chemokines | 40 | 3.93e-02 | -0.188000 | 1.92e-01 |
| SUMOylation of SUMOylation proteins | 35 | 5.47e-02 | 0.188000 | 2.36e-01 |
| MET activates RAS signaling | 10 | 3.05e-01 | 0.187000 | 5.97e-01 |
| Separation of Sister Chromatids | 168 | 2.91e-05 | 0.187000 | 7.65e-04 |
| Negative regulation of FGFR2 signaling | 23 | 1.21e-01 | -0.187000 | 3.75e-01 |
| Vpr-mediated nuclear import of PICs | 34 | 6.02e-02 | 0.186000 | 2.54e-01 |
| Arachidonic acid metabolism | 44 | 3.29e-02 | -0.186000 | 1.78e-01 |
| Deactivation of the beta-catenin transactivating complex | 36 | 5.51e-02 | -0.185000 | 2.36e-01 |
| Long-term potentiation | 15 | 2.16e-01 | -0.184000 | 5.08e-01 |
| HDMs demethylate histones | 22 | 1.36e-01 | -0.184000 | 3.92e-01 |
| Inositol phosphate metabolism | 43 | 3.74e-02 | -0.183000 | 1.88e-01 |
| Synthesis of PIPs at the early endosome membrane | 16 | 2.04e-01 | 0.183000 | 4.93e-01 |
| Condensation of Prophase Chromosomes | 29 | 8.79e-02 | -0.183000 | 3.23e-01 |
| Formation of Incision Complex in GG-NER | 43 | 3.81e-02 | 0.183000 | 1.89e-01 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | 42 | 4.08e-02 | -0.182000 | 1.95e-01 |
| HIV Transcription Elongation | 42 | 4.08e-02 | -0.182000 | 1.95e-01 |
| Tat-mediated elongation of the HIV-1 transcript | 42 | 4.08e-02 | -0.182000 | 1.95e-01 |
| Cell death signalling via NRAGE, NRIF and NADE | 69 | 8.92e-03 | -0.182000 | 7.10e-02 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | 22 | 1.40e-01 | -0.182000 | 3.99e-01 |
| G1/S-Specific Transcription | 29 | 9.07e-02 | 0.181000 | 3.31e-01 |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 124 | 4.81e-04 | -0.181000 | 8.43e-03 |
| PIWI-interacting RNA (piRNA) biogenesis | 24 | 1.26e-01 | -0.181000 | 3.81e-01 |
| Metabolism of carbohydrates | 242 | 1.29e-06 | -0.181000 | 4.41e-05 |
| Tight junction interactions | 19 | 1.73e-01 | -0.180000 | 4.55e-01 |
| RHO GTPases activate IQGAPs | 11 | 3.01e-01 | 0.180000 | 5.90e-01 |
| Cell junction organization | 59 | 1.68e-02 | -0.180000 | 1.10e-01 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | 20 | 1.64e-01 | -0.180000 | 4.40e-01 |
| Trafficking of AMPA receptors | 20 | 1.64e-01 | -0.180000 | 4.40e-01 |
| Serotonin Neurotransmitter Release Cycle | 14 | 2.45e-01 | -0.179000 | 5.35e-01 |
| Ephrin signaling | 18 | 1.88e-01 | -0.179000 | 4.78e-01 |
| Synthesis of very long-chain fatty acyl-CoAs | 22 | 1.46e-01 | 0.179000 | 4.08e-01 |
| Ca-dependent events | 29 | 9.53e-02 | -0.179000 | 3.33e-01 |
| Interactions of Rev with host cellular proteins | 37 | 6.02e-02 | 0.179000 | 2.54e-01 |
| Postmitotic nuclear pore complex (NPC) reformation | 27 | 1.09e-01 | 0.178000 | 3.57e-01 |
| Transcriptional Regulation by E2F6 | 34 | 7.25e-02 | 0.178000 | 2.85e-01 |
| Pregnenolone biosynthesis | 10 | 3.32e-01 | -0.177000 | 6.24e-01 |
| RNA polymerase II transcribes snRNA genes | 72 | 9.94e-03 | 0.176000 | 7.59e-02 |
| PERK regulates gene expression | 31 | 9.12e-02 | 0.175000 | 3.31e-01 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 12 | 2.93e-01 | -0.175000 | 5.80e-01 |
| Heme biosynthesis | 14 | 2.56e-01 | -0.175000 | 5.51e-01 |
| Axon guidance | 459 | 1.35e-10 | -0.175000 | 7.40e-09 |
| Signaling by NOTCH1 | 67 | 1.33e-02 | -0.175000 | 9.12e-02 |
| Mitotic Telophase/Cytokinesis | 13 | 2.76e-01 | 0.174000 | 5.70e-01 |
| Oxidative Stress Induced Senescence | 79 | 7.57e-03 | -0.174000 | 6.43e-02 |
| Nervous system development | 478 | 7.99e-11 | -0.173000 | 4.55e-09 |
| Chromatin modifying enzymes | 218 | 1.02e-05 | -0.173000 | 2.85e-04 |
| Chromatin organization | 218 | 1.02e-05 | -0.173000 | 2.85e-04 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 34 | 8.05e-02 | -0.173000 | 3.06e-01 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 13 | 2.82e-01 | -0.172000 | 5.70e-01 |
| Gastrin-CREB signalling pathway via PKC and MAPK | 14 | 2.66e-01 | -0.172000 | 5.62e-01 |
| SUMOylation of transcription cofactors | 44 | 4.87e-02 | -0.172000 | 2.21e-01 |
| Respiratory electron transport | 101 | 2.90e-03 | -0.171000 | 3.57e-02 |
| Caspase activation via Death Receptors in the presence of ligand | 16 | 2.35e-01 | 0.171000 | 5.28e-01 |
| Mitotic Prometaphase | 184 | 6.05e-05 | 0.171000 | 1.50e-03 |
| Vitamin D (calciferol) metabolism | 10 | 3.48e-01 | -0.171000 | 6.34e-01 |
| Regulation of KIT signaling | 15 | 2.51e-01 | -0.171000 | 5.41e-01 |
| Branched-chain amino acid catabolism | 21 | 1.75e-01 | 0.171000 | 4.59e-01 |
| FGFR2 alternative splicing | 25 | 1.39e-01 | -0.171000 | 3.98e-01 |
| PINK1-PRKN Mediated Mitophagy | 21 | 1.76e-01 | -0.171000 | 4.60e-01 |
| Non-integrin membrane-ECM interactions | 37 | 7.26e-02 | -0.171000 | 2.85e-01 |
| Intrinsic Pathway of Fibrin Clot Formation | 16 | 2.39e-01 | -0.170000 | 5.33e-01 |
| Smooth Muscle Contraction | 31 | 1.02e-01 | -0.170000 | 3.44e-01 |
| NOTCH3 Intracellular Domain Regulates Transcription | 21 | 1.79e-01 | -0.169000 | 4.65e-01 |
| Cell-Cell communication | 88 | 6.17e-03 | -0.169000 | 5.70e-02 |
| SUMOylation of transcription factors | 16 | 2.43e-01 | 0.169000 | 5.35e-01 |
| HATs acetylate histones | 93 | 4.96e-03 | -0.169000 | 5.10e-02 |
| RUNX3 regulates NOTCH signaling | 14 | 2.75e-01 | -0.168000 | 5.70e-01 |
| Mitophagy | 28 | 1.23e-01 | -0.168000 | 3.76e-01 |
| Activation of SMO | 13 | 2.94e-01 | -0.168000 | 5.81e-01 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | 25 | 1.47e-01 | -0.167000 | 4.10e-01 |
| Glycosphingolipid metabolism | 36 | 8.24e-02 | -0.167000 | 3.10e-01 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | 16 | 2.47e-01 | -0.167000 | 5.37e-01 |
| APC/C-mediated degradation of cell cycle proteins | 87 | 7.31e-03 | 0.166000 | 6.33e-02 |
| Regulation of mitotic cell cycle | 87 | 7.31e-03 | 0.166000 | 6.33e-02 |
| Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 2.65e-01 | 0.166000 | 5.62e-01 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 36 | 8.48e-02 | 0.166000 | 3.17e-01 |
| Syndecan interactions | 19 | 2.10e-01 | -0.166000 | 5.02e-01 |
| CASP8 activity is inhibited | 11 | 3.41e-01 | 0.166000 | 6.27e-01 |
| Dimerization of procaspase-8 | 11 | 3.41e-01 | 0.166000 | 6.27e-01 |
| Regulation by c-FLIP | 11 | 3.41e-01 | 0.166000 | 6.27e-01 |
| Activation of the pre-replicative complex | 32 | 1.06e-01 | 0.165000 | 3.51e-01 |
| Signaling by FGFR4 in disease | 11 | 3.43e-01 | 0.165000 | 6.30e-01 |
| Rev-mediated nuclear export of HIV RNA | 35 | 9.11e-02 | 0.165000 | 3.31e-01 |
| Signaling by FGFR1 in disease | 30 | 1.18e-01 | 0.165000 | 3.69e-01 |
| Degradation of the extracellular matrix | 81 | 1.04e-02 | -0.165000 | 7.79e-02 |
| ECM proteoglycans | 36 | 8.78e-02 | -0.164000 | 3.23e-01 |
| G-protein mediated events | 44 | 6.03e-02 | -0.164000 | 2.54e-01 |
| Signaling by FGFR2 IIIa TM | 18 | 2.30e-01 | -0.163000 | 5.24e-01 |
| p75 NTR receptor-mediated signalling | 88 | 8.08e-03 | -0.163000 | 6.77e-02 |
| HuR (ELAVL1) binds and stabilizes mRNA | 10 | 3.74e-01 | 0.162000 | 6.54e-01 |
| RAF-independent MAPK1/3 activation | 21 | 1.98e-01 | -0.162000 | 4.87e-01 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | 11 | 3.52e-01 | -0.162000 | 6.37e-01 |
| G0 and Early G1 | 27 | 1.45e-01 | 0.162000 | 4.08e-01 |
| Base Excision Repair | 58 | 3.30e-02 | -0.162000 | 1.78e-01 |
| Integrin cell surface interactions | 52 | 4.37e-02 | -0.162000 | 2.06e-01 |
| Estrogen-dependent gene expression | 99 | 5.44e-03 | -0.162000 | 5.23e-02 |
| Translation | 295 | 1.90e-06 | -0.161000 | 6.18e-05 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 2.96e-01 | 0.161000 | 5.84e-01 |
| Negative regulation of the PI3K/AKT network | 87 | 9.38e-03 | -0.161000 | 7.28e-02 |
| Formation of the Early Elongation Complex | 33 | 1.10e-01 | -0.161000 | 3.58e-01 |
| Formation of the HIV-1 Early Elongation Complex | 33 | 1.10e-01 | -0.161000 | 3.58e-01 |
| Polo-like kinase mediated events | 15 | 2.82e-01 | 0.160000 | 5.70e-01 |
| PECAM1 interactions | 12 | 3.36e-01 | -0.160000 | 6.25e-01 |
| Cellular hexose transport | 15 | 2.84e-01 | -0.160000 | 5.70e-01 |
| Protein-protein interactions at synapses | 59 | 3.40e-02 | -0.160000 | 1.80e-01 |
| Lysosome Vesicle Biogenesis | 32 | 1.20e-01 | -0.159000 | 3.72e-01 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 13 | 3.21e-01 | 0.159000 | 6.10e-01 |
| Heme degradation | 10 | 3.87e-01 | -0.158000 | 6.62e-01 |
| RAF activation | 32 | 1.23e-01 | 0.158000 | 3.76e-01 |
| Phase 4 - resting membrane potential | 10 | 3.90e-01 | 0.157000 | 6.66e-01 |
| Elastic fibre formation | 32 | 1.25e-01 | -0.157000 | 3.80e-01 |
| Initial triggering of complement | 78 | 1.73e-02 | 0.156000 | 1.11e-01 |
| Platelet calcium homeostasis | 22 | 2.06e-01 | -0.156000 | 4.93e-01 |
| FGFR2 mutant receptor activation | 22 | 2.09e-01 | -0.155000 | 5.01e-01 |
| Synaptic adhesion-like molecules | 16 | 2.85e-01 | -0.155000 | 5.70e-01 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 17 | 2.70e-01 | -0.154000 | 5.67e-01 |
| Signaling by NTRKs | 117 | 3.91e-03 | -0.154000 | 4.35e-02 |
| cGMP effects | 12 | 3.55e-01 | -0.154000 | 6.39e-01 |
| G alpha (z) signalling events | 36 | 1.09e-01 | -0.154000 | 3.57e-01 |
| Processing of DNA double-strand break ends | 71 | 2.49e-02 | 0.154000 | 1.47e-01 |
| DNA Replication | 126 | 3.02e-03 | 0.153000 | 3.69e-02 |
| G2/M Checkpoints | 139 | 1.88e-03 | 0.153000 | 2.68e-02 |
| Signaling by NTRK1 (TRKA) | 102 | 7.90e-03 | -0.152000 | 6.66e-02 |
| HSF1 activation | 26 | 1.81e-01 | -0.152000 | 4.67e-01 |
| Extra-nuclear estrogen signaling | 66 | 3.33e-02 | -0.151000 | 1.79e-01 |
| ESR-mediated signaling | 161 | 9.11e-04 | -0.151000 | 1.54e-02 |
| PLC beta mediated events | 43 | 8.58e-02 | -0.151000 | 3.20e-01 |
| Signaling by FGFR3 in disease | 13 | 3.45e-01 | 0.151000 | 6.31e-01 |
| Signaling by FGFR3 point mutants in cancer | 13 | 3.45e-01 | 0.151000 | 6.31e-01 |
| Ion homeostasis | 41 | 9.41e-02 | -0.151000 | 3.33e-01 |
| Signaling by Nuclear Receptors | 219 | 1.24e-04 | -0.150000 | 2.88e-03 |
| NOTCH1 Intracellular Domain Regulates Transcription | 45 | 8.13e-02 | -0.150000 | 3.09e-01 |
| Formation of HIV elongation complex in the absence of HIV Tat | 44 | 8.66e-02 | -0.149000 | 3.21e-01 |
| Caspase-mediated cleavage of cytoskeletal proteins | 12 | 3.71e-01 | -0.149000 | 6.52e-01 |
| Phase 2 - plateau phase | 11 | 3.93e-01 | 0.149000 | 6.66e-01 |
| Late endosomal microautophagy | 30 | 1.60e-01 | -0.148000 | 4.34e-01 |
| RUNX2 regulates osteoblast differentiation | 19 | 2.64e-01 | -0.148000 | 5.62e-01 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | 16 | 3.08e-01 | -0.147000 | 5.98e-01 |
| Class B/2 (Secretin family receptors) | 57 | 5.47e-02 | -0.147000 | 2.36e-01 |
| PI3K Cascade | 30 | 1.64e-01 | -0.147000 | 4.40e-01 |
| BBSome-mediated cargo-targeting to cilium | 22 | 2.34e-01 | 0.147000 | 5.28e-01 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | 75 | 2.83e-02 | 0.146000 | 1.59e-01 |
| Infection with Mycobacterium tuberculosis | 26 | 1.97e-01 | -0.146000 | 4.87e-01 |
| B-WICH complex positively regulates rRNA expression | 44 | 9.37e-02 | -0.146000 | 3.33e-01 |
| TGF-beta receptor signaling activates SMADs | 32 | 1.55e-01 | -0.145000 | 4.27e-01 |
| Lagging Strand Synthesis | 20 | 2.61e-01 | 0.145000 | 5.58e-01 |
| RHO GTPases Activate Formins | 117 | 6.77e-03 | 0.145000 | 6.01e-02 |
| Developmental Biology | 738 | 2.08e-11 | -0.145000 | 1.36e-09 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 80 | 2.52e-02 | -0.145000 | 1.47e-01 |
| Mitotic Metaphase and Anaphase | 225 | 1.88e-04 | 0.144000 | 4.03e-03 |
| Creation of C4 and C2 activators | 71 | 3.55e-02 | 0.144000 | 1.83e-01 |
| Glycogen breakdown (glycogenolysis) | 13 | 3.69e-01 | -0.144000 | 6.50e-01 |
| Positive epigenetic regulation of rRNA expression | 59 | 5.61e-02 | -0.144000 | 2.39e-01 |
| Signaling by EGFR in Cancer | 23 | 2.33e-01 | -0.144000 | 5.27e-01 |
| Diseases associated with O-glycosylation of proteins | 49 | 8.24e-02 | -0.143000 | 3.10e-01 |
| Plasma lipoprotein remodeling | 19 | 2.81e-01 | -0.143000 | 5.70e-01 |
| Platelet Adhesion to exposed collagen | 13 | 3.72e-01 | -0.143000 | 6.53e-01 |
| Nicotinamide salvaging | 15 | 3.41e-01 | 0.142000 | 6.27e-01 |
| ADORA2B mediated anti-inflammatory cytokines production | 74 | 3.46e-02 | -0.142000 | 1.82e-01 |
| Mitochondrial protein import | 64 | 4.96e-02 | -0.142000 | 2.23e-01 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 46 | 9.63e-02 | -0.142000 | 3.34e-01 |
| Transcriptional Regulation by MECP2 | 47 | 9.41e-02 | -0.141000 | 3.33e-01 |
| Signaling by WNT in cancer | 30 | 1.81e-01 | -0.141000 | 4.67e-01 |
| Classical antibody-mediated complement activation | 69 | 4.29e-02 | 0.141000 | 2.03e-01 |
| Mitotic Anaphase | 224 | 2.79e-04 | 0.141000 | 5.30e-03 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 76 | 3.37e-02 | 0.141000 | 1.79e-01 |
| Constitutive Signaling by Aberrant PI3K in Cancer | 54 | 7.38e-02 | -0.141000 | 2.88e-01 |
| TRAF3-dependent IRF activation pathway | 13 | 3.81e-01 | 0.140000 | 6.56e-01 |
| Response to elevated platelet cytosolic Ca2+ | 108 | 1.20e-02 | -0.140000 | 8.67e-02 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | 12 | 4.04e-01 | 0.139000 | 6.74e-01 |
| Formation of apoptosome | 11 | 4.25e-01 | 0.139000 | 6.85e-01 |
| Regulation of the apoptosome activity | 11 | 4.25e-01 | 0.139000 | 6.85e-01 |
| ATF4 activates genes in response to endoplasmic reticulum stress | 26 | 2.22e-01 | 0.138000 | 5.13e-01 |
| Platelet degranulation | 104 | 1.53e-02 | -0.138000 | 1.01e-01 |
| RET signaling | 32 | 1.78e-01 | -0.137000 | 4.65e-01 |
| Transcriptional regulation of granulopoiesis | 46 | 1.08e-01 | -0.137000 | 3.57e-01 |
| Biotin transport and metabolism | 11 | 4.34e-01 | -0.136000 | 6.96e-01 |
| RNA Polymerase I Promoter Clearance | 63 | 6.15e-02 | -0.136000 | 2.56e-01 |
| RNA Polymerase I Transcription | 63 | 6.15e-02 | -0.136000 | 2.56e-01 |
| Scavenging of heme from plasma | 71 | 4.85e-02 | 0.135000 | 2.21e-01 |
| Glutamate and glutamine metabolism | 12 | 4.17e-01 | -0.135000 | 6.82e-01 |
| Signaling by Receptor Tyrosine Kinases | 413 | 2.41e-06 | -0.135000 | 7.67e-05 |
| G beta:gamma signalling through CDC42 | 17 | 3.35e-01 | 0.135000 | 6.25e-01 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 11 | 4.38e-01 | 0.135000 | 6.97e-01 |
| tRNA Aminoacylation | 42 | 1.31e-01 | 0.135000 | 3.90e-01 |
| Signaling by NOTCH | 183 | 1.67e-03 | -0.135000 | 2.49e-02 |
| Regulation of APC/C activators between G1/S and early anaphase | 80 | 3.79e-02 | 0.134000 | 1.89e-01 |
| Synthesis of DNA | 119 | 1.16e-02 | 0.134000 | 8.40e-02 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 73 | 4.78e-02 | 0.134000 | 2.19e-01 |
| Transport of Mature Transcript to Cytoplasm | 81 | 3.75e-02 | 0.134000 | 1.88e-01 |
| Assembly and cell surface presentation of NMDA receptors | 19 | 3.13e-01 | -0.134000 | 6.04e-01 |
| Regulation of Complement cascade | 94 | 2.51e-02 | 0.134000 | 1.47e-01 |
| Telomere Maintenance | 80 | 3.91e-02 | -0.133000 | 1.92e-01 |
| Signaling by Hippo | 18 | 3.28e-01 | 0.133000 | 6.18e-01 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 11 | 4.46e-01 | -0.133000 | 6.98e-01 |
| RNA Polymerase III Chain Elongation | 18 | 3.31e-01 | -0.132000 | 6.22e-01 |
| Erythrocytes take up carbon dioxide and release oxygen | 11 | 4.49e-01 | -0.132000 | 6.98e-01 |
| O2/CO2 exchange in erythrocytes | 11 | 4.49e-01 | -0.132000 | 6.98e-01 |
| Amino acid transport across the plasma membrane | 24 | 2.63e-01 | -0.132000 | 5.62e-01 |
| Sema4D induced cell migration and growth-cone collapse | 19 | 3.21e-01 | -0.132000 | 6.10e-01 |
| Constitutive Signaling by EGFRvIII | 14 | 3.94e-01 | 0.131000 | 6.66e-01 |
| Signaling by EGFRvIII in Cancer | 14 | 3.94e-01 | 0.131000 | 6.66e-01 |
| Interleukin-27 signaling | 11 | 4.51e-01 | 0.131000 | 6.99e-01 |
| Cellular Senescence | 144 | 6.60e-03 | -0.131000 | 5.92e-02 |
| ZBP1(DAI) mediated induction of type I IFNs | 20 | 3.11e-01 | -0.131000 | 6.00e-01 |
| Switching of origins to a post-replicative state | 90 | 3.21e-02 | 0.131000 | 1.75e-01 |
| ERKs are inactivated | 13 | 4.17e-01 | -0.130000 | 6.82e-01 |
| Complement cascade | 98 | 2.63e-02 | 0.130000 | 1.51e-01 |
| CD28 co-stimulation | 33 | 1.97e-01 | -0.130000 | 4.87e-01 |
| Activation of the AP-1 family of transcription factors | 10 | 4.78e-01 | -0.130000 | 7.17e-01 |
| Interactions of Vpr with host cellular proteins | 37 | 1.72e-01 | 0.130000 | 4.53e-01 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 24 | 2.72e-01 | -0.130000 | 5.67e-01 |
| Cellular responses to stress | 500 | 6.97e-07 | -0.130000 | 2.51e-05 |
| Cross-presentation of soluble exogenous antigens (endosomes) | 48 | 1.20e-01 | 0.130000 | 3.74e-01 |
| Signaling by cytosolic FGFR1 fusion mutants | 17 | 3.56e-01 | 0.129000 | 6.39e-01 |
| EPHB-mediated forward signaling | 33 | 1.99e-01 | 0.129000 | 4.89e-01 |
| Apoptotic factor-mediated response | 18 | 3.44e-01 | 0.129000 | 6.31e-01 |
| Nuclear Envelope Breakdown | 53 | 1.06e-01 | 0.128000 | 3.51e-01 |
| Glyoxylate metabolism and glycine degradation | 24 | 2.76e-01 | 0.128000 | 5.70e-01 |
| Cellular responses to external stimuli | 506 | 7.84e-07 | -0.128000 | 2.75e-05 |
| Cargo trafficking to the periciliary membrane | 47 | 1.28e-01 | 0.128000 | 3.87e-01 |
| DNA Double Strand Break Response | 47 | 1.29e-01 | -0.128000 | 3.87e-01 |
| mitochondrial fatty acid beta-oxidation of saturated fatty acids | 11 | 4.63e-01 | -0.128000 | 7.07e-01 |
| SHC-mediated cascade:FGFR2 | 12 | 4.44e-01 | 0.128000 | 6.98e-01 |
| Cholesterol biosynthesis | 24 | 2.84e-01 | 0.126000 | 5.70e-01 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 1.90e-01 | 0.126000 | 4.80e-01 |
| Diseases of mitotic cell cycle | 36 | 1.90e-01 | 0.126000 | 4.80e-01 |
| Mitotic G2-G2/M phases | 181 | 3.43e-03 | 0.126000 | 3.94e-02 |
| Metabolism of amino acids and derivatives | 326 | 9.17e-05 | -0.126000 | 2.20e-03 |
| Signaling by Non-Receptor Tyrosine Kinases | 48 | 1.31e-01 | -0.126000 | 3.90e-01 |
| Signaling by PTK6 | 48 | 1.31e-01 | -0.126000 | 3.90e-01 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 14 | 4.15e-01 | 0.126000 | 6.82e-01 |
| Prolactin receptor signaling | 11 | 4.70e-01 | 0.126000 | 7.11e-01 |
| Oncogene Induced Senescence | 33 | 2.11e-01 | -0.126000 | 5.02e-01 |
| Interleukin-4 and Interleukin-13 signaling | 94 | 3.52e-02 | -0.126000 | 1.83e-01 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | 12 | 4.52e-01 | 0.125000 | 7.00e-01 |
| Orc1 removal from chromatin | 70 | 7.02e-02 | 0.125000 | 2.79e-01 |
| TCF dependent signaling in response to WNT | 167 | 5.32e-03 | -0.125000 | 5.16e-02 |
| The citric acid (TCA) cycle and respiratory electron transport | 172 | 4.80e-03 | -0.125000 | 5.05e-02 |
| Signaling by FGFR2 | 60 | 9.50e-02 | -0.125000 | 3.33e-01 |
| Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) | 10 | 4.95e-01 | 0.125000 | 7.32e-01 |
| Nitric oxide stimulates guanylate cyclase | 15 | 4.04e-01 | -0.125000 | 6.74e-01 |
| Recycling pathway of L1 | 26 | 2.72e-01 | -0.124000 | 5.67e-01 |
| S Phase | 161 | 6.54e-03 | 0.124000 | 5.92e-02 |
| Aquaporin-mediated transport | 38 | 1.85e-01 | -0.124000 | 4.75e-01 |
| Keratinization | 34 | 2.11e-01 | -0.124000 | 5.02e-01 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 12 | 4.57e-01 | -0.124000 | 7.02e-01 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 72 | 6.89e-02 | 0.124000 | 2.75e-01 |
| PCP/CE pathway | 87 | 4.60e-02 | -0.124000 | 2.14e-01 |
| RIP-mediated NFkB activation via ZBP1 | 17 | 3.77e-01 | -0.124000 | 6.55e-01 |
| Activation of BH3-only proteins | 30 | 2.43e-01 | -0.123000 | 5.35e-01 |
| CDT1 association with the CDC6:ORC:origin complex | 58 | 1.05e-01 | 0.123000 | 3.51e-01 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 13 | 4.43e-01 | 0.123000 | 6.98e-01 |
| G2/M Transition | 179 | 4.62e-03 | 0.123000 | 4.90e-02 |
| Nucleobase biosynthesis | 13 | 4.45e-01 | -0.122000 | 6.98e-01 |
| Interferon gamma signaling | 83 | 5.41e-02 | 0.122000 | 2.36e-01 |
| Glucagon signaling in metabolic regulation | 27 | 2.74e-01 | -0.122000 | 5.69e-01 |
| SARS-CoV-2 Infection | 63 | 9.51e-02 | -0.122000 | 3.33e-01 |
| Regulation of beta-cell development | 20 | 3.47e-01 | -0.122000 | 6.33e-01 |
| G1/S Transition | 130 | 1.69e-02 | 0.121000 | 1.10e-01 |
| Inflammasomes | 20 | 3.48e-01 | 0.121000 | 6.34e-01 |
| FOXO-mediated transcription of cell cycle genes | 15 | 4.17e-01 | -0.121000 | 6.82e-01 |
| Carboxyterminal post-translational modifications of tubulin | 27 | 2.77e-01 | -0.121000 | 5.70e-01 |
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 27 | 2.77e-01 | -0.121000 | 5.70e-01 |
| Platelet activation, signaling and aggregation | 219 | 2.12e-03 | -0.120000 | 2.81e-02 |
| DCC mediated attractive signaling | 13 | 4.54e-01 | -0.120000 | 7.00e-01 |
| Signaling by ERBB2 | 44 | 1.69e-01 | -0.120000 | 4.49e-01 |
| CS/DS degradation | 10 | 5.12e-01 | -0.120000 | 7.37e-01 |
| Caspase activation via extrinsic apoptotic signalling pathway | 25 | 3.01e-01 | 0.120000 | 5.90e-01 |
| Regulation of FOXO transcriptional activity by acetylation | 10 | 5.14e-01 | -0.119000 | 7.37e-01 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 54 | 1.32e-01 | -0.118000 | 3.90e-01 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | 54 | 1.32e-01 | -0.118000 | 3.90e-01 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 54 | 1.32e-01 | -0.118000 | 3.90e-01 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | 54 | 1.32e-01 | -0.118000 | 3.90e-01 |
| Signaling by NOTCH1 in Cancer | 54 | 1.32e-01 | -0.118000 | 3.90e-01 |
| Circadian Clock | 67 | 9.56e-02 | -0.118000 | 3.33e-01 |
| Synthesis of bile acids and bile salts | 24 | 3.18e-01 | 0.118000 | 6.08e-01 |
| TICAM1-dependent activation of IRF3/IRF7 | 12 | 4.80e-01 | -0.118000 | 7.19e-01 |
| Intracellular signaling by second messengers | 273 | 8.21e-04 | -0.118000 | 1.40e-02 |
| EPH-Ephrin signaling | 80 | 6.97e-02 | -0.117000 | 2.78e-01 |
| Mitotic G1 phase and G1/S transition | 148 | 1.39e-02 | 0.117000 | 9.38e-02 |
| O-glycosylation of TSR domain-containing proteins | 27 | 2.93e-01 | -0.117000 | 5.80e-01 |
| MAP2K and MAPK activation | 34 | 2.38e-01 | -0.117000 | 5.32e-01 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 20 | 3.67e-01 | -0.116000 | 6.50e-01 |
| Neurodegenerative Diseases | 20 | 3.67e-01 | -0.116000 | 6.50e-01 |
| O-linked glycosylation | 84 | 6.56e-02 | -0.116000 | 2.67e-01 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 37 | 2.22e-01 | -0.116000 | 5.13e-01 |
| Transcriptional regulation by RUNX1 | 185 | 6.97e-03 | -0.115000 | 6.10e-02 |
| IRAK1 recruits IKK complex | 10 | 5.30e-01 | -0.115000 | 7.45e-01 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 10 | 5.30e-01 | -0.115000 | 7.45e-01 |
| G beta:gamma signalling through PI3Kgamma | 22 | 3.53e-01 | -0.114000 | 6.37e-01 |
| Synthesis, secretion, and deacylation of Ghrelin | 11 | 5.12e-01 | 0.114000 | 7.37e-01 |
| Chaperone Mediated Autophagy | 20 | 3.77e-01 | -0.114000 | 6.55e-01 |
| Metabolism of cofactors | 19 | 3.90e-01 | 0.114000 | 6.66e-01 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | 72 | 9.47e-02 | 0.114000 | 3.33e-01 |
| RUNX3 regulates p14-ARF | 10 | 5.33e-01 | -0.114000 | 7.48e-01 |
| RHO GTPases activate CIT | 18 | 4.03e-01 | 0.114000 | 6.74e-01 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | 17 | 4.17e-01 | 0.114000 | 6.82e-01 |
| Semaphorin interactions | 57 | 1.38e-01 | -0.114000 | 3.95e-01 |
| Cargo concentration in the ER | 30 | 2.83e-01 | 0.113000 | 5.70e-01 |
| Signaling by ERBB2 ECD mutants | 15 | 4.48e-01 | 0.113000 | 6.98e-01 |
| RNA Polymerase I Promoter Escape | 44 | 1.95e-01 | -0.113000 | 4.85e-01 |
| Voltage gated Potassium channels | 27 | 3.10e-01 | -0.113000 | 6.00e-01 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 12 | 4.99e-01 | -0.113000 | 7.33e-01 |
| Signaling by FGFR4 | 31 | 2.77e-01 | -0.113000 | 5.70e-01 |
| DNA Damage/Telomere Stress Induced Senescence | 44 | 1.96e-01 | -0.113000 | 4.86e-01 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | 59 | 1.35e-01 | 0.112000 | 3.92e-01 |
| Suppression of phagosomal maturation | 12 | 5.01e-01 | -0.112000 | 7.33e-01 |
| Tryptophan catabolism | 12 | 5.01e-01 | 0.112000 | 7.33e-01 |
| VEGFR2 mediated cell proliferation | 18 | 4.10e-01 | -0.112000 | 6.77e-01 |
| Downregulation of TGF-beta receptor signaling | 26 | 3.23e-01 | -0.112000 | 6.11e-01 |
| Visual phototransduction | 60 | 1.34e-01 | -0.112000 | 3.91e-01 |
| Downstream signaling of activated FGFR2 | 19 | 3.99e-01 | 0.112000 | 6.73e-01 |
| TP53 Regulates Transcription of DNA Repair Genes | 61 | 1.33e-01 | -0.111000 | 3.90e-01 |
| DNA Replication Pre-Initiation | 83 | 7.96e-02 | 0.111000 | 3.05e-01 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 35 | 2.56e-01 | -0.111000 | 5.50e-01 |
| FCGR activation | 76 | 9.47e-02 | 0.111000 | 3.33e-01 |
| Downstream signaling of activated FGFR1 | 20 | 3.92e-01 | 0.111000 | 6.66e-01 |
| Interleukin-12 family signaling | 54 | 1.60e-01 | 0.110000 | 4.34e-01 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 104 | 5.20e-02 | 0.110000 | 2.32e-01 |
| SARS-CoV-1 Infection | 47 | 1.92e-01 | -0.110000 | 4.83e-01 |
| Meiotic synapsis | 45 | 2.02e-01 | -0.110000 | 4.93e-01 |
| Keratan sulfate biosynthesis | 22 | 3.74e-01 | -0.110000 | 6.54e-01 |
| FRS-mediated FGFR2 signaling | 14 | 4.81e-01 | 0.109000 | 7.19e-01 |
| Phase I - Functionalization of compounds | 64 | 1.33e-01 | -0.109000 | 3.91e-01 |
| Integrin signaling | 22 | 3.78e-01 | -0.109000 | 6.55e-01 |
| Synthesis of glycosylphosphatidylinositol (GPI) | 17 | 4.40e-01 | 0.108000 | 6.98e-01 |
| XBP1(S) activates chaperone genes | 47 | 2.00e-01 | -0.108000 | 4.90e-01 |
| Formation of the cornified envelope | 21 | 3.92e-01 | -0.108000 | 6.66e-01 |
| MET activates PTK2 signaling | 15 | 4.70e-01 | -0.108000 | 7.11e-01 |
| Nucleotide salvage | 21 | 3.94e-01 | -0.108000 | 6.66e-01 |
| Insulin receptor signalling cascade | 39 | 2.45e-01 | -0.108000 | 5.35e-01 |
| Inwardly rectifying K+ channels | 24 | 3.62e-01 | 0.107000 | 6.47e-01 |
| IRE1alpha activates chaperones | 49 | 1.93e-01 | -0.107000 | 4.83e-01 |
| CDK-mediated phosphorylation and removal of Cdc6 | 72 | 1.15e-01 | 0.107000 | 3.65e-01 |
| mRNA Splicing - Minor Pathway | 52 | 1.81e-01 | -0.107000 | 4.67e-01 |
| ERBB2 Regulates Cell Motility | 10 | 5.58e-01 | -0.107000 | 7.70e-01 |
| Fertilization | 13 | 5.04e-01 | -0.107000 | 7.33e-01 |
| Trafficking and processing of endosomal TLR | 13 | 5.05e-01 | 0.107000 | 7.33e-01 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 4.75e-01 | -0.107000 | 7.15e-01 |
| Vasopressin regulates renal water homeostasis via Aquaporins | 34 | 2.82e-01 | -0.107000 | 5.70e-01 |
| CD22 mediated BCR regulation | 59 | 1.57e-01 | 0.106000 | 4.31e-01 |
| Processing of Capped Intronless Pre-mRNA | 28 | 3.30e-01 | 0.106000 | 6.22e-01 |
| Dopamine Neurotransmitter Release Cycle | 19 | 4.24e-01 | -0.106000 | 6.85e-01 |
| MyD88 cascade initiated on plasma membrane | 82 | 9.78e-02 | -0.106000 | 3.37e-01 |
| Toll Like Receptor 10 (TLR10) Cascade | 82 | 9.78e-02 | -0.106000 | 3.37e-01 |
| Toll Like Receptor 5 (TLR5) Cascade | 82 | 9.78e-02 | -0.106000 | 3.37e-01 |
| G alpha (q) signalling events | 134 | 3.47e-02 | -0.106000 | 1.82e-01 |
| Regulation of RUNX2 expression and activity | 67 | 1.35e-01 | 0.106000 | 3.92e-01 |
| Presynaptic function of Kainate receptors | 18 | 4.38e-01 | -0.106000 | 6.97e-01 |
| SHC-mediated cascade:FGFR1 | 12 | 5.27e-01 | 0.105000 | 7.43e-01 |
| Molecules associated with elastic fibres | 22 | 3.93e-01 | -0.105000 | 6.66e-01 |
| Cell Cycle, Mitotic | 501 | 5.66e-05 | 0.105000 | 1.43e-03 |
| Peptide hormone metabolism | 49 | 2.04e-01 | 0.105000 | 4.93e-01 |
| Constitutive Signaling by Overexpressed ERBB2 | 11 | 5.47e-01 | 0.105000 | 7.62e-01 |
| Cell Cycle | 623 | 8.32e-06 | 0.105000 | 2.47e-04 |
| G alpha (s) signalling events | 145 | 2.98e-02 | 0.105000 | 1.66e-01 |
| DNA Double-Strand Break Repair | 135 | 3.60e-02 | 0.104000 | 1.84e-01 |
| Regulation of Apoptosis | 52 | 1.94e-01 | 0.104000 | 4.83e-01 |
| SUMOylation of DNA damage response and repair proteins | 77 | 1.15e-01 | 0.104000 | 3.65e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE | 27 | 3.50e-01 | -0.104000 | 6.36e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 27 | 3.50e-01 | -0.104000 | 6.36e-01 |
| Interleukin-12 signaling | 44 | 2.33e-01 | 0.104000 | 5.27e-01 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 16 | 4.72e-01 | 0.104000 | 7.13e-01 |
| Transport of inorganic cations/anions and amino acids/oligopeptides | 80 | 1.09e-01 | -0.104000 | 3.57e-01 |
| FGFR1 mutant receptor activation | 23 | 3.91e-01 | 0.103000 | 6.66e-01 |
| PIP3 activates AKT signaling | 241 | 5.74e-03 | -0.103000 | 5.45e-02 |
| Cell recruitment (pro-inflammatory response) | 22 | 4.02e-01 | 0.103000 | 6.74e-01 |
| Purinergic signaling in leishmaniasis infection | 22 | 4.02e-01 | 0.103000 | 6.74e-01 |
| Cell-cell junction organization | 38 | 2.71e-01 | -0.103000 | 5.67e-01 |
| Initiation of Nuclear Envelope (NE) Reformation | 19 | 4.37e-01 | 0.103000 | 6.96e-01 |
| IRS-related events triggered by IGF1R | 35 | 2.93e-01 | -0.103000 | 5.80e-01 |
| Signaling by high-kinase activity BRAF mutants | 31 | 3.23e-01 | -0.103000 | 6.11e-01 |
| Nephrin family interactions | 18 | 4.52e-01 | -0.102000 | 6.99e-01 |
| Signaling by WNT | 255 | 4.86e-03 | -0.102000 | 5.07e-02 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 73 | 1.31e-01 | 0.102000 | 3.90e-01 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 5.58e-01 | -0.102000 | 7.70e-01 |
| TNFs bind their physiological receptors | 25 | 3.78e-01 | -0.102000 | 6.55e-01 |
| G beta:gamma signalling through PLC beta | 17 | 4.68e-01 | -0.102000 | 7.11e-01 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 53 | 2.01e-01 | 0.102000 | 4.91e-01 |
| G alpha (12/13) signalling events | 68 | 1.48e-01 | -0.101000 | 4.12e-01 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 19 | 4.45e-01 | -0.101000 | 6.98e-01 |
| Regulation of PTEN mRNA translation | 13 | 5.27e-01 | 0.101000 | 7.43e-01 |
| IGF1R signaling cascade | 36 | 2.93e-01 | -0.101000 | 5.80e-01 |
| Diseases of glycosylation | 110 | 6.80e-02 | -0.101000 | 2.74e-01 |
| Bile acid and bile salt metabolism | 28 | 3.57e-01 | 0.101000 | 6.39e-01 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 3.68e-01 | -0.100000 | 6.50e-01 |
| Neutrophil degranulation | 458 | 2.42e-04 | -0.100000 | 4.80e-03 |
| Apoptosis induced DNA fragmentation | 10 | 5.84e-01 | 0.100000 | 7.84e-01 |
| Cargo recognition for clathrin-mediated endocytosis | 90 | 1.01e-01 | -0.099900 | 3.44e-01 |
| PI3K events in ERBB2 signaling | 11 | 5.66e-01 | -0.099800 | 7.74e-01 |
| rRNA modification in the nucleus and cytosol | 59 | 1.86e-01 | -0.099600 | 4.76e-01 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 79 | 1.26e-01 | -0.099500 | 3.81e-01 |
| MECP2 regulates neuronal receptors and channels | 13 | 5.35e-01 | -0.099300 | 7.51e-01 |
| TICAM1, RIP1-mediated IKK complex recruitment | 19 | 4.54e-01 | 0.099200 | 7.00e-01 |
| Downstream signaling of activated FGFR3 | 16 | 4.92e-01 | 0.099100 | 7.28e-01 |
| Defective B3GALTL causes Peters-plus syndrome (PpS) | 26 | 3.82e-01 | -0.099000 | 6.56e-01 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 4.43e-01 | 0.099000 | 6.98e-01 |
| Synthesis of PE | 12 | 5.53e-01 | 0.098900 | 7.68e-01 |
| Thrombin signalling through proteinase activated receptors (PARs) | 27 | 3.75e-01 | -0.098700 | 6.54e-01 |
| Binding and Uptake of Ligands by Scavenger Receptors | 92 | 1.02e-01 | 0.098700 | 3.44e-01 |
| SCF(Skp2)-mediated degradation of p27/p21 | 60 | 1.86e-01 | 0.098700 | 4.76e-01 |
| Homology Directed Repair | 110 | 7.43e-02 | 0.098500 | 2.89e-01 |
| Transcription of E2F targets under negative control by DREAM complex | 19 | 4.58e-01 | 0.098400 | 7.02e-01 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 14 | 5.24e-01 | 0.098400 | 7.41e-01 |
| SUMOylation of intracellular receptors | 27 | 3.77e-01 | -0.098300 | 6.55e-01 |
| Phase 0 - rapid depolarisation | 23 | 4.15e-01 | 0.098300 | 6.82e-01 |
| Metabolism of folate and pterines | 17 | 4.83e-01 | 0.098200 | 7.22e-01 |
| RUNX2 regulates bone development | 24 | 4.08e-01 | -0.097600 | 6.76e-01 |
| DNA Damage Recognition in GG-NER | 38 | 2.98e-01 | -0.097600 | 5.86e-01 |
| Post-chaperonin tubulin folding pathway | 19 | 4.62e-01 | -0.097500 | 7.07e-01 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 74 | 1.47e-01 | 0.097500 | 4.10e-01 |
| Diseases of metabolism | 190 | 2.07e-02 | -0.097300 | 1.27e-01 |
| Signaling by FGFR | 69 | 1.63e-01 | -0.097100 | 4.40e-01 |
| RHO GTPases activate PKNs | 47 | 2.50e-01 | -0.097000 | 5.41e-01 |
| Interleukin-17 signaling | 68 | 1.67e-01 | -0.096800 | 4.46e-01 |
| Nonhomologous End-Joining (NHEJ) | 42 | 2.81e-01 | 0.096100 | 5.70e-01 |
| mRNA 3’-end processing | 56 | 2.17e-01 | 0.095300 | 5.08e-01 |
| The NLRP3 inflammasome | 15 | 5.23e-01 | 0.095200 | 7.41e-01 |
| G1/S DNA Damage Checkpoints | 66 | 1.82e-01 | 0.095100 | 4.67e-01 |
| Signaling by VEGF | 97 | 1.07e-01 | -0.094700 | 3.54e-01 |
| Activation of NMDA receptors and postsynaptic events | 60 | 2.05e-01 | -0.094600 | 4.93e-01 |
| Early Phase of HIV Life Cycle | 14 | 5.40e-01 | 0.094600 | 7.56e-01 |
| VxPx cargo-targeting to cilium | 19 | 4.76e-01 | 0.094500 | 7.16e-01 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 64 | 1.91e-01 | -0.094500 | 4.81e-01 |
| Mitochondrial calcium ion transport | 22 | 4.45e-01 | -0.094100 | 6.98e-01 |
| p53-Dependent G1 DNA Damage Response | 64 | 1.94e-01 | 0.094000 | 4.83e-01 |
| p53-Dependent G1/S DNA damage checkpoint | 64 | 1.94e-01 | 0.094000 | 4.83e-01 |
| Phase II - Conjugation of compounds | 66 | 1.89e-01 | 0.093500 | 4.79e-01 |
| HCMV Late Events | 69 | 1.80e-01 | -0.093400 | 4.66e-01 |
| Rab regulation of trafficking | 120 | 7.77e-02 | -0.093200 | 2.99e-01 |
| APC/C:Cdc20 mediated degradation of Securin | 67 | 1.88e-01 | 0.093000 | 4.78e-01 |
| M Phase | 360 | 2.48e-03 | 0.092800 | 3.23e-02 |
| APC-Cdc20 mediated degradation of Nek2A | 26 | 4.14e-01 | 0.092600 | 6.82e-01 |
| Uptake and actions of bacterial toxins | 27 | 4.07e-01 | -0.092200 | 6.76e-01 |
| Signaling by Erythropoietin | 24 | 4.35e-01 | -0.092000 | 6.96e-01 |
| NoRC negatively regulates rRNA expression | 59 | 2.24e-01 | -0.091600 | 5.16e-01 |
| IKK complex recruitment mediated by RIP1 | 23 | 4.48e-01 | 0.091500 | 6.98e-01 |
| Glucagon-type ligand receptors | 20 | 4.80e-01 | -0.091300 | 7.19e-01 |
| Signaling by BMP | 21 | 4.70e-01 | 0.091100 | 7.11e-01 |
| ERK/MAPK targets | 22 | 4.60e-01 | -0.091000 | 7.05e-01 |
| Assembly of the pre-replicative complex | 67 | 1.98e-01 | 0.091000 | 4.87e-01 |
| Removal of the Flap Intermediate | 14 | 5.56e-01 | 0.090900 | 7.69e-01 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 87 | 1.44e-01 | -0.090700 | 4.04e-01 |
| DNA Damage Bypass | 47 | 2.83e-01 | 0.090500 | 5.70e-01 |
| SUMOylation of RNA binding proteins | 47 | 2.85e-01 | 0.090100 | 5.71e-01 |
| Death Receptor Signalling | 131 | 7.53e-02 | -0.090000 | 2.91e-01 |
| FRS-mediated FGFR3 signaling | 11 | 6.06e-01 | 0.089900 | 7.96e-01 |
| FRS-mediated FGFR1 signaling | 14 | 5.60e-01 | 0.089900 | 7.71e-01 |
| CTLA4 inhibitory signaling | 21 | 4.77e-01 | -0.089700 | 7.17e-01 |
| Interleukin-15 signaling | 14 | 5.62e-01 | -0.089600 | 7.72e-01 |
| WNT ligand biogenesis and trafficking | 21 | 4.77e-01 | 0.089600 | 7.17e-01 |
| Infectious disease | 778 | 2.16e-05 | -0.089500 | 5.79e-04 |
| Ion transport by P-type ATPases | 43 | 3.10e-01 | -0.089400 | 6.00e-01 |
| GABA receptor activation | 36 | 3.54e-01 | 0.089300 | 6.38e-01 |
| Peroxisomal lipid metabolism | 27 | 4.23e-01 | 0.089100 | 6.85e-01 |
| Negative epigenetic regulation of rRNA expression | 62 | 2.26e-01 | -0.088800 | 5.18e-01 |
| Lysosphingolipid and LPA receptors | 11 | 6.12e-01 | -0.088400 | 7.98e-01 |
| Metabolism | 1771 | 6.38e-10 | -0.088400 | 3.23e-08 |
| Integration of energy metabolism | 86 | 1.57e-01 | -0.088300 | 4.31e-01 |
| Signaling by Insulin receptor | 59 | 2.41e-01 | -0.088200 | 5.35e-01 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 4.21e-01 | -0.087900 | 6.83e-01 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 19 | 5.08e-01 | 0.087700 | 7.35e-01 |
| Post NMDA receptor activation events | 50 | 2.85e-01 | -0.087500 | 5.70e-01 |
| Regulation of MECP2 expression and activity | 28 | 4.24e-01 | -0.087400 | 6.85e-01 |
| Cytosolic sensors of pathogen-associated DNA | 62 | 2.36e-01 | -0.086900 | 5.29e-01 |
| Signaling by TGF-beta Receptor Complex | 72 | 2.05e-01 | -0.086400 | 4.93e-01 |
| Resolution of Abasic Sites (AP sites) | 37 | 3.64e-01 | -0.086300 | 6.48e-01 |
| Miscellaneous transport and binding events | 20 | 5.05e-01 | -0.086100 | 7.33e-01 |
| Formation of RNA Pol II elongation complex | 57 | 2.66e-01 | -0.085200 | 5.62e-01 |
| RNA Polymerase II Transcription Elongation | 57 | 2.66e-01 | -0.085200 | 5.62e-01 |
| GRB2 events in EGFR signaling | 11 | 6.25e-01 | -0.085100 | 8.07e-01 |
| Butyrophilin (BTN) family interactions | 10 | 6.42e-01 | 0.085000 | 8.17e-01 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 184 | 4.68e-02 | -0.085000 | 2.16e-01 |
| VEGFA-VEGFR2 Pathway | 90 | 1.65e-01 | -0.084700 | 4.40e-01 |
| Termination of translesion DNA synthesis | 32 | 4.07e-01 | 0.084700 | 6.76e-01 |
| Transcriptional regulation by small RNAs | 63 | 2.46e-01 | -0.084600 | 5.35e-01 |
| Neuronal System | 262 | 1.86e-02 | -0.084500 | 1.18e-01 |
| Post-translational protein phosphorylation | 69 | 2.27e-01 | -0.084200 | 5.18e-01 |
| Mitochondrial biogenesis | 89 | 1.71e-01 | -0.084000 | 4.50e-01 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 4.67e-01 | -0.084000 | 7.11e-01 |
| FCERI mediated MAPK activation | 90 | 1.70e-01 | 0.083600 | 4.50e-01 |
| MyD88 dependent cascade initiated on endosome | 88 | 1.76e-01 | -0.083400 | 4.60e-01 |
| Cyclin E associated events during G1/S transition | 83 | 1.89e-01 | 0.083300 | 4.79e-01 |
| Diseases of programmed cell death | 27 | 4.54e-01 | -0.083300 | 7.00e-01 |
| Hedgehog ligand biogenesis | 59 | 2.68e-01 | 0.083300 | 5.64e-01 |
| Frs2-mediated activation | 11 | 6.32e-01 | -0.083300 | 8.11e-01 |
| Regulation of ornithine decarboxylase (ODC) | 50 | 3.09e-01 | 0.083100 | 5.99e-01 |
| Activation of gene expression by SREBF (SREBP) | 42 | 3.52e-01 | -0.083100 | 6.37e-01 |
| Metabolism of polyamines | 58 | 2.74e-01 | 0.083000 | 5.70e-01 |
| HIV Transcription Initiation | 45 | 3.37e-01 | 0.082800 | 6.25e-01 |
| RNA Polymerase II HIV Promoter Escape | 45 | 3.37e-01 | 0.082800 | 6.25e-01 |
| RNA Polymerase II Promoter Escape | 45 | 3.37e-01 | 0.082800 | 6.25e-01 |
| RNA Polymerase II Transcription Initiation | 45 | 3.37e-01 | 0.082800 | 6.25e-01 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | 45 | 3.37e-01 | 0.082800 | 6.25e-01 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 45 | 3.37e-01 | 0.082800 | 6.25e-01 |
| SHC1 events in EGFR signaling | 12 | 6.22e-01 | -0.082100 | 8.07e-01 |
| Stabilization of p53 | 55 | 2.92e-01 | 0.082100 | 5.80e-01 |
| Sema3A PAK dependent Axon repulsion | 16 | 5.71e-01 | -0.081700 | 7.77e-01 |
| Disease | 1354 | 4.44e-07 | -0.081700 | 1.69e-05 |
| Activation of kainate receptors upon glutamate binding | 26 | 4.71e-01 | -0.081700 | 7.11e-01 |
| Sema4D in semaphorin signaling | 22 | 5.08e-01 | -0.081400 | 7.35e-01 |
| Anchoring of the basal body to the plasma membrane | 96 | 1.68e-01 | 0.081400 | 4.46e-01 |
| Hemostasis | 546 | 1.15e-03 | -0.081400 | 1.89e-02 |
| NOD1/2 Signaling Pathway | 32 | 4.26e-01 | 0.081300 | 6.87e-01 |
| Cilium Assembly | 180 | 6.12e-02 | 0.080900 | 2.56e-01 |
| Transcriptional activation of mitochondrial biogenesis | 51 | 3.19e-01 | -0.080700 | 6.08e-01 |
| Aggrephagy | 22 | 5.13e-01 | -0.080500 | 7.37e-01 |
| Advanced glycosylation endproduct receptor signaling | 12 | 6.30e-01 | -0.080300 | 8.11e-01 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | 40 | 3.79e-01 | -0.080300 | 6.56e-01 |
| Keratan sulfate/keratin metabolism | 27 | 4.70e-01 | -0.080200 | 7.11e-01 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 51 | 3.22e-01 | 0.080200 | 6.10e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 6.07e-01 | 0.079500 | 7.96e-01 |
| Acyl chain remodelling of PS | 14 | 6.07e-01 | 0.079300 | 7.96e-01 |
| Glutathione conjugation | 26 | 4.85e-01 | 0.079100 | 7.23e-01 |
| Budding and maturation of HIV virion | 26 | 4.85e-01 | -0.079100 | 7.23e-01 |
| Beta-catenin independent WNT signaling | 137 | 1.12e-01 | -0.078600 | 3.61e-01 |
| Platelet sensitization by LDL | 16 | 5.87e-01 | 0.078400 | 7.85e-01 |
| Ub-specific processing proteases | 171 | 7.73e-02 | 0.078300 | 2.98e-01 |
| MAP kinase activation | 63 | 2.83e-01 | -0.078100 | 5.70e-01 |
| Deadenylation-dependent mRNA decay | 53 | 3.27e-01 | 0.077800 | 6.18e-01 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 89 | 2.04e-01 | -0.077800 | 4.93e-01 |
| Opioid Signalling | 75 | 2.45e-01 | -0.077700 | 5.35e-01 |
| Hh mutants abrogate ligand secretion | 55 | 3.19e-01 | 0.077600 | 6.09e-01 |
| mRNA decay by 3’ to 5’ exoribonuclease | 16 | 5.91e-01 | -0.077600 | 7.88e-01 |
| Degradation of GLI1 by the proteasome | 58 | 3.08e-01 | 0.077400 | 5.98e-01 |
| Mitochondrial translation elongation | 91 | 2.02e-01 | -0.077300 | 4.93e-01 |
| Protein localization | 157 | 9.45e-02 | -0.077300 | 3.33e-01 |
| G alpha (i) signalling events | 245 | 3.74e-02 | -0.077200 | 1.88e-01 |
| IRS-mediated signalling | 34 | 4.36e-01 | -0.077200 | 6.96e-01 |
| Regulation of PLK1 Activity at G2/M Transition | 86 | 2.16e-01 | 0.077100 | 5.08e-01 |
| Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 17 | 5.82e-01 | -0.077100 | 7.83e-01 |
| Neurotransmitter receptors and postsynaptic signal transmission | 127 | 1.34e-01 | -0.077100 | 3.91e-01 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 5.83e-01 | 0.077000 | 7.83e-01 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 5.83e-01 | 0.077000 | 7.83e-01 |
| G-protein activation | 23 | 5.24e-01 | 0.076800 | 7.41e-01 |
| Clathrin-mediated endocytosis | 127 | 1.36e-01 | -0.076600 | 3.92e-01 |
| Rho GTPase cycle | 125 | 1.40e-01 | -0.076300 | 3.99e-01 |
| Signaling by TGFB family members | 91 | 2.10e-01 | -0.076100 | 5.01e-01 |
| Formation of TC-NER Pre-Incision Complex | 53 | 3.39e-01 | -0.075900 | 6.27e-01 |
| Regulation of RAS by GAPs | 67 | 2.83e-01 | 0.075900 | 5.70e-01 |
| Interleukin-6 family signaling | 19 | 5.67e-01 | -0.075800 | 7.74e-01 |
| Hh mutants that don’t undergo autocatalytic processing are degraded by ERAD | 54 | 3.37e-01 | 0.075500 | 6.25e-01 |
| Interleukin receptor SHC signaling | 23 | 5.32e-01 | -0.075300 | 7.48e-01 |
| mTORC1-mediated signalling | 24 | 5.25e-01 | -0.075000 | 7.42e-01 |
| Striated Muscle Contraction | 25 | 5.16e-01 | -0.075000 | 7.39e-01 |
| RHO GTPases Activate ROCKs | 18 | 5.82e-01 | 0.074900 | 7.83e-01 |
| RAS processing | 19 | 5.74e-01 | -0.074500 | 7.79e-01 |
| RHO GTPases activate PAKs | 20 | 5.65e-01 | 0.074400 | 7.73e-01 |
| ADP signalling through P2Y purinoceptor 12 | 18 | 5.90e-01 | 0.073300 | 7.87e-01 |
| FCERI mediated Ca+2 mobilization | 89 | 2.33e-01 | 0.073200 | 5.27e-01 |
| Transcriptional regulation of white adipocyte differentiation | 77 | 2.67e-01 | -0.073100 | 5.63e-01 |
| SCF-beta-TrCP mediated degradation of Emi1 | 54 | 3.53e-01 | 0.073100 | 6.37e-01 |
| CD28 dependent Vav1 pathway | 12 | 6.61e-01 | 0.073100 | 8.30e-01 |
| Ion channel transport | 136 | 1.43e-01 | -0.072700 | 4.04e-01 |
| Fatty acyl-CoA biosynthesis | 34 | 4.63e-01 | 0.072700 | 7.07e-01 |
| Signal Transduction | 1899 | 1.85e-07 | -0.072200 | 8.10e-06 |
| Acyl chain remodelling of PC | 19 | 5.86e-01 | 0.072200 | 7.85e-01 |
| Cyclin A:Cdk2-associated events at S phase entry | 85 | 2.51e-01 | 0.072100 | 5.41e-01 |
| Epigenetic regulation of gene expression | 100 | 2.13e-01 | -0.072000 | 5.05e-01 |
| AURKA Activation by TPX2 | 71 | 2.95e-01 | 0.071900 | 5.81e-01 |
| GPVI-mediated activation cascade | 31 | 4.88e-01 | -0.071900 | 7.24e-01 |
| RNA Polymerase I Transcription Termination | 27 | 5.19e-01 | 0.071700 | 7.39e-01 |
| RIPK1-mediated regulated necrosis | 29 | 5.04e-01 | 0.071700 | 7.33e-01 |
| Regulated Necrosis | 29 | 5.04e-01 | 0.071700 | 7.33e-01 |
| Regulation of necroptotic cell death | 29 | 5.04e-01 | 0.071700 | 7.33e-01 |
| Sphingolipid metabolism | 78 | 2.77e-01 | -0.071200 | 5.70e-01 |
| DNA strand elongation | 32 | 4.86e-01 | 0.071200 | 7.23e-01 |
| GRB2 events in ERBB2 signaling | 11 | 6.83e-01 | -0.071000 | 8.46e-01 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | 38 | 4.50e-01 | -0.070900 | 6.98e-01 |
| Signaling by RAS mutants | 38 | 4.50e-01 | -0.070900 | 6.98e-01 |
| Signaling by moderate kinase activity BRAF mutants | 38 | 4.50e-01 | -0.070900 | 6.98e-01 |
| Signaling downstream of RAS mutants | 38 | 4.50e-01 | -0.070900 | 6.98e-01 |
| GABA synthesis, release, reuptake and degradation | 13 | 6.59e-01 | -0.070600 | 8.29e-01 |
| Recognition of DNA damage by PCNA-containing replication complex | 30 | 5.04e-01 | 0.070500 | 7.33e-01 |
| Synthesis of PIPs at the plasma membrane | 52 | 3.80e-01 | -0.070400 | 6.56e-01 |
| Transport of small molecules | 563 | 4.43e-03 | -0.070100 | 4.76e-02 |
| UCH proteinases | 87 | 2.59e-01 | -0.070100 | 5.54e-01 |
| Cell surface interactions at the vascular wall | 174 | 1.11e-01 | -0.070000 | 3.59e-01 |
| Iron uptake and transport | 52 | 3.84e-01 | -0.069800 | 6.58e-01 |
| SARS-CoV Infections | 140 | 1.54e-01 | -0.069800 | 4.26e-01 |
| FCERI mediated NF-kB activation | 138 | 1.57e-01 | 0.069700 | 4.31e-01 |
| Beta-oxidation of very long chain fatty acids | 10 | 7.03e-01 | -0.069700 | 8.59e-01 |
| PI-3K cascade:FGFR2 | 12 | 6.76e-01 | 0.069600 | 8.42e-01 |
| Regulation of signaling by CBL | 18 | 6.09e-01 | -0.069600 | 7.96e-01 |
| RNA Polymerase III Transcription Termination | 23 | 5.64e-01 | -0.069600 | 7.73e-01 |
| FOXO-mediated transcription | 59 | 3.57e-01 | -0.069400 | 6.39e-01 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 49 | 4.01e-01 | 0.069300 | 6.74e-01 |
| DAP12 interactions | 39 | 4.56e-01 | -0.069000 | 7.02e-01 |
| Beta-catenin phosphorylation cascade | 17 | 6.24e-01 | -0.068600 | 8.07e-01 |
| Sulfur amino acid metabolism | 23 | 5.69e-01 | -0.068500 | 7.76e-01 |
| SLC-mediated transmembrane transport | 180 | 1.13e-01 | -0.068400 | 3.62e-01 |
| G beta:gamma signalling through BTK | 15 | 6.48e-01 | 0.068100 | 8.21e-01 |
| Cyclin D associated events in G1 | 47 | 4.20e-01 | 0.068000 | 6.83e-01 |
| G1 Phase | 47 | 4.20e-01 | 0.068000 | 6.83e-01 |
| Translesion synthesis by POLK | 17 | 6.30e-01 | 0.067400 | 8.11e-01 |
| Toll Like Receptor 9 (TLR9) Cascade | 92 | 2.66e-01 | -0.067100 | 5.62e-01 |
| Carnitine metabolism | 10 | 7.14e-01 | -0.067100 | 8.65e-01 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 51 | 4.09e-01 | 0.066800 | 6.76e-01 |
| p53-Independent DNA Damage Response | 51 | 4.09e-01 | 0.066800 | 6.76e-01 |
| p53-Independent G1/S DNA damage checkpoint | 51 | 4.09e-01 | 0.066800 | 6.76e-01 |
| Insulin receptor recycling | 21 | 5.98e-01 | -0.066400 | 7.93e-01 |
| IL-6-type cytokine receptor ligand interactions | 13 | 6.79e-01 | -0.066200 | 8.45e-01 |
| Class I peroxisomal membrane protein import | 20 | 6.09e-01 | 0.066000 | 7.96e-01 |
| Alpha-protein kinase 1 signaling pathway | 11 | 7.05e-01 | -0.065900 | 8.61e-01 |
| PKMTs methylate histone lysines | 45 | 4.45e-01 | -0.065800 | 6.98e-01 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 17 | 6.39e-01 | 0.065600 | 8.16e-01 |
| Unblocking of NMDA receptors, glutamate binding and activation | 13 | 6.85e-01 | -0.065100 | 8.47e-01 |
| ER-Phagosome pathway | 83 | 3.06e-01 | 0.064900 | 5.97e-01 |
| Antigen processing-Cross presentation | 98 | 2.67e-01 | 0.064800 | 5.63e-01 |
| Neurotransmitter release cycle | 37 | 4.97e-01 | 0.064600 | 7.32e-01 |
| Energy dependent regulation of mTOR by LKB1-AMPK | 28 | 5.55e-01 | 0.064500 | 7.69e-01 |
| Listeria monocytogenes entry into host cells | 17 | 6.46e-01 | -0.064400 | 8.20e-01 |
| APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 5.85e-01 | 0.064400 | 7.85e-01 |
| Interaction between L1 and Ankyrins | 22 | 6.02e-01 | 0.064300 | 7.96e-01 |
| Signaling by RAF1 mutants | 34 | 5.18e-01 | -0.064100 | 7.39e-01 |
| IRF3-mediated induction of type I IFN | 12 | 7.02e-01 | -0.063900 | 8.59e-01 |
| Adrenaline,noradrenaline inhibits insulin secretion | 24 | 5.88e-01 | -0.063800 | 7.85e-01 |
| Degradation of GLI2 by the proteasome | 57 | 4.06e-01 | 0.063600 | 6.76e-01 |
| RNA Polymerase II Transcription Termination | 65 | 3.76e-01 | 0.063400 | 6.55e-01 |
| SHC1 events in ERBB2 signaling | 17 | 6.51e-01 | -0.063400 | 8.22e-01 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 31 | 5.42e-01 | -0.063300 | 7.58e-01 |
| Autodegradation of Cdh1 by Cdh1:APC/C | 64 | 3.81e-01 | 0.063300 | 6.56e-01 |
| Global Genome Nucleotide Excision Repair (GG-NER) | 84 | 3.17e-01 | 0.063200 | 6.07e-01 |
| Vif-mediated degradation of APOBEC3G | 53 | 4.28e-01 | 0.062900 | 6.89e-01 |
| Translesion synthesis by POLI | 17 | 6.54e-01 | 0.062900 | 8.24e-01 |
| Signaling by Activin | 10 | 7.31e-01 | -0.062700 | 8.76e-01 |
| Degradation of AXIN | 54 | 4.27e-01 | 0.062500 | 6.88e-01 |
| activated TAK1 mediates p38 MAPK activation | 19 | 6.38e-01 | -0.062300 | 8.16e-01 |
| Signaling by Interleukins | 388 | 3.80e-02 | -0.061400 | 1.89e-01 |
| Interleukin-10 signaling | 37 | 5.19e-01 | -0.061200 | 7.39e-01 |
| MAPK6/MAPK4 signaling | 83 | 3.36e-01 | 0.061100 | 6.25e-01 |
| Mismatch Repair | 15 | 6.83e-01 | 0.060900 | 8.46e-01 |
| Signaling by ERBB4 | 44 | 4.87e-01 | -0.060500 | 7.23e-01 |
| COPII-mediated vesicle transport | 65 | 3.99e-01 | 0.060400 | 6.73e-01 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 92 | 3.17e-01 | -0.060300 | 6.07e-01 |
| Toll Like Receptor 2 (TLR2) Cascade | 92 | 3.17e-01 | -0.060300 | 6.07e-01 |
| Toll Like Receptor TLR1:TLR2 Cascade | 92 | 3.17e-01 | -0.060300 | 6.07e-01 |
| Toll Like Receptor TLR6:TLR2 Cascade | 92 | 3.17e-01 | -0.060300 | 6.07e-01 |
| Defective CFTR causes cystic fibrosis | 60 | 4.20e-01 | 0.060200 | 6.83e-01 |
| COPI-dependent Golgi-to-ER retrograde traffic | 78 | 3.58e-01 | 0.060200 | 6.41e-01 |
| Dual Incision in GG-NER | 41 | 5.05e-01 | 0.060200 | 7.33e-01 |
| TRAF6 mediated NF-kB activation | 23 | 6.18e-01 | -0.060000 | 8.05e-01 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 7.31e-01 | 0.059900 | 8.76e-01 |
| Negative regulation of MAPK pathway | 42 | 5.02e-01 | -0.059900 | 7.33e-01 |
| ROS and RNS production in phagocytes | 31 | 5.65e-01 | -0.059700 | 7.73e-01 |
| Prefoldin mediated transfer of substrate to CCT/TriC | 26 | 5.98e-01 | -0.059700 | 7.93e-01 |
| RHO GTPases activate KTN1 | 11 | 7.35e-01 | 0.058900 | 8.79e-01 |
| Signaling by NTRK3 (TRKC) | 16 | 6.83e-01 | -0.058900 | 8.46e-01 |
| Regulated proteolysis of p75NTR | 11 | 7.36e-01 | -0.058800 | 8.79e-01 |
| ER to Golgi Anterograde Transport | 129 | 2.49e-01 | 0.058800 | 5.41e-01 |
| Folding of actin by CCT/TriC | 10 | 7.48e-01 | 0.058700 | 8.90e-01 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 29 | 5.87e-01 | -0.058300 | 7.85e-01 |
| Metalloprotease DUBs | 21 | 6.44e-01 | 0.058200 | 8.19e-01 |
| Platelet homeostasis | 69 | 4.03e-01 | -0.058200 | 6.74e-01 |
| Role of phospholipids in phagocytosis | 88 | 3.45e-01 | 0.058200 | 6.31e-01 |
| G-protein beta:gamma signalling | 29 | 5.88e-01 | -0.058100 | 7.85e-01 |
| Golgi-to-ER retrograde transport | 111 | 2.90e-01 | 0.058100 | 5.80e-01 |
| COPI-mediated anterograde transport | 78 | 3.76e-01 | 0.058000 | 6.55e-01 |
| FLT3 Signaling | 245 | 1.19e-01 | -0.057900 | 3.71e-01 |
| Signaling by FGFR3 | 31 | 5.77e-01 | -0.057900 | 7.81e-01 |
| Mitochondrial tRNA aminoacylation | 21 | 6.49e-01 | 0.057300 | 8.21e-01 |
| Class I MHC mediated antigen processing & presentation | 349 | 6.61e-02 | 0.057300 | 2.68e-01 |
| NOTCH2 intracellular domain regulates transcription | 11 | 7.43e-01 | -0.057100 | 8.85e-01 |
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | 25 | 6.22e-01 | -0.056900 | 8.07e-01 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 25 | 6.23e-01 | 0.056700 | 8.07e-01 |
| Costimulation by the CD28 family | 74 | 4.00e-01 | -0.056600 | 6.73e-01 |
| Loss of Nlp from mitotic centrosomes | 68 | 4.20e-01 | 0.056600 | 6.83e-01 |
| Loss of proteins required for interphase microtubule organization from the centrosome | 68 | 4.20e-01 | 0.056600 | 6.83e-01 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 84 | 3.70e-01 | 0.056500 | 6.52e-01 |
| GPCR ligand binding | 237 | 1.34e-01 | -0.056500 | 3.91e-01 |
| Metabolism of nucleotides | 86 | 3.71e-01 | -0.055800 | 6.52e-01 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 6.92e-01 | 0.055600 | 8.53e-01 |
| Vpu mediated degradation of CD4 | 51 | 4.97e-01 | 0.055000 | 7.32e-01 |
| PTEN Regulation | 139 | 2.63e-01 | -0.055000 | 5.62e-01 |
| Zinc transporters | 14 | 7.22e-01 | 0.054900 | 8.73e-01 |
| Transmission across Chemical Synapses | 173 | 2.13e-01 | -0.054900 | 5.05e-01 |
| Mitochondrial translation initiation | 91 | 3.66e-01 | -0.054900 | 6.50e-01 |
| Glucose metabolism | 83 | 3.88e-01 | -0.054800 | 6.64e-01 |
| Formation of tubulin folding intermediates by CCT/TriC | 22 | 6.58e-01 | -0.054600 | 8.28e-01 |
| tRNA modification in the nucleus and cytosol | 43 | 5.36e-01 | 0.054600 | 7.51e-01 |
| Metabolism of RNA | 688 | 1.52e-02 | -0.054300 | 1.01e-01 |
| VEGFR2 mediated vascular permeability | 26 | 6.32e-01 | -0.054300 | 8.11e-01 |
| Regulation of TP53 Degradation | 35 | 5.80e-01 | -0.054000 | 7.83e-01 |
| Regulation of PTEN stability and activity | 67 | 4.45e-01 | 0.054000 | 6.98e-01 |
| SUMOylation of chromatin organization proteins | 57 | 4.86e-01 | 0.053400 | 7.23e-01 |
| Mitochondrial iron-sulfur cluster biogenesis | 13 | 7.40e-01 | 0.053200 | 8.82e-01 |
| Mitochondrial translation termination | 91 | 3.82e-01 | -0.053000 | 6.56e-01 |
| COPI-independent Golgi-to-ER retrograde traffic | 33 | 6.00e-01 | 0.052700 | 7.94e-01 |
| MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 6.11e-01 | -0.052700 | 7.98e-01 |
| PI-3K cascade:FGFR4 | 10 | 7.73e-01 | -0.052700 | 9.02e-01 |
| Stimuli-sensing channels | 75 | 4.30e-01 | -0.052700 | 6.91e-01 |
| NIK–>noncanonical NF-kB signaling | 58 | 4.89e-01 | 0.052500 | 7.24e-01 |
| FCGR3A-mediated IL10 synthesis | 99 | 3.68e-01 | 0.052300 | 6.50e-01 |
| Unwinding of DNA | 12 | 7.54e-01 | -0.052200 | 8.92e-01 |
| Signaling by FGFR1 | 38 | 5.77e-01 | -0.052200 | 7.81e-01 |
| Intra-Golgi traffic | 43 | 5.54e-01 | -0.052200 | 7.68e-01 |
| Translesion Synthesis by POLH | 18 | 7.03e-01 | -0.051900 | 8.59e-01 |
| Amine ligand-binding receptors | 10 | 7.76e-01 | 0.051900 | 9.05e-01 |
| Activation of BAD and translocation to mitochondria | 15 | 7.31e-01 | -0.051200 | 8.76e-01 |
| Negative regulators of DDX58/IFIH1 signaling | 34 | 6.06e-01 | 0.051100 | 7.96e-01 |
| Regulation of TNFR1 signaling | 34 | 6.07e-01 | -0.051000 | 7.96e-01 |
| HIV Life Cycle | 144 | 2.91e-01 | 0.050900 | 5.80e-01 |
| Triglyceride catabolism | 16 | 7.26e-01 | -0.050700 | 8.73e-01 |
| RAF/MAP kinase cascade | 231 | 1.85e-01 | -0.050600 | 4.75e-01 |
| Negative regulation of NOTCH4 signaling | 54 | 5.21e-01 | 0.050500 | 7.39e-01 |
| NCAM1 interactions | 23 | 6.75e-01 | 0.050500 | 8.42e-01 |
| Activation of GABAB receptors | 31 | 6.29e-01 | 0.050200 | 8.11e-01 |
| GABA B receptor activation | 31 | 6.29e-01 | 0.050200 | 8.11e-01 |
| RA biosynthesis pathway | 13 | 7.54e-01 | -0.050200 | 8.92e-01 |
| Signaling by Retinoic Acid | 32 | 6.25e-01 | -0.050000 | 8.07e-01 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 29 | 6.43e-01 | -0.049800 | 8.18e-01 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 78 | 4.49e-01 | -0.049500 | 6.98e-01 |
| Intraflagellar transport | 39 | 5.94e-01 | 0.049400 | 7.90e-01 |
| Dectin-2 family | 19 | 7.10e-01 | 0.049200 | 8.65e-01 |
| Association of TriC/CCT with target proteins during biosynthesis | 37 | 6.05e-01 | -0.049100 | 7.96e-01 |
| Detoxification of Reactive Oxygen Species | 32 | 6.31e-01 | -0.049100 | 8.11e-01 |
| Transcriptional regulation of pluripotent stem cells | 21 | 6.97e-01 | 0.049000 | 8.57e-01 |
| RAB geranylgeranylation | 62 | 5.05e-01 | 0.049000 | 7.33e-01 |
| TP53 Regulates Transcription of Cell Cycle Genes | 47 | 5.64e-01 | 0.048600 | 7.73e-01 |
| Vitamin B5 (pantothenate) metabolism | 17 | 7.29e-01 | 0.048600 | 8.76e-01 |
| Peptide ligand-binding receptors | 97 | 4.09e-01 | -0.048500 | 6.76e-01 |
| Signal amplification | 28 | 6.57e-01 | 0.048400 | 8.28e-01 |
| Class A/1 (Rhodopsin-like receptors) | 170 | 2.79e-01 | -0.048200 | 5.70e-01 |
| Dual incision in TC-NER | 65 | 5.03e-01 | -0.048000 | 7.33e-01 |
| Metabolism of steroids | 119 | 3.68e-01 | 0.047800 | 6.50e-01 |
| EPHA-mediated growth cone collapse | 13 | 7.66e-01 | 0.047600 | 8.99e-01 |
| Defects in vitamin and cofactor metabolism | 21 | 7.06e-01 | 0.047600 | 8.61e-01 |
| PI-3K cascade:FGFR1 | 12 | 7.76e-01 | 0.047500 | 9.05e-01 |
| Signal transduction by L1 | 20 | 7.14e-01 | -0.047400 | 8.65e-01 |
| Regulation of actin dynamics for phagocytic cup formation | 123 | 3.65e-01 | 0.047300 | 6.49e-01 |
| Metabolic disorders of biological oxidation enzymes | 24 | 6.88e-01 | -0.047300 | 8.50e-01 |
| Diseases of signal transduction by growth factor receptors and second messengers | 342 | 1.35e-01 | -0.047000 | 3.92e-01 |
| MAPK1/MAPK3 signaling | 236 | 2.14e-01 | -0.047000 | 5.06e-01 |
| Processive synthesis on the lagging strand | 15 | 7.53e-01 | 0.047000 | 8.92e-01 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 25 | 6.86e-01 | -0.046700 | 8.48e-01 |
| Signaling by the B Cell Receptor (BCR) | 163 | 3.07e-01 | 0.046400 | 5.97e-01 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 30 | 6.61e-01 | 0.046300 | 8.30e-01 |
| Selective autophagy | 59 | 5.44e-01 | -0.045600 | 7.60e-01 |
| Muscle contraction | 138 | 3.56e-01 | -0.045600 | 6.39e-01 |
| GLI3 is processed to GLI3R by the proteasome | 58 | 5.50e-01 | 0.045400 | 7.66e-01 |
| Acyl chain remodelling of PE | 20 | 7.26e-01 | 0.045300 | 8.73e-01 |
| RNA Polymerase I Transcription Initiation | 44 | 6.04e-01 | -0.045200 | 7.96e-01 |
| Transferrin endocytosis and recycling | 26 | 6.91e-01 | -0.045000 | 8.53e-01 |
| Fc epsilon receptor (FCERI) signaling | 191 | 2.84e-01 | 0.044900 | 5.70e-01 |
| Late Phase of HIV Life Cycle | 131 | 3.75e-01 | 0.044900 | 6.54e-01 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 10 | 8.06e-01 | -0.044800 | 9.23e-01 |
| Downstream signaling of activated FGFR4 | 17 | 7.50e-01 | 0.044600 | 8.90e-01 |
| Signaling by GPCR | 547 | 7.60e-02 | -0.044300 | 2.94e-01 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 7.52e-01 | 0.044300 | 8.91e-01 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 73 | 5.14e-01 | 0.044200 | 7.37e-01 |
| Antigen processing: Ubiquitination & Proteasome degradation | 288 | 1.98e-01 | 0.044100 | 4.87e-01 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 36 | 6.49e-01 | 0.043800 | 8.21e-01 |
| Calnexin/calreticulin cycle | 26 | 7.02e-01 | -0.043300 | 8.59e-01 |
| Innate Immune System | 968 | 2.26e-02 | -0.043300 | 1.36e-01 |
| HCMV Infection | 96 | 4.64e-01 | -0.043200 | 7.07e-01 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | 83 | 4.96e-01 | -0.043200 | 7.32e-01 |
| Centrosome maturation | 80 | 5.06e-01 | 0.043000 | 7.33e-01 |
| Recruitment of mitotic centrosome proteins and complexes | 80 | 5.06e-01 | 0.043000 | 7.33e-01 |
| Gene Silencing by RNA | 88 | 4.87e-01 | -0.042900 | 7.23e-01 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 7.97e-01 | -0.042800 | 9.17e-01 |
| E3 ubiquitin ligases ubiquitinate target proteins | 52 | 5.95e-01 | -0.042600 | 7.91e-01 |
| Regulation of TP53 Activity | 153 | 3.64e-01 | 0.042500 | 6.48e-01 |
| Regulation of HSF1-mediated heat shock response | 79 | 5.14e-01 | 0.042500 | 7.37e-01 |
| Amino acids regulate mTORC1 | 50 | 6.04e-01 | -0.042400 | 7.96e-01 |
| Autodegradation of the E3 ubiquitin ligase COP1 | 50 | 6.04e-01 | 0.042400 | 7.96e-01 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 65 | 5.59e-01 | 0.041900 | 7.70e-01 |
| RNA Polymerase III Transcription Initiation | 36 | 6.64e-01 | -0.041900 | 8.32e-01 |
| Processing of Capped Intron-Containing Pre-mRNA | 238 | 2.68e-01 | 0.041700 | 5.64e-01 |
| Signaling by SCF-KIT | 40 | 6.50e-01 | -0.041500 | 8.21e-01 |
| p130Cas linkage to MAPK signaling for integrins | 11 | 8.12e-01 | -0.041500 | 9.25e-01 |
| Signalling to RAS | 18 | 7.62e-01 | 0.041200 | 8.97e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 7.90e-01 | 0.041100 | 9.14e-01 |
| Nuclear Envelope (NE) Reassembly | 69 | 5.55e-01 | 0.041100 | 7.69e-01 |
| Glutathione synthesis and recycling | 10 | 8.22e-01 | -0.041000 | 9.31e-01 |
| Interleukin-35 Signalling | 12 | 8.07e-01 | 0.040800 | 9.23e-01 |
| ABC transporters in lipid homeostasis | 14 | 7.92e-01 | 0.040600 | 9.15e-01 |
| Nucleobase catabolism | 28 | 7.12e-01 | -0.040400 | 8.65e-01 |
| Regulation of TP53 Expression and Degradation | 36 | 6.77e-01 | -0.040200 | 8.42e-01 |
| Macroautophagy | 111 | 4.66e-01 | -0.040100 | 7.09e-01 |
| Glutamate Neurotransmitter Release Cycle | 20 | 7.57e-01 | 0.039900 | 8.93e-01 |
| Downstream signal transduction | 27 | 7.23e-01 | 0.039500 | 8.73e-01 |
| Toll Like Receptor 3 (TLR3) Cascade | 92 | 5.13e-01 | -0.039500 | 7.37e-01 |
| Potential therapeutics for SARS | 78 | 5.48e-01 | -0.039300 | 7.64e-01 |
| Dectin-1 mediated noncanonical NF-kB signaling | 60 | 5.99e-01 | 0.039300 | 7.93e-01 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 32 | 7.02e-01 | -0.039100 | 8.59e-01 |
| DNA Repair | 289 | 2.58e-01 | 0.038700 | 5.53e-01 |
| Deubiquitination | 242 | 3.01e-01 | 0.038600 | 5.90e-01 |
| Autophagy | 125 | 4.64e-01 | -0.038000 | 7.07e-01 |
| Downstream signaling events of B Cell Receptor (BCR) | 80 | 5.57e-01 | 0.037900 | 7.70e-01 |
| O-linked glycosylation of mucins | 47 | 6.53e-01 | -0.037900 | 8.24e-01 |
| Leishmania infection | 246 | 3.06e-01 | -0.037900 | 5.97e-01 |
| Regulation of insulin secretion | 60 | 6.14e-01 | -0.037700 | 8.00e-01 |
| Chaperonin-mediated protein folding | 84 | 5.52e-01 | -0.037500 | 7.68e-01 |
| CLEC7A (Dectin-1) induces NFAT activation | 11 | 8.29e-01 | -0.037500 | 9.32e-01 |
| Signaling by KIT in disease | 20 | 7.73e-01 | 0.037300 | 9.02e-01 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 20 | 7.73e-01 | 0.037300 | 9.02e-01 |
| Regulation of IFNA signaling | 12 | 8.24e-01 | 0.037200 | 9.31e-01 |
| GPCR downstream signalling | 501 | 1.54e-01 | -0.037200 | 4.26e-01 |
| Inactivation, recovery and regulation of the phototransduction cascade | 25 | 7.49e-01 | 0.036900 | 8.90e-01 |
| Interleukin-2 family signaling | 38 | 6.97e-01 | -0.036500 | 8.57e-01 |
| Receptor Mediated Mitophagy | 11 | 8.34e-01 | 0.036400 | 9.32e-01 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 18 | 7.89e-01 | -0.036400 | 9.14e-01 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | 18 | 7.89e-01 | -0.036400 | 9.14e-01 |
| Peroxisomal protein import | 57 | 6.38e-01 | 0.036100 | 8.16e-01 |
| Signaling by NTRK2 (TRKB) | 20 | 7.82e-01 | 0.035700 | 9.10e-01 |
| SUMO E3 ligases SUMOylate target proteins | 161 | 4.35e-01 | -0.035700 | 6.96e-01 |
| ADP signalling through P2Y purinoceptor 1 | 21 | 7.79e-01 | 0.035400 | 9.07e-01 |
| Apoptotic execution phase | 45 | 6.82e-01 | 0.035400 | 8.46e-01 |
| Programmed Cell Death | 180 | 4.13e-01 | 0.035400 | 6.82e-01 |
| MAPK family signaling cascades | 270 | 3.20e-01 | -0.035200 | 6.09e-01 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | 88 | 5.71e-01 | 0.034900 | 7.77e-01 |
| Signaling by ERBB2 in Cancer | 21 | 7.86e-01 | 0.034200 | 9.13e-01 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 24 | 7.72e-01 | 0.034200 | 9.02e-01 |
| Protein folding | 90 | 5.75e-01 | -0.034200 | 7.79e-01 |
| Metabolism of proteins | 1721 | 1.86e-02 | -0.034100 | 1.18e-01 |
| Tie2 Signaling | 16 | 8.14e-01 | 0.033900 | 9.27e-01 |
| Toll Like Receptor 4 (TLR4) Cascade | 121 | 5.20e-01 | -0.033900 | 7.39e-01 |
| Transport of bile salts and organic acids, metal ions and amine compounds | 55 | 6.64e-01 | -0.033900 | 8.32e-01 |
| FCGR3A-mediated phagocytosis | 121 | 5.21e-01 | 0.033800 | 7.39e-01 |
| Leishmania phagocytosis | 121 | 5.21e-01 | 0.033800 | 7.39e-01 |
| Parasite infection | 121 | 5.21e-01 | 0.033800 | 7.39e-01 |
| Phospholipid metabolism | 184 | 4.36e-01 | -0.033300 | 6.96e-01 |
| Mitochondrial translation | 97 | 5.74e-01 | -0.033100 | 7.79e-01 |
| TNFR1-induced proapoptotic signaling | 12 | 8.44e-01 | 0.032800 | 9.36e-01 |
| Regulation of RUNX1 Expression and Activity | 18 | 8.10e-01 | -0.032700 | 9.24e-01 |
| Chromosome Maintenance | 105 | 5.65e-01 | -0.032500 | 7.73e-01 |
| Adherens junctions interactions | 17 | 8.17e-01 | -0.032400 | 9.27e-01 |
| mRNA Capping | 29 | 7.65e-01 | -0.032000 | 8.99e-01 |
| DARPP-32 events | 22 | 7.97e-01 | -0.031700 | 9.17e-01 |
| Glycerophospholipid biosynthesis | 106 | 5.74e-01 | -0.031600 | 7.79e-01 |
| Acyl chain remodelling of PI | 10 | 8.63e-01 | -0.031600 | 9.52e-01 |
| Signaling by ERBB2 KD Mutants | 20 | 8.07e-01 | 0.031500 | 9.23e-01 |
| Diseases associated with the TLR signaling cascade | 23 | 7.95e-01 | 0.031300 | 9.16e-01 |
| Diseases of Immune System | 23 | 7.95e-01 | 0.031300 | 9.16e-01 |
| ABC-family proteins mediated transport | 94 | 6.08e-01 | 0.030600 | 7.96e-01 |
| Recruitment of NuMA to mitotic centrosomes | 79 | 6.40e-01 | 0.030500 | 8.16e-01 |
| Triglyceride metabolism | 25 | 7.96e-01 | 0.029900 | 9.17e-01 |
| Cytosolic sulfonation of small molecules | 18 | 8.28e-01 | -0.029500 | 9.32e-01 |
| L1CAM interactions | 85 | 6.38e-01 | -0.029500 | 8.16e-01 |
| HIV Infection | 225 | 4.48e-01 | 0.029400 | 6.98e-01 |
| Apoptosis | 168 | 5.11e-01 | 0.029400 | 7.37e-01 |
| Oncogenic MAPK signaling | 73 | 6.64e-01 | 0.029400 | 8.32e-01 |
| MyD88-independent TLR4 cascade | 96 | 6.25e-01 | -0.028900 | 8.07e-01 |
| TRIF(TICAM1)-mediated TLR4 signaling | 96 | 6.25e-01 | -0.028900 | 8.07e-01 |
| Meiotic recombination | 38 | 7.59e-01 | -0.028800 | 8.94e-01 |
| Surfactant metabolism | 22 | 8.15e-01 | 0.028700 | 9.27e-01 |
| trans-Golgi Network Vesicle Budding | 69 | 6.80e-01 | -0.028700 | 8.45e-01 |
| Diseases of DNA repair | 10 | 8.75e-01 | 0.028700 | 9.61e-01 |
| Ubiquitin-dependent degradation of Cyclin D | 51 | 7.26e-01 | 0.028400 | 8.73e-01 |
| TNF signaling | 43 | 7.48e-01 | -0.028300 | 8.90e-01 |
| Signaling by FGFR in disease | 50 | 7.32e-01 | 0.028000 | 8.77e-01 |
| Viral Messenger RNA Synthesis | 44 | 7.48e-01 | 0.028000 | 8.90e-01 |
| Interleukin-6 signaling | 10 | 8.79e-01 | -0.027800 | 9.62e-01 |
| RNA Polymerase II Pre-transcription Events | 78 | 6.71e-01 | 0.027800 | 8.39e-01 |
| Metabolism of steroid hormones | 20 | 8.30e-01 | 0.027700 | 9.32e-01 |
| Pyruvate metabolism | 28 | 8.04e-01 | 0.027100 | 9.22e-01 |
| TRP channels | 19 | 8.39e-01 | 0.027000 | 9.33e-01 |
| Myogenesis | 21 | 8.32e-01 | 0.026800 | 9.32e-01 |
| Biological oxidations | 136 | 5.93e-01 | -0.026500 | 7.90e-01 |
| Metabolism of vitamins and cofactors | 158 | 5.66e-01 | -0.026500 | 7.73e-01 |
| PCNA-Dependent Long Patch Base Excision Repair | 21 | 8.34e-01 | 0.026500 | 9.32e-01 |
| Signaling by MET | 61 | 7.21e-01 | -0.026400 | 8.72e-01 |
| Organelle biogenesis and maintenance | 269 | 4.57e-01 | 0.026300 | 7.02e-01 |
| Protein ubiquitination | 72 | 7.02e-01 | -0.026100 | 8.59e-01 |
| Glycolysis | 66 | 7.14e-01 | -0.026100 | 8.65e-01 |
| Transcriptional regulation by RUNX2 | 102 | 6.49e-01 | 0.026100 | 8.21e-01 |
| RHO GTPases Activate WASPs and WAVEs | 35 | 7.90e-01 | -0.026000 | 9.14e-01 |
| Fatty acid metabolism | 153 | 5.82e-01 | -0.025800 | 7.83e-01 |
| Transcription of the HIV genome | 67 | 7.18e-01 | 0.025500 | 8.69e-01 |
| Removal of the Flap Intermediate from the C-strand | 17 | 8.57e-01 | 0.025200 | 9.48e-01 |
| Immune System | 1896 | 7.16e-02 | -0.025000 | 2.83e-01 |
| The canonical retinoid cycle in rods (twilight vision) | 10 | 8.92e-01 | -0.024800 | 9.63e-01 |
| Interconversion of nucleotide di- and triphosphates | 27 | 8.24e-01 | 0.024700 | 9.31e-01 |
| Scavenging by Class A Receptors | 12 | 8.83e-01 | 0.024500 | 9.63e-01 |
| RAB GEFs exchange GTP for GDP on RABs | 87 | 6.95e-01 | -0.024300 | 8.56e-01 |
| Signaling by Rho GTPases | 365 | 4.36e-01 | -0.023700 | 6.96e-01 |
| Signaling by FGFR2 in disease | 32 | 8.17e-01 | -0.023600 | 9.27e-01 |
| Degradation of DVL | 55 | 7.62e-01 | 0.023600 | 8.97e-01 |
| Eicosanoid ligand-binding receptors | 13 | 8.83e-01 | -0.023500 | 9.63e-01 |
| Aflatoxin activation and detoxification | 15 | 8.75e-01 | -0.023500 | 9.61e-01 |
| Hedgehog ‘on’ state | 76 | 7.25e-01 | 0.023300 | 8.73e-01 |
| Synthesis of PIPs at the Golgi membrane | 16 | 8.72e-01 | 0.023200 | 9.61e-01 |
| Nucleotide Excision Repair | 110 | 6.76e-01 | -0.023100 | 8.42e-01 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | 16 | 8.74e-01 | -0.022900 | 9.61e-01 |
| Regulation of RUNX3 expression and activity | 55 | 7.71e-01 | 0.022700 | 9.02e-01 |
| PI Metabolism | 79 | 7.28e-01 | -0.022600 | 8.76e-01 |
| Retrograde transport at the Trans-Golgi-Network | 49 | 7.86e-01 | 0.022400 | 9.13e-01 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 63 | 7.63e-01 | 0.022000 | 8.97e-01 |
| Metabolism of amine-derived hormones | 10 | 9.05e-01 | -0.021700 | 9.65e-01 |
| Purine salvage | 12 | 8.99e-01 | 0.021200 | 9.63e-01 |
| Anti-inflammatory response favouring Leishmania parasite infection | 170 | 6.33e-01 | -0.021200 | 8.11e-01 |
| Leishmania parasite growth and survival | 170 | 6.33e-01 | -0.021200 | 8.11e-01 |
| STING mediated induction of host immune responses | 15 | 8.88e-01 | 0.021000 | 9.63e-01 |
| Transcriptional Regulation by VENTX | 38 | 8.24e-01 | 0.020800 | 9.31e-01 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 43 | 8.16e-01 | -0.020500 | 9.27e-01 |
| Telomere C-strand (Lagging Strand) Synthesis | 34 | 8.43e-01 | 0.019700 | 9.36e-01 |
| Diseases associated with glycosylation precursor biosynthesis | 18 | 8.86e-01 | 0.019500 | 9.63e-01 |
| Generic Transcription Pathway | 1087 | 2.80e-01 | -0.019400 | 5.70e-01 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 38 | 8.36e-01 | 0.019400 | 9.33e-01 |
| AMER1 mutants destabilize the destruction complex | 14 | 9.02e-01 | -0.019100 | 9.63e-01 |
| APC truncation mutants have impaired AXIN binding | 14 | 9.02e-01 | -0.019100 | 9.63e-01 |
| AXIN missense mutants destabilize the destruction complex | 14 | 9.02e-01 | -0.019100 | 9.63e-01 |
| AXIN mutants destabilize the destruction complex, activating WNT signaling | 14 | 9.02e-01 | -0.019100 | 9.63e-01 |
| Truncations of AMER1 destabilize the destruction complex | 14 | 9.02e-01 | -0.019100 | 9.63e-01 |
| truncated APC mutants destabilize the destruction complex | 14 | 9.02e-01 | -0.019100 | 9.63e-01 |
| NCAM signaling for neurite out-growth | 43 | 8.29e-01 | 0.019000 | 9.32e-01 |
| Signalling to ERKs | 31 | 8.55e-01 | 0.018900 | 9.47e-01 |
| Asymmetric localization of PCP proteins | 61 | 7.99e-01 | -0.018800 | 9.18e-01 |
| CD209 (DC-SIGN) signaling | 20 | 8.85e-01 | -0.018600 | 9.63e-01 |
| mRNA Splicing - Major Pathway | 179 | 6.67e-01 | -0.018600 | 8.35e-01 |
| TP53 Regulates Transcription of Cell Death Genes | 43 | 8.34e-01 | 0.018500 | 9.32e-01 |
| tRNA processing | 136 | 7.10e-01 | -0.018400 | 8.65e-01 |
| Synthesis of IP2, IP, and Ins in the cytosol | 13 | 9.09e-01 | 0.018400 | 9.66e-01 |
| Thromboxane signalling through TP receptor | 20 | 8.89e-01 | -0.018100 | 9.63e-01 |
| Downstream TCR signaling | 101 | 7.56e-01 | 0.017900 | 8.92e-01 |
| Negative regulation of MET activity | 18 | 8.96e-01 | -0.017800 | 9.63e-01 |
| Metabolism of lipids | 624 | 4.49e-01 | -0.017800 | 6.98e-01 |
| Growth hormone receptor signaling | 20 | 8.91e-01 | -0.017700 | 9.63e-01 |
| RNA Polymerase III Abortive And Retractive Initiation | 41 | 8.45e-01 | -0.017700 | 9.36e-01 |
| RNA Polymerase III Transcription | 41 | 8.45e-01 | -0.017700 | 9.36e-01 |
| SUMOylation | 167 | 6.95e-01 | -0.017600 | 8.56e-01 |
| Activation of NF-kappaB in B cells | 66 | 8.07e-01 | 0.017400 | 9.23e-01 |
| mRNA decay by 5’ to 3’ exoribonuclease | 15 | 9.08e-01 | -0.017200 | 9.66e-01 |
| SHC-mediated cascade:FGFR4 | 10 | 9.26e-01 | 0.016900 | 9.76e-01 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 14 | 9.13e-01 | -0.016900 | 9.68e-01 |
| SLC transporter disorders | 76 | 8.00e-01 | -0.016800 | 9.19e-01 |
| Erythropoietin activates RAS | 13 | 9.17e-01 | 0.016700 | 9.71e-01 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 23 | 8.91e-01 | 0.016500 | 9.63e-01 |
| Pyruvate metabolism and Citric Acid (TCA) cycle | 52 | 8.40e-01 | 0.016200 | 9.34e-01 |
| TNFR2 non-canonical NF-kB pathway | 96 | 7.84e-01 | 0.016200 | 9.11e-01 |
| MET promotes cell motility | 26 | 8.86e-01 | 0.016200 | 9.63e-01 |
| Ca2+ pathway | 57 | 8.34e-01 | -0.016000 | 9.32e-01 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 9.27e-01 | -0.015900 | 9.76e-01 |
| C-type lectin receptors (CLRs) | 130 | 7.56e-01 | 0.015800 | 8.92e-01 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 18 | 9.08e-01 | -0.015800 | 9.66e-01 |
| Membrane Trafficking | 559 | 5.27e-01 | -0.015600 | 7.43e-01 |
| Synthesis of PA | 32 | 8.79e-01 | 0.015600 | 9.62e-01 |
| Metal ion SLC transporters | 21 | 9.07e-01 | 0.014700 | 9.66e-01 |
| Translesion synthesis by REV1 | 16 | 9.19e-01 | 0.014600 | 9.72e-01 |
| Reproduction | 81 | 8.22e-01 | -0.014400 | 9.31e-01 |
| Signaling by ERBB2 TMD/JMD mutants | 17 | 9.18e-01 | -0.014400 | 9.72e-01 |
| DAP12 signaling | 28 | 8.95e-01 | 0.014300 | 9.63e-01 |
| Dissolution of Fibrin Clot | 12 | 9.32e-01 | 0.014200 | 9.78e-01 |
| Mitotic Prophase | 98 | 8.09e-01 | 0.014200 | 9.23e-01 |
| Interleukin-1 signaling | 98 | 8.09e-01 | -0.014100 | 9.23e-01 |
| Sialic acid metabolism | 28 | 8.97e-01 | 0.014100 | 9.63e-01 |
| Transport to the Golgi and subsequent modification | 155 | 7.70e-01 | 0.013600 | 9.02e-01 |
| Telomere Extension By Telomerase | 23 | 9.10e-01 | -0.013600 | 9.67e-01 |
| Unfolded Protein Response (UPR) | 88 | 8.27e-01 | 0.013500 | 9.32e-01 |
| FRS-mediated FGFR4 signaling | 12 | 9.36e-01 | 0.013500 | 9.78e-01 |
| Signaling by NOTCH4 | 79 | 8.37e-01 | -0.013400 | 9.33e-01 |
| Interleukin-37 signaling | 19 | 9.20e-01 | -0.013400 | 9.72e-01 |
| Signaling by PDGF | 44 | 8.79e-01 | 0.013300 | 9.62e-01 |
| Ovarian tumor domain proteases | 37 | 8.89e-01 | 0.013300 | 9.63e-01 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | 10 | 9.43e-01 | 0.013200 | 9.78e-01 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 16 | 9.27e-01 | 0.013200 | 9.76e-01 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) | 36 | 8.96e-01 | -0.012600 | 9.63e-01 |
| Generation of second messenger molecules | 38 | 8.94e-01 | -0.012500 | 9.63e-01 |
| RHO GTPase Effectors | 249 | 7.36e-01 | 0.012400 | 8.79e-01 |
| Purine ribonucleoside monophosphate biosynthesis | 10 | 9.47e-01 | 0.012200 | 9.78e-01 |
| TNFR1-induced NFkappaB signaling pathway | 25 | 9.17e-01 | 0.012000 | 9.71e-01 |
| Intrinsic Pathway for Apoptosis | 53 | 8.81e-01 | -0.011900 | 9.63e-01 |
| PPARA activates gene expression | 104 | 8.35e-01 | 0.011800 | 9.32e-01 |
| Mitochondrial Fatty Acid Beta-Oxidation | 36 | 9.02e-01 | -0.011800 | 9.63e-01 |
| TCR signaling | 122 | 8.25e-01 | 0.011600 | 9.31e-01 |
| Cellular response to heat stress | 93 | 8.47e-01 | -0.011600 | 9.39e-01 |
| Sphingolipid de novo biosynthesis | 42 | 8.99e-01 | 0.011300 | 9.63e-01 |
| Potassium Channels | 66 | 8.77e-01 | 0.011000 | 9.62e-01 |
| Methylation | 12 | 9.48e-01 | 0.010800 | 9.78e-01 |
| Interleukin-1 family signaling | 125 | 8.39e-01 | -0.010600 | 9.33e-01 |
| Misspliced GSK3beta mutants stabilize beta-catenin | 15 | 9.44e-01 | 0.010400 | 9.78e-01 |
| S33 mutants of beta-catenin aren’t phosphorylated | 15 | 9.44e-01 | 0.010400 | 9.78e-01 |
| S37 mutants of beta-catenin aren’t phosphorylated | 15 | 9.44e-01 | 0.010400 | 9.78e-01 |
| S45 mutants of beta-catenin aren’t phosphorylated | 15 | 9.44e-01 | 0.010400 | 9.78e-01 |
| T41 mutants of beta-catenin aren’t phosphorylated | 15 | 9.44e-01 | 0.010400 | 9.78e-01 |
| phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex | 15 | 9.44e-01 | 0.010400 | 9.78e-01 |
| Nucleotide-like (purinergic) receptors | 13 | 9.48e-01 | 0.010300 | 9.78e-01 |
| Toll-like Receptor Cascades | 143 | 8.31e-01 | -0.010300 | 9.32e-01 |
| Prolonged ERK activation events | 13 | 9.49e-01 | -0.010200 | 9.78e-01 |
| KSRP (KHSRP) binds and destabilizes mRNA | 17 | 9.42e-01 | 0.010200 | 9.78e-01 |
| Fcgamma receptor (FCGR) dependent phagocytosis | 147 | 8.31e-01 | 0.010200 | 9.32e-01 |
| Kinesins | 39 | 9.13e-01 | -0.010100 | 9.68e-01 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | 54 | 8.99e-01 | 0.010000 | 9.63e-01 |
| Telomere C-strand synthesis initiation | 13 | 9.51e-01 | 0.009860 | 9.78e-01 |
| MHC class II antigen presentation | 101 | 8.73e-01 | 0.009230 | 9.61e-01 |
| Processing of SMDT1 | 15 | 9.51e-01 | -0.009120 | 9.78e-01 |
| Processive synthesis on the C-strand of the telomere | 19 | 9.46e-01 | 0.009020 | 9.78e-01 |
| Ras activation upon Ca2+ influx through NMDA receptor | 16 | 9.50e-01 | -0.009000 | 9.78e-01 |
| Citric acid cycle (TCA cycle) | 22 | 9.44e-01 | 0.008700 | 9.78e-01 |
| Translocation of ZAP-70 to Immunological synapse | 24 | 9.42e-01 | -0.008600 | 9.78e-01 |
| TP53 Regulates Metabolic Genes | 86 | 8.91e-01 | -0.008580 | 9.63e-01 |
| Disorders of transmembrane transporters | 147 | 8.62e-01 | -0.008300 | 9.52e-01 |
| Endogenous sterols | 16 | 9.55e-01 | -0.008090 | 9.79e-01 |
| Diseases associated with N-glycosylation of proteins | 17 | 9.54e-01 | 0.008000 | 9.79e-01 |
| Apoptotic cleavage of cellular proteins | 34 | 9.40e-01 | 0.007470 | 9.78e-01 |
| Hedgehog ‘off’ state | 93 | 9.02e-01 | -0.007350 | 9.63e-01 |
| Depolymerisation of the Nuclear Lamina | 15 | 9.61e-01 | -0.007250 | 9.79e-01 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 9.28e-01 | 0.007030 | 9.76e-01 |
| Netrin-1 signaling | 40 | 9.40e-01 | 0.006930 | 9.78e-01 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 9.50e-01 | -0.006830 | 9.78e-01 |
| Factors involved in megakaryocyte development and platelet production | 116 | 8.99e-01 | -0.006800 | 9.63e-01 |
| Lysine catabolism | 11 | 9.69e-01 | -0.006740 | 9.83e-01 |
| Cellular response to hypoxia | 72 | 9.22e-01 | 0.006650 | 9.73e-01 |
| PD-1 signaling | 28 | 9.53e-01 | 0.006470 | 9.78e-01 |
| Signaling by BRAF and RAF fusions | 57 | 9.35e-01 | -0.006270 | 9.78e-01 |
| Degradation of beta-catenin by the destruction complex | 84 | 9.22e-01 | -0.006210 | 9.73e-01 |
| Phosphorylation of CD3 and TCR zeta chains | 27 | 9.56e-01 | -0.006160 | 9.79e-01 |
| The phototransduction cascade | 26 | 9.57e-01 | 0.006090 | 9.79e-01 |
| Transport of vitamins, nucleosides, and related molecules | 33 | 9.52e-01 | -0.006040 | 9.78e-01 |
| Gene expression (Transcription) | 1334 | 7.12e-01 | 0.006020 | 8.65e-01 |
| p38MAPK events | 13 | 9.70e-01 | 0.005930 | 9.83e-01 |
| Asparagine N-linked glycosylation | 269 | 8.68e-01 | 0.005870 | 9.57e-01 |
| Deposition of new CENPA-containing nucleosomes at the centromere | 40 | 9.50e-01 | 0.005750 | 9.78e-01 |
| Nucleosome assembly | 40 | 9.50e-01 | 0.005750 | 9.78e-01 |
| Transcriptional regulation by RUNX3 | 90 | 9.29e-01 | -0.005420 | 9.76e-01 |
| mRNA Splicing | 187 | 9.01e-01 | -0.005290 | 9.63e-01 |
| Fanconi Anemia Pathway | 36 | 9.59e-01 | -0.004980 | 9.79e-01 |
| Cytochrome P450 - arranged by substrate type | 36 | 9.59e-01 | 0.004900 | 9.79e-01 |
| Prostacyclin signalling through prostacyclin receptor | 16 | 9.74e-01 | 0.004630 | 9.84e-01 |
| Post-translational protein modification | 1196 | 7.92e-01 | -0.004520 | 9.15e-01 |
| Nicotinate metabolism | 26 | 9.68e-01 | -0.004510 | 9.83e-01 |
| MTOR signalling | 40 | 9.61e-01 | 0.004410 | 9.79e-01 |
| Transcriptional Regulation by TP53 | 352 | 8.88e-01 | 0.004370 | 9.63e-01 |
| Polymerase switching on the C-strand of the telomere | 26 | 9.71e-01 | -0.004080 | 9.83e-01 |
| Regulation of lipid metabolism by PPARalpha | 106 | 9.45e-01 | 0.003910 | 9.78e-01 |
| Cytokine Signaling in Immune system | 738 | 8.58e-01 | 0.003860 | 9.48e-01 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | 179 | 9.36e-01 | 0.003490 | 9.78e-01 |
| Meiosis | 68 | 9.62e-01 | 0.003310 | 9.80e-01 |
| ER Quality Control Compartment (ERQC) | 21 | 9.81e-01 | -0.003070 | 9.89e-01 |
| Protein methylation | 15 | 9.84e-01 | -0.002920 | 9.92e-01 |
| Synthesis of substrates in N-glycan biosythesis | 58 | 9.69e-01 | -0.002910 | 9.83e-01 |
| Signaling by Hedgehog | 121 | 9.56e-01 | 0.002890 | 9.79e-01 |
| Post-translational modification: synthesis of GPI-anchored proteins | 58 | 9.70e-01 | -0.002860 | 9.83e-01 |
| Xenobiotics | 12 | 9.87e-01 | -0.002620 | 9.93e-01 |
| Cardiac conduction | 87 | 9.71e-01 | 0.002290 | 9.83e-01 |
| HCMV Early Events | 74 | 9.73e-01 | -0.002240 | 9.84e-01 |
| Neddylation | 219 | 9.57e-01 | 0.002130 | 9.79e-01 |
| Golgi Associated Vesicle Biogenesis | 55 | 9.79e-01 | -0.002100 | 9.88e-01 |
| SHC1 events in ERBB4 signaling | 10 | 9.91e-01 | 0.002060 | 9.95e-01 |
| Extension of Telomeres | 51 | 9.81e-01 | -0.001960 | 9.89e-01 |
| Interleukin-20 family signaling | 17 | 9.93e-01 | 0.001290 | 9.95e-01 |
| Receptor-type tyrosine-protein phosphatases | 12 | 9.94e-01 | 0.001270 | 9.95e-01 |
| Vesicle-mediated transport | 649 | 9.68e-01 | 0.000910 | 9.83e-01 |
| ABC transporter disorders | 71 | 9.90e-01 | 0.000845 | 9.95e-01 |
| RNA Polymerase II Transcription | 1206 | 9.61e-01 | 0.000843 | 9.79e-01 |
| Host Interactions of HIV factors | 130 | 9.87e-01 | 0.000801 | 9.93e-01 |
| SLBP independent Processing of Histone Pre-mRNAs | 10 | 9.97e-01 | 0.000778 | 9.97e-01 |
| CLEC7A (Dectin-1) signaling | 98 | 9.93e-01 | 0.000533 | 9.95e-01 |
| Metabolism of water-soluble vitamins and cofactors | 112 | 9.94e-01 | 0.000417 | 9.95e-01 |
| Adaptive Immune System | 758 | 9.89e-01 | -0.000294 | 9.94e-01 |
Peptide chain elongation
| 810 | |
|---|---|
| set | Peptide chain elongation |
| setSize | 88 |
| pANOVA | 6.36e-25 |
| s.dist | -0.635 |
| p.adjustANOVA | 4.35e-22 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| EEF2 | -10214 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| EEF2 | -10214 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| EEF1A1 | -7887 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| RPL19 | -6701 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| RPL36A | -5966 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| RPL5 | -5445 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| RPL10A | -4820 |
| RPL23 | -4456 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| RPS24 | -89 |
| RPL23A | 138 |
| RPL6 | 1290 |
| RPS4X | 1825 |
| RPS3A | 3173 |
| RPSA | 5249 |
| RPL22L1 | 8317 |
| RPL3L | 8978 |
| RPS27L | 9625 |
Eukaryotic Translation Elongation
| 353 | |
|---|---|
| set | Eukaryotic Translation Elongation |
| setSize | 93 |
| pANOVA | 5.98e-26 |
| s.dist | -0.631 |
| p.adjustANOVA | 8.18e-23 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| EEF2 | -10214 |
| RPLP2 | -10185 |
| EEF1G | -10158 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| EEF1D | -9841 |
| EEF1B2 | -9772 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| EEF2 | -10214 |
| RPLP2 | -10185 |
| EEF1G | -10158 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| EEF1D | -9841 |
| EEF1B2 | -9772 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| EEF1A1 | -7887 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| RPL19 | -6701 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| RPL36A | -5966 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| EEF1A1P5 | -5668 |
| RPL5 | -5445 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| RPL10A | -4820 |
| RPL23 | -4456 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| RPS24 | -89 |
| RPL23A | 138 |
| RPL6 | 1290 |
| RPS4X | 1825 |
| RPS3A | 3173 |
| RPSA | 5249 |
| EEF1A2 | 7880 |
| RPL22L1 | 8317 |
| RPL3L | 8978 |
| RPS27L | 9625 |
Viral mRNA Translation
| 1318 | |
|---|---|
| set | Viral mRNA Translation |
| setSize | 88 |
| pANOVA | 1.04e-22 |
| s.dist | -0.604 |
| p.adjustANOVA | 2.37e-20 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| RPL19 | -6701 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| RPL36A | -5966 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| RPL5 | -5445 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| RPL10A | -4820 |
| RPL23 | -4456 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| RPS24 | -89 |
| RPL23A | 138 |
| RPL6 | 1290 |
| RPS4X | 1825 |
| RPS3A | 3173 |
| GRSF1 | 4059 |
| RPSA | 5249 |
| DNAJC3 | 7755 |
| RPL22L1 | 8317 |
| RPL3L | 8978 |
| RPS27L | 9625 |
Eukaryotic Translation Termination
| 355 | |
|---|---|
| set | Eukaryotic Translation Termination |
| setSize | 92 |
| pANOVA | 5.46e-23 |
| s.dist | -0.595 |
| p.adjustANOVA | 1.87e-20 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| TRMT112 | -8912 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| APEH | -8642 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| RPL19 | -6701 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| RPL36A | -5966 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| RPL5 | -5445 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| RPL10A | -4820 |
| RPL23 | -4456 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| GSPT2 | -972 |
| RPS24 | -89 |
| RPL23A | 138 |
| N6AMT1 | 251 |
| RPL6 | 1290 |
| RPS4X | 1825 |
| RPS3A | 3173 |
| RPSA | 5249 |
| GSPT1 | 7510 |
| ETF1 | 8214 |
| RPL22L1 | 8317 |
| RPL3L | 8978 |
| RPS27L | 9625 |
Selenocysteine synthesis
| 1063 | |
|---|---|
| set | Selenocysteine synthesis |
| setSize | 92 |
| pANOVA | 8.98e-23 |
| s.dist | -0.592 |
| p.adjustANOVA | 2.37e-20 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| RPL19 | -6701 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| SARS1 | -6084 |
| RPL36A | -5966 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| RPL5 | -5445 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| EEFSEC | -5241 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| RPL10A | -4820 |
| RPL23 | -4456 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| PSTK | -2534 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| RPS24 | -89 |
| SEPHS2 | -59 |
| RPL23A | 138 |
| RPL6 | 1290 |
| RPS4X | 1825 |
| RPS3A | 3173 |
| RPSA | 5249 |
| SEPSECS | 7020 |
| SECISBP2 | 7391 |
| RPL22L1 | 8317 |
| RPL3L | 8978 |
| RPS27L | 9625 |
Formation of a pool of free 40S subunits
| 395 | |
|---|---|
| set | Formation of a pool of free 40S subunits |
| setSize | 100 |
| pANOVA | 1.32e-23 |
| s.dist | -0.579 |
| p.adjustANOVA | 6.02e-21 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| EIF3C | -9873 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| EIF3G | -9710 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| EIF3C | -9873 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| EIF3G | -9710 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| EIF3L | -9269 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| EIF3B | -8804 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| EIF3I | -7931 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| RPL19 | -6701 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| EIF3K | -6222 |
| RPL36A | -5966 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| EIF3D | -5647 |
| RPL5 | -5445 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| RPL10A | -4820 |
| RPL23 | -4456 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| EIF3H | -1365 |
| RPS24 | -89 |
| RPL23A | 138 |
| RPL6 | 1290 |
| RPS4X | 1825 |
| EIF3A | 1969 |
| RPS3A | 3173 |
| RPSA | 5249 |
| EIF3E | 8272 |
| RPL22L1 | 8317 |
| EIF3M | 8578 |
| EIF1AX | 8776 |
| RPL3L | 8978 |
| RPS27L | 9625 |
| EIF3J | 9804 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
| 746 | |
|---|---|
| set | Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) |
| setSize | 94 |
| pANOVA | 1.41e-20 |
| s.dist | -0.554 |
| p.adjustANOVA | 2.75e-18 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| EIF4G1 | -7029 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| UPF1 | -6778 |
| RPL19 | -6701 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| RPL36A | -5966 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| RPL5 | -5445 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| RPL10A | -4820 |
| RPL23 | -4456 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| GSPT2 | -972 |
| RPS24 | -89 |
| RPL23A | 138 |
| RPL6 | 1290 |
| RPS4X | 1825 |
| RPS3A | 3173 |
| PABPC1 | 4591 |
| RPSA | 5249 |
| GSPT1 | 7510 |
| ETF1 | 8214 |
| RPL22L1 | 8317 |
| RPL3L | 8978 |
| RPS27L | 9625 |
| NCBP1 | 10864 |
| NCBP2 | 11208 |
Incretin synthesis, secretion, and inactivation
| 525 | |
|---|---|
| set | Incretin synthesis, secretion, and inactivation |
| setSize | 10 |
| pANOVA | 0.0036 |
| s.dist | 0.532 |
| p.adjustANOVA | 0.0406 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TCF7L2 | 11426 |
| SPCS2 | 11036 |
| SEC11C | 10820 |
| SPCS3 | 10797 |
| GNB3 | 6586 |
| CTNNB1 | 5359 |
| SPCS1 | 4379 |
| FFAR4 | 4223 |
| SEC11A | 1049 |
| DPP4 | -128 |
| GeneID | Gene Rank |
|---|---|
| TCF7L2 | 11426 |
| SPCS2 | 11036 |
| SEC11C | 10820 |
| SPCS3 | 10797 |
| GNB3 | 6586 |
| CTNNB1 | 5359 |
| SPCS1 | 4379 |
| FFAR4 | 4223 |
| SEC11A | 1049 |
| DPP4 | -128 |
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
| 1185 | |
|---|---|
| set | Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) |
| setSize | 10 |
| pANOVA | 0.0036 |
| s.dist | 0.532 |
| p.adjustANOVA | 0.0406 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TCF7L2 | 11426 |
| SPCS2 | 11036 |
| SEC11C | 10820 |
| SPCS3 | 10797 |
| GNB3 | 6586 |
| CTNNB1 | 5359 |
| SPCS1 | 4379 |
| FFAR4 | 4223 |
| SEC11A | 1049 |
| DPP4 | -128 |
| GeneID | Gene Rank |
|---|---|
| TCF7L2 | 11426 |
| SPCS2 | 11036 |
| SEC11C | 10820 |
| SPCS3 | 10797 |
| GNB3 | 6586 |
| CTNNB1 | 5359 |
| SPCS1 | 4379 |
| FFAR4 | 4223 |
| SEC11A | 1049 |
| DPP4 | -128 |
NF-kB is activated and signals survival
| 700 | |
|---|---|
| set | NF-kB is activated and signals survival |
| setSize | 12 |
| pANOVA | 0.00207 |
| s.dist | -0.513 |
| p.adjustANOVA | 0.0281 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RELA | -9628 |
| IRAK1 | -9487 |
| RPS27A | -8388 |
| SQSTM1 | -7746 |
| UBA52 | -7375 |
| UBB | -4944 |
| NFKBIA | -4692 |
| IKBKB | -4462 |
| UBC | -4177 |
| NGFR | -2692 |
| NFKB1 | 1266 |
| TRAF6 | 2326 |
| GeneID | Gene Rank |
|---|---|
| RELA | -9628 |
| IRAK1 | -9487 |
| RPS27A | -8388 |
| SQSTM1 | -7746 |
| UBA52 | -7375 |
| UBB | -4944 |
| NFKBIA | -4692 |
| IKBKB | -4462 |
| UBC | -4177 |
| NGFR | -2692 |
| NFKB1 | 1266 |
| TRAF6 | 2326 |
WNT5A-dependent internalization of FZD4
| 1328 | |
|---|---|
| set | WNT5A-dependent internalization of FZD4 |
| setSize | 13 |
| pANOVA | 0.00153 |
| s.dist | -0.508 |
| p.adjustANOVA | 0.0237 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| DVL2 | -9361 |
| AP2M1 | -8930 |
| CLTB | -8800 |
| PRKCB | -8270 |
| AP2A2 | -7814 |
| AP2A1 | -6826 |
| PRKCA | -6088 |
| ARRB2 | -5337 |
| AP2S1 | -3863 |
| AP2B1 | -3395 |
| CLTA | 509 |
| CLTC | 1283 |
| FZD4 | 2728 |
| GeneID | Gene Rank |
|---|---|
| DVL2 | -9361 |
| AP2M1 | -8930 |
| CLTB | -8800 |
| PRKCB | -8270 |
| AP2A2 | -7814 |
| AP2A1 | -6826 |
| PRKCA | -6088 |
| ARRB2 | -5337 |
| AP2S1 | -3863 |
| AP2B1 | -3395 |
| CLTA | 509 |
| CLTC | 1283 |
| FZD4 | 2728 |
L13a-mediated translational silencing of Ceruloplasmin expression
| 591 | |
|---|---|
| set | L13a-mediated translational silencing of Ceruloplasmin expression |
| setSize | 110 |
| pANOVA | 5.78e-20 |
| s.dist | -0.504 |
| p.adjustANOVA | 9.88e-18 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| EIF3C | -9873 |
| RPL3 | -9867 |
| EIF4H | -9779 |
| RPL8 | -9738 |
| EIF3G | -9710 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| EIF3C | -9873 |
| RPL3 | -9867 |
| EIF4H | -9779 |
| RPL8 | -9738 |
| EIF3G | -9710 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| EIF3L | -9269 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| EIF3B | -8804 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| EIF3I | -7931 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| EIF4G1 | -7029 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| RPL19 | -6701 |
| EIF4B | -6655 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| EIF3K | -6222 |
| RPL36A | -5966 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| EIF3D | -5647 |
| RPL5 | -5445 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| RPL10A | -4820 |
| RPL23 | -4456 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| EIF3H | -1365 |
| RPS24 | -89 |
| RPL23A | 138 |
| RPL6 | 1290 |
| EIF4A1 | 1541 |
| RPS4X | 1825 |
| EIF3A | 1969 |
| RPS3A | 3173 |
| PABPC1 | 4591 |
| RPSA | 5249 |
| EIF3E | 8272 |
| RPL22L1 | 8317 |
| EIF3M | 8578 |
| EIF1AX | 8776 |
| RPL3L | 8978 |
| EIF2S2 | 9317 |
| EIF2S1 | 9563 |
| RPS27L | 9625 |
| EIF3J | 9804 |
| EIF4A2 | 10043 |
| EIF2S3 | 10258 |
| EIF4E | 11624 |
DNA methylation
| 247 | |
|---|---|
| set | DNA methylation |
| setSize | 20 |
| pANOVA | 0.000126 |
| s.dist | -0.495 |
| p.adjustANOVA | 0.00288 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| DNMT3B | -9878.0 |
| H2AZ1 | -8776.0 |
| H2BC12 | -8742.0 |
| DNMT1 | -8737.0 |
| DNMT3A | -8681.0 |
| H2BC17 | -8346.0 |
| H3C15 | -8038.5 |
| H2BC4 | -7928.0 |
| H2AJ | -7536.0 |
| H2BC9 | -6894.0 |
| H2BC11 | -5751.0 |
| H2BC21 | -5415.0 |
| H2BC15 | -4416.0 |
| H2AC6 | -4383.0 |
| H2BC5 | -3070.0 |
| H2AZ2 | -2475.0 |
| UHRF1 | 1351.0 |
| H2BU1 | 2721.0 |
| H2AC20 | 3907.0 |
| H3-3A | 5193.0 |
| GeneID | Gene Rank |
|---|---|
| DNMT3B | -9878.0 |
| H2AZ1 | -8776.0 |
| H2BC12 | -8742.0 |
| DNMT1 | -8737.0 |
| DNMT3A | -8681.0 |
| H2BC17 | -8346.0 |
| H3C15 | -8038.5 |
| H2BC4 | -7928.0 |
| H2AJ | -7536.0 |
| H2BC9 | -6894.0 |
| H2BC11 | -5751.0 |
| H2BC21 | -5415.0 |
| H2BC15 | -4416.0 |
| H2AC6 | -4383.0 |
| H2BC5 | -3070.0 |
| H2AZ2 | -2475.0 |
| UHRF1 | 1351.0 |
| H2BU1 | 2721.0 |
| H2AC20 | 3907.0 |
| H3-3A | 5193.0 |
Response of EIF2AK4 (GCN2) to amino acid deficiency
| 1010 | |
|---|---|
| set | Response of EIF2AK4 (GCN2) to amino acid deficiency |
| setSize | 100 |
| pANOVA | 1.78e-17 |
| s.dist | -0.492 |
| p.adjustANOVA | 2.02e-15 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| RPL19 | -6701 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| RPL36A | -5966 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| RPL5 | -5445 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| RPL10A | -4820 |
| RPL23 | -4456 |
| GCN1 | -4393 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| ATF4 | -3557 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| EIF2AK4 | -2072 |
| TRIB3 | -1393 |
| RPS24 | -89 |
| RPL23A | 138 |
| ATF3 | 451 |
| CEBPB | 621 |
| RPL6 | 1290 |
| RPS4X | 1825 |
| DDIT3 | 2994 |
| RPS3A | 3173 |
| RPSA | 5249 |
| RPL22L1 | 8317 |
| RPL3L | 8978 |
| ASNS | 9230 |
| EIF2S2 | 9317 |
| EIF2S1 | 9563 |
| RPS27L | 9625 |
| EIF2S3 | 10258 |
| IMPACT | 10622 |
| CEBPG | 11104 |
| ATF2 | 11312 |
VLDLR internalisation and degradation
| 1313 | |
|---|---|
| set | VLDLR internalisation and degradation |
| setSize | 11 |
| pANOVA | 0.005 |
| s.dist | -0.489 |
| p.adjustANOVA | 0.051 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NR1H2 | -9025 |
| AP2M1 | -8930 |
| AP2A2 | -7814 |
| AP2A1 | -6826 |
| NR1H3 | -4903 |
| MYLIP | -4778 |
| VLDLR | -4257 |
| AP2S1 | -3863 |
| AP2B1 | -3395 |
| CLTA | 509 |
| CLTC | 1283 |
| GeneID | Gene Rank |
|---|---|
| NR1H2 | -9025 |
| AP2M1 | -8930 |
| AP2A2 | -7814 |
| AP2A1 | -6826 |
| NR1H3 | -4903 |
| MYLIP | -4778 |
| VLDLR | -4257 |
| AP2S1 | -3863 |
| AP2B1 | -3395 |
| CLTA | 509 |
| CLTC | 1283 |
tRNA processing in the mitochondrion
| 1364 | |
|---|---|
| set | tRNA processing in the mitochondrion |
| setSize | 32 |
| pANOVA | 1.71e-06 |
| s.dist | -0.489 |
| p.adjustANOVA | 5.69e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MT-TS1 | -10372 |
| MT-TN | -10345 |
| MT-ATP8 | -10332 |
| MT-TC | -9831 |
| MT-ATP6 | -9606 |
| MT-TA | -9596 |
| MT-TP | -9309 |
| MT-ND4L | -9074 |
| MT-CO3 | -8680 |
| MT-ND3 | -8450 |
| MT-TV | -8443 |
| MT-TF | -8294 |
| MT-TL2 | -7298 |
| MT-TY | -7272 |
| MT-CYB | -7017 |
| MT-TM | -6674 |
| MT-ND1 | -6593 |
| MT-ND5 | -6176 |
| MT-CO2 | -5700 |
| MT-ND2 | -4966 |
| GeneID | Gene Rank |
|---|---|
| MT-TS1 | -10372 |
| MT-TN | -10345 |
| MT-ATP8 | -10332 |
| MT-TC | -9831 |
| MT-ATP6 | -9606 |
| MT-TA | -9596 |
| MT-TP | -9309 |
| MT-ND4L | -9074 |
| MT-CO3 | -8680 |
| MT-ND3 | -8450 |
| MT-TV | -8443 |
| MT-TF | -8294 |
| MT-TL2 | -7298 |
| MT-TY | -7272 |
| MT-CYB | -7017 |
| MT-TM | -6674 |
| MT-ND1 | -6593 |
| MT-ND5 | -6176 |
| MT-CO2 | -5700 |
| MT-ND2 | -4966 |
| MT-TL1 | -3853 |
| MT-TE | -3693 |
| MT-RNR2 | -3648 |
| MT-RNR1 | -3295 |
| HSD17B10 | -2865 |
| ELAC2 | -2324 |
| MT-CO1 | -685 |
| MT-ND6 | 1775 |
| MT-ND4 | 3305 |
| PRORP | 6071 |
| TRMT10C | 10717 |
| TRNT1 | 11446 |
GTP hydrolysis and joining of the 60S ribosomal subunit
| 437 | |
|---|---|
| set | GTP hydrolysis and joining of the 60S ribosomal subunit |
| setSize | 111 |
| pANOVA | 6.92e-19 |
| s.dist | -0.487 |
| p.adjustANOVA | 1.05e-16 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| EIF3C | -9873 |
| RPL3 | -9867 |
| EIF4H | -9779 |
| RPL8 | -9738 |
| EIF3G | -9710 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| EIF3C | -9873 |
| RPL3 | -9867 |
| EIF4H | -9779 |
| RPL8 | -9738 |
| EIF3G | -9710 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| EIF3L | -9269 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| EIF3B | -8804 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| EIF3I | -7931 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| EIF4G1 | -7029 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| RPL19 | -6701 |
| EIF4B | -6655 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| EIF3K | -6222 |
| RPL36A | -5966 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| EIF3D | -5647 |
| RPL5 | -5445 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| RPL10A | -4820 |
| RPL23 | -4456 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| EIF3H | -1365 |
| RPS24 | -89 |
| RPL23A | 138 |
| RPL6 | 1290 |
| EIF4A1 | 1541 |
| RPS4X | 1825 |
| EIF3A | 1969 |
| RPS3A | 3173 |
| RPSA | 5249 |
| EIF3E | 8272 |
| RPL22L1 | 8317 |
| EIF3M | 8578 |
| EIF1AX | 8776 |
| RPL3L | 8978 |
| EIF2S2 | 9317 |
| EIF2S1 | 9563 |
| RPS27L | 9625 |
| EIF3J | 9804 |
| EIF5B | 9825 |
| EIF4A2 | 10043 |
| EIF2S3 | 10258 |
| EIF5 | 10905 |
| EIF4E | 11624 |
AKT phosphorylates targets in the nucleus
| 9 | |
|---|---|
| set | AKT phosphorylates targets in the nucleus |
| setSize | 10 |
| pANOVA | 0.00821 |
| s.dist | -0.483 |
| p.adjustANOVA | 0.0681 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AKT2 | -10102 |
| FOXO4 | -9911 |
| AKT1 | -9799 |
| FOXO1 | -8143 |
| FOXO3 | -7061 |
| FOXO6 | -6422 |
| RPS6KB2 | -6218 |
| NR4A1 | 2131 |
| AKT3 | 2465 |
| CREB1 | 6457 |
| GeneID | Gene Rank |
|---|---|
| AKT2 | -10102 |
| FOXO4 | -9911 |
| AKT1 | -9799 |
| FOXO1 | -8143 |
| FOXO3 | -7061 |
| FOXO6 | -6422 |
| RPS6KB2 | -6218 |
| NR4A1 | 2131 |
| AKT3 | 2465 |
| CREB1 | 6457 |
CDC6 association with the ORC:origin complex
| 127 | |
|---|---|
| set | CDC6 association with the ORC:origin complex |
| setSize | 11 |
| pANOVA | 0.00597 |
| s.dist | 0.479 |
| p.adjustANOVA | 0.0562 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ORC3 | 11135 |
| ORC5 | 9801 |
| ORC4 | 9610 |
| E2F3 | 7730 |
| ORC2 | 7384 |
| CDC6 | 6081 |
| E2F2 | 4801 |
| MCM8 | 3500 |
| E2F1 | 3051 |
| ORC6 | 1568 |
| ORC1 | 1006 |
| GeneID | Gene Rank |
|---|---|
| ORC3 | 11135 |
| ORC5 | 9801 |
| ORC4 | 9610 |
| E2F3 | 7730 |
| ORC2 | 7384 |
| CDC6 | 6081 |
| E2F2 | 4801 |
| MCM8 | 3500 |
| E2F1 | 3051 |
| ORC6 | 1568 |
| ORC1 | 1006 |
Josephin domain DUBs
| 585 | |
|---|---|
| set | Josephin domain DUBs |
| setSize | 10 |
| pANOVA | 0.00889 |
| s.dist | -0.478 |
| p.adjustANOVA | 0.071 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| JOSD2 | -9000 |
| RPS27A | -8388 |
| JOSD1 | -8057 |
| UBA52 | -7375 |
| VCP | -5402 |
| UBB | -4944 |
| RAD23A | -4413 |
| UBC | -4177 |
| RAD23B | -1815 |
| ATXN3 | 7508 |
| GeneID | Gene Rank |
|---|---|
| JOSD2 | -9000 |
| RPS27A | -8388 |
| JOSD1 | -8057 |
| UBA52 | -7375 |
| VCP | -5402 |
| UBB | -4944 |
| RAD23A | -4413 |
| UBC | -4177 |
| RAD23B | -1815 |
| ATXN3 | 7508 |
Cytosolic iron-sulfur cluster assembly
| 229 | |
|---|---|
| set | Cytosolic iron-sulfur cluster assembly |
| setSize | 13 |
| pANOVA | 0.00362 |
| s.dist | -0.466 |
| p.adjustANOVA | 0.0406 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NUBP2 | -9876 |
| POLD1 | -8854 |
| CIAO2B | -8649 |
| CIAO3 | -8269 |
| CIAO1 | -7175 |
| CIAPIN1 | -6967 |
| ERCC2 | -6248 |
| RTEL1 | -6202 |
| NDOR1 | -4525 |
| MMS19 | -2760 |
| NUBP1 | -2271 |
| BRIP1 | 6803 |
| ABCB7 | 6813 |
| GeneID | Gene Rank |
|---|---|
| NUBP2 | -9876 |
| POLD1 | -8854 |
| CIAO2B | -8649 |
| CIAO3 | -8269 |
| CIAO1 | -7175 |
| CIAPIN1 | -6967 |
| ERCC2 | -6248 |
| RTEL1 | -6202 |
| NDOR1 | -4525 |
| MMS19 | -2760 |
| NUBP1 | -2271 |
| BRIP1 | 6803 |
| ABCB7 | 6813 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
| 745 | |
|---|---|
| set | Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) |
| setSize | 114 |
| pANOVA | 4.58e-17 |
| s.dist | -0.455 |
| p.adjustANOVA | 4.47e-15 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| MAGOH | -9339 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| MAGOH | -9339 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| PPP2R1A | -7631 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| EIF4G1 | -7029 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| SMG5 | -6880 |
| UPF1 | -6778 |
| RPL19 | -6701 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| RPL36A | -5966 |
| EIF4A3 | -5845 |
| RNPS1 | -5842 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| SMG6 | -5602 |
| RPL5 | -5445 |
| RBM8A | -5382 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| CASC3 | -5239 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| RPL10A | -4820 |
| RPL23 | -4456 |
| UPF3A | -4433 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| GSPT2 | -972 |
| RPS24 | -89 |
| RPL23A | 138 |
| SMG1 | 158 |
| SMG9 | 235 |
| RPL6 | 1290 |
| RPS4X | 1825 |
| RPS3A | 3173 |
| SMG7 | 4285 |
| PABPC1 | 4591 |
| RPSA | 5249 |
| PPP2CA | 5682 |
| SMG8 | 6313 |
| MAGOHB | 7179 |
| DCP1A | 7220 |
| GSPT1 | 7510 |
| UPF3B | 8196 |
| ETF1 | 8214 |
| RPL22L1 | 8317 |
| RPL3L | 8978 |
| RPS27L | 9625 |
| UPF2 | 10521 |
| NCBP1 | 10864 |
| NCBP2 | 11208 |
| PNRC2 | 11638 |
| PPP2R2A | 11691 |
Nonsense-Mediated Decay (NMD)
| 747 | |
|---|---|
| set | Nonsense-Mediated Decay (NMD) |
| setSize | 114 |
| pANOVA | 4.58e-17 |
| s.dist | -0.455 |
| p.adjustANOVA | 4.47e-15 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| MAGOH | -9339 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| MAGOH | -9339 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| PPP2R1A | -7631 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| EIF4G1 | -7029 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| SMG5 | -6880 |
| UPF1 | -6778 |
| RPL19 | -6701 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| RPL36A | -5966 |
| EIF4A3 | -5845 |
| RNPS1 | -5842 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| SMG6 | -5602 |
| RPL5 | -5445 |
| RBM8A | -5382 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| CASC3 | -5239 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| RPL10A | -4820 |
| RPL23 | -4456 |
| UPF3A | -4433 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| GSPT2 | -972 |
| RPS24 | -89 |
| RPL23A | 138 |
| SMG1 | 158 |
| SMG9 | 235 |
| RPL6 | 1290 |
| RPS4X | 1825 |
| RPS3A | 3173 |
| SMG7 | 4285 |
| PABPC1 | 4591 |
| RPSA | 5249 |
| PPP2CA | 5682 |
| SMG8 | 6313 |
| MAGOHB | 7179 |
| DCP1A | 7220 |
| GSPT1 | 7510 |
| UPF3B | 8196 |
| ETF1 | 8214 |
| RPL22L1 | 8317 |
| RPL3L | 8978 |
| RPS27L | 9625 |
| UPF2 | 10521 |
| NCBP1 | 10864 |
| NCBP2 | 11208 |
| PNRC2 | 11638 |
| PPP2R2A | 11691 |
Cap-dependent Translation Initiation
| 145 | |
|---|---|
| set | Cap-dependent Translation Initiation |
| setSize | 118 |
| pANOVA | 1.45e-17 |
| s.dist | -0.454 |
| p.adjustANOVA | 1.8e-15 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| EIF3C | -9873 |
| RPL3 | -9867 |
| EIF4H | -9779 |
| RPL8 | -9738 |
| EIF3G | -9710 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| EIF3C | -9873 |
| RPL3 | -9867 |
| EIF4H | -9779 |
| RPL8 | -9738 |
| EIF3G | -9710 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| EIF3L | -9269 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| EIF3B | -8804 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| EIF3I | -7931 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| EIF4G1 | -7029 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| RPL19 | -6701 |
| EIF4B | -6655 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| EIF3K | -6222 |
| RPL36A | -5966 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| EIF3D | -5647 |
| RPL5 | -5445 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| RPL10A | -4820 |
| EIF2B4 | -4674 |
| EIF4EBP1 | -4513 |
| RPL23 | -4456 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| EIF3H | -1365 |
| RPS24 | -89 |
| RPL23A | 138 |
| EIF2B2 | 679 |
| EIF2B5 | 1132 |
| RPL6 | 1290 |
| EIF4A1 | 1541 |
| RPS4X | 1825 |
| EIF3A | 1969 |
| RPS3A | 3173 |
| EIF2B3 | 3221 |
| PABPC1 | 4591 |
| RPSA | 5249 |
| EIF3E | 8272 |
| RPL22L1 | 8317 |
| EIF3M | 8578 |
| EIF1AX | 8776 |
| RPL3L | 8978 |
| EIF2S2 | 9317 |
| EIF2S1 | 9563 |
| RPS27L | 9625 |
| EIF2B1 | 9745 |
| EIF3J | 9804 |
| EIF5B | 9825 |
| EIF4A2 | 10043 |
| EIF2S3 | 10258 |
| EIF5 | 10905 |
| EIF4E | 11624 |
Eukaryotic Translation Initiation
| 354 | |
|---|---|
| set | Eukaryotic Translation Initiation |
| setSize | 118 |
| pANOVA | 1.45e-17 |
| s.dist | -0.454 |
| p.adjustANOVA | 1.8e-15 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| EIF3C | -9873 |
| RPL3 | -9867 |
| EIF4H | -9779 |
| RPL8 | -9738 |
| EIF3G | -9710 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| EIF3C | -9873 |
| RPL3 | -9867 |
| EIF4H | -9779 |
| RPL8 | -9738 |
| EIF3G | -9710 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| EIF3L | -9269 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| EIF3B | -8804 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| EIF3I | -7931 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| EIF4G1 | -7029 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| RPL19 | -6701 |
| EIF4B | -6655 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| EIF3K | -6222 |
| RPL36A | -5966 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| EIF3D | -5647 |
| RPL5 | -5445 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| RPL10A | -4820 |
| EIF2B4 | -4674 |
| EIF4EBP1 | -4513 |
| RPL23 | -4456 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| EIF3H | -1365 |
| RPS24 | -89 |
| RPL23A | 138 |
| EIF2B2 | 679 |
| EIF2B5 | 1132 |
| RPL6 | 1290 |
| EIF4A1 | 1541 |
| RPS4X | 1825 |
| EIF3A | 1969 |
| RPS3A | 3173 |
| EIF2B3 | 3221 |
| PABPC1 | 4591 |
| RPSA | 5249 |
| EIF3E | 8272 |
| RPL22L1 | 8317 |
| EIF3M | 8578 |
| EIF1AX | 8776 |
| RPL3L | 8978 |
| EIF2S2 | 9317 |
| EIF2S1 | 9563 |
| RPS27L | 9625 |
| EIF2B1 | 9745 |
| EIF3J | 9804 |
| EIF5B | 9825 |
| EIF4A2 | 10043 |
| EIF2S3 | 10258 |
| EIF5 | 10905 |
| EIF4E | 11624 |
Formation of the ternary complex, and subsequently, the 43S complex
| 401 | |
|---|---|
| set | Formation of the ternary complex, and subsequently, the 43S complex |
| setSize | 51 |
| pANOVA | 4.73e-08 |
| s.dist | -0.442 |
| p.adjustANOVA | 2.31e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| EIF3C | -9873 |
| EIF3G | -9710 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| EIF3L | -9269 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPS28 | -8941 |
| RPS19 | -8814 |
| EIF3B | -8804 |
| RPS11 | -8677 |
| GeneID | Gene Rank |
|---|---|
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| EIF3C | -9873 |
| EIF3G | -9710 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| EIF3L | -9269 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPS28 | -8941 |
| RPS19 | -8814 |
| EIF3B | -8804 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPS14 | -8173 |
| EIF3I | -7931 |
| RPS15A | -7835 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPS6 | -7364 |
| RPS7 | -6568 |
| EIF3K | -6222 |
| RPS25 | -5670 |
| EIF3D | -5647 |
| RPS13 | -5170 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| EIF3H | -1365 |
| RPS24 | -89 |
| RPS4X | 1825 |
| EIF3A | 1969 |
| RPS3A | 3173 |
| RPSA | 5249 |
| EIF3E | 8272 |
| EIF3M | 8578 |
| EIF1AX | 8776 |
| EIF2S2 | 9317 |
| EIF2S1 | 9563 |
| RPS27L | 9625 |
| EIF3J | 9804 |
| EIF2S3 | 10258 |
GP1b-IX-V activation signalling
| 430 | |
|---|---|
| set | GP1b-IX-V activation signalling |
| setSize | 10 |
| pANOVA | 0.0156 |
| s.dist | -0.442 |
| p.adjustANOVA | 0.102 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| VWF | -8805 |
| GP9 | -8734 |
| FLNA | -8138 |
| GP1BB | -7511 |
| GP1BA | -6740 |
| PIK3R1 | -5056 |
| SRC | -4258 |
| GP5 | -3922 |
| RAF1 | 1476 |
| YWHAZ | 9618 |
| GeneID | Gene Rank |
|---|---|
| VWF | -8805 |
| GP9 | -8734 |
| FLNA | -8138 |
| GP1BB | -7511 |
| GP1BA | -6740 |
| PIK3R1 | -5056 |
| SRC | -4258 |
| GP5 | -3922 |
| RAF1 | 1476 |
| YWHAZ | 9618 |
RNA Polymerase I Promoter Opening
| 904 | |
|---|---|
| set | RNA Polymerase I Promoter Opening |
| setSize | 19 |
| pANOVA | 0.001 |
| s.dist | -0.436 |
| p.adjustANOVA | 0.0167 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAPK3 | -10100.0 |
| H2AZ1 | -8776.0 |
| H2BC12 | -8742.0 |
| H2BC17 | -8346.0 |
| H3C15 | -8038.5 |
| UBTF | -8001.0 |
| H2BC4 | -7928.0 |
| H2AJ | -7536.0 |
| H2BC9 | -6894.0 |
| H2BC11 | -5751.0 |
| H2BC21 | -5415.0 |
| H2BC15 | -4416.0 |
| H2AC6 | -4383.0 |
| H2BC5 | -3070.0 |
| H2AZ2 | -2475.0 |
| H2BU1 | 2721.0 |
| H2AC20 | 3907.0 |
| H3-3A | 5193.0 |
| MBD2 | 9375.0 |
| GeneID | Gene Rank |
|---|---|
| MAPK3 | -10100.0 |
| H2AZ1 | -8776.0 |
| H2BC12 | -8742.0 |
| H2BC17 | -8346.0 |
| H3C15 | -8038.5 |
| UBTF | -8001.0 |
| H2BC4 | -7928.0 |
| H2AJ | -7536.0 |
| H2BC9 | -6894.0 |
| H2BC11 | -5751.0 |
| H2BC21 | -5415.0 |
| H2BC15 | -4416.0 |
| H2AC6 | -4383.0 |
| H2BC5 | -3070.0 |
| H2AZ2 | -2475.0 |
| H2BU1 | 2721.0 |
| H2AC20 | 3907.0 |
| H3-3A | 5193.0 |
| MBD2 | 9375.0 |
Condensation of Prometaphase Chromosomes
| 205 | |
|---|---|
| set | Condensation of Prometaphase Chromosomes |
| setSize | 11 |
| pANOVA | 0.0125 |
| s.dist | 0.435 |
| p.adjustANOVA | 0.0883 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SMC4 | 11305 |
| SMC2 | 10493 |
| CDK1 | 9135 |
| NCAPG | 8163 |
| NCAPH | 6083 |
| CCNB1 | 5971 |
| CCNB2 | 5588 |
| CSNK2A1 | 3172 |
| CSNK2A2 | 2068 |
| CSNK2B | 178 |
| NCAPD2 | -1837 |
| GeneID | Gene Rank |
|---|---|
| SMC4 | 11305 |
| SMC2 | 10493 |
| CDK1 | 9135 |
| NCAPG | 8163 |
| NCAPH | 6083 |
| CCNB1 | 5971 |
| CCNB2 | 5588 |
| CSNK2A1 | 3172 |
| CSNK2A2 | 2068 |
| CSNK2B | 178 |
| NCAPD2 | -1837 |
Trafficking of GluR2-containing AMPA receptors
| 1251 | |
|---|---|
| set | Trafficking of GluR2-containing AMPA receptors |
| setSize | 12 |
| pANOVA | 0.00931 |
| s.dist | -0.433 |
| p.adjustANOVA | 0.0728 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PICK1 | -9237 |
| AP2M1 | -8930 |
| PRKCB | -8270 |
| AP2A2 | -7814 |
| AP2A1 | -6826 |
| PRKCA | -6088 |
| AP2S1 | -3863 |
| AP2B1 | -3395 |
| TSPAN7 | -2479 |
| GRIP1 | -1255 |
| NSF | 2368 |
| GRIA4 | 6394 |
| GeneID | Gene Rank |
|---|---|
| PICK1 | -9237 |
| AP2M1 | -8930 |
| PRKCB | -8270 |
| AP2A2 | -7814 |
| AP2A1 | -6826 |
| PRKCA | -6088 |
| AP2S1 | -3863 |
| AP2B1 | -3395 |
| TSPAN7 | -2479 |
| GRIP1 | -1255 |
| NSF | 2368 |
| GRIA4 | 6394 |
Regulation of FZD by ubiquitination
| 954 | |
|---|---|
| set | Regulation of FZD by ubiquitination |
| setSize | 16 |
| pANOVA | 0.00272 |
| s.dist | -0.433 |
| p.adjustANOVA | 0.0338 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| FZD8 | -10178 |
| LRP6 | -8827 |
| RPS27A | -8388 |
| LRP5 | -7595 |
| UBA52 | -7375 |
| LGR4 | -6601 |
| ZNRF3 | -6501 |
| FZD6 | -5293 |
| UBB | -4944 |
| LGR6 | -4753 |
| UBC | -4177 |
| RSPO4 | -4068 |
| RNF43 | -2783 |
| FZD5 | 1477 |
| FZD4 | 2728 |
| USP8 | 11545 |
| GeneID | Gene Rank |
|---|---|
| FZD8 | -10178 |
| LRP6 | -8827 |
| RPS27A | -8388 |
| LRP5 | -7595 |
| UBA52 | -7375 |
| LGR4 | -6601 |
| ZNRF3 | -6501 |
| FZD6 | -5293 |
| UBB | -4944 |
| LGR6 | -4753 |
| UBC | -4177 |
| RSPO4 | -4068 |
| RNF43 | -2783 |
| FZD5 | 1477 |
| FZD4 | 2728 |
| USP8 | 11545 |
Presynaptic phase of homologous DNA pairing and strand exchange
| 854 | |
|---|---|
| set | Presynaptic phase of homologous DNA pairing and strand exchange |
| setSize | 39 |
| pANOVA | 3.16e-06 |
| s.dist | 0.431 |
| p.adjustANOVA | 9.81e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RAD51B | 11348 |
| RBBP8 | 11241 |
| RMI1 | 11215 |
| RMI2 | 11085 |
| NBN | 10610 |
| RAD50 | 10371 |
| DNA2 | 9957 |
| RAD17 | 9946 |
| RFC4 | 9891 |
| BRCA2 | 9757 |
| RAD9B | 9234 |
| RAD51C | 9158 |
| HUS1 | 9132 |
| BARD1 | 9023 |
| TOPBP1 | 8826 |
| BRCA1 | 8138 |
| RFC3 | 7972 |
| CHEK1 | 7791 |
| BRIP1 | 6803 |
| RAD1 | 6800 |
| GeneID | Gene Rank |
|---|---|
| RAD51B | 11348 |
| RBBP8 | 11241 |
| RMI1 | 11215 |
| RMI2 | 11085 |
| NBN | 10610 |
| RAD50 | 10371 |
| DNA2 | 9957 |
| RAD17 | 9946 |
| RFC4 | 9891 |
| BRCA2 | 9757 |
| RAD9B | 9234 |
| RAD51C | 9158 |
| HUS1 | 9132 |
| BARD1 | 9023 |
| TOPBP1 | 8826 |
| BRCA1 | 8138 |
| RFC3 | 7972 |
| CHEK1 | 7791 |
| BRIP1 | 6803 |
| RAD1 | 6800 |
| RAD51 | 6337 |
| RPA2 | 5538 |
| ATR | 4908 |
| BLM | 4120 |
| WRN | 4117 |
| RHNO1 | 3076 |
| EXO1 | 2398 |
| RPA3 | 2293 |
| ATRIP | 2287 |
| MRE11 | 2275 |
| RFC5 | 919 |
| KAT5 | -301 |
| XRCC2 | -645 |
| RFC2 | -697 |
| ATM | -768 |
| RAD9A | -1761 |
| TOP3A | -2746 |
| RAD51D | -2821 |
| RPA1 | -4771 |
SUMOylation of DNA methylation proteins
| 1048 | |
|---|---|
| set | SUMOylation of DNA methylation proteins |
| setSize | 16 |
| pANOVA | 0.00305 |
| s.dist | -0.428 |
| p.adjustANOVA | 0.0369 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| DNMT3B | -9878 |
| RING1 | -9757 |
| CBX4 | -9599 |
| CBX2 | -9370 |
| DNMT1 | -8737 |
| PHC1 | -8697 |
| DNMT3A | -8681 |
| PHC2 | -6906 |
| PCGF2 | -6871 |
| SCMH1 | -6232 |
| UBE2I | -5999 |
| CBX8 | -4050 |
| PHC3 | 4542 |
| BMI1 | 5940 |
| RNF2 | 9121 |
| SUMO1 | 10348 |
| GeneID | Gene Rank |
|---|---|
| DNMT3B | -9878 |
| RING1 | -9757 |
| CBX4 | -9599 |
| CBX2 | -9370 |
| DNMT1 | -8737 |
| PHC1 | -8697 |
| DNMT3A | -8681 |
| PHC2 | -6906 |
| PCGF2 | -6871 |
| SCMH1 | -6232 |
| UBE2I | -5999 |
| CBX8 | -4050 |
| PHC3 | 4542 |
| BMI1 | 5940 |
| RNF2 | 9121 |
| SUMO1 | 10348 |
Selenoamino acid metabolism
| 1062 | |
|---|---|
| set | Selenoamino acid metabolism |
| setSize | 114 |
| pANOVA | 6.82e-15 |
| s.dist | -0.422 |
| p.adjustANOVA | 6.22e-13 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| QARS1 | -9481 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| QARS1 | -9481 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| AHCY | -9076 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| RPL19 | -6701 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| SCLY | -6549 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| SARS1 | -6084 |
| RPL36A | -5966 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| RPL5 | -5445 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| EEFSEC | -5241 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| RPL10A | -4820 |
| RPL23 | -4456 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| AIMP2 | -3560 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| PSTK | -2534 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| GNMT | -2001 |
| GSR | -1712 |
| RPS24 | -89 |
| SEPHS2 | -59 |
| RPL23A | 138 |
| IARS1 | 657 |
| MARS1 | 916 |
| RPL6 | 1290 |
| RPS4X | 1825 |
| INMT | 2731 |
| RPS3A | 3173 |
| TXNRD1 | 4413 |
| KARS1 | 4630 |
| RPSA | 5249 |
| SEPSECS | 7020 |
| HNMT | 7288 |
| SECISBP2 | 7391 |
| EPRS1 | 7458 |
| CBS | 7520 |
| CTH | 7660 |
| RPL22L1 | 8317 |
| RPL3L | 8978 |
| RPS27L | 9625 |
| LARS1 | 9915 |
| PAPSS1 | 10005 |
| EEF1E1 | 10288 |
| RARS1 | 10725 |
| PAPSS2 | 10749 |
| DARS1 | 11223 |
| AIMP1 | 11596 |
Processing and activation of SUMO
| 855 | |
|---|---|
| set | Processing and activation of SUMO |
| setSize | 10 |
| pANOVA | 0.0218 |
| s.dist | 0.419 |
| p.adjustANOVA | 0.132 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SUMO1 | 10348 |
| SENP5 | 9908 |
| SENP2 | 9874 |
| RWDD3 | 9390 |
| SUMO2 | 9303 |
| SENP1 | 8191 |
| UBA2 | 6139 |
| SUMO3 | 4470 |
| UBE2I | -5999 |
| SAE1 | -8538 |
| GeneID | Gene Rank |
|---|---|
| SUMO1 | 10348 |
| SENP5 | 9908 |
| SENP2 | 9874 |
| RWDD3 | 9390 |
| SUMO2 | 9303 |
| SENP1 | 8191 |
| UBA2 | 6139 |
| SUMO3 | 4470 |
| UBE2I | -5999 |
| SAE1 | -8538 |
SRP-dependent cotranslational protein targeting to membrane
| 1043 | |
|---|---|
| set | SRP-dependent cotranslational protein targeting to membrane |
| setSize | 111 |
| pANOVA | 1.48e-13 |
| s.dist | -0.406 |
| p.adjustANOVA | 1.13e-11 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| DDOST | -8281 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| RPL19 | -6701 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| SSR4 | -6292 |
| RPN1 | -6289 |
| RPL21 | -6288 |
| RPL36A | -5966 |
| SRPRA | -5918 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| RPL5 | -5445 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| RPL10A | -4820 |
| RPL23 | -4456 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| SEC61B | -2646 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| SEC61A1 | -977 |
| RPS24 | -89 |
| RPL23A | 138 |
| SEC11A | 1049 |
| RPL6 | 1290 |
| RPS4X | 1825 |
| SSR2 | 2011 |
| RPS3A | 3173 |
| SPCS1 | 4379 |
| SRP68 | 4427 |
| RPN2 | 4596 |
| RPSA | 5249 |
| SRP72 | 6253 |
| SRPRB | 6450 |
| SRP14 | 6458 |
| SSR1 | 7422 |
| SSR3 | 8240 |
| RPL22L1 | 8317 |
| RPL3L | 8978 |
| SEC61A2 | 9571 |
| RPS27L | 9625 |
| TRAM1 | 9735 |
| SPCS3 | 10797 |
| SEC11C | 10820 |
| SRP9 | 10867 |
| SRP19 | 11022 |
| SPCS2 | 11036 |
| SEC61G | 11123 |
| SRP54 | 11724 |
Olfactory Signaling Pathway
| 768 | |
|---|---|
| set | Olfactory Signaling Pathway |
| setSize | 61 |
| pANOVA | 5.11e-08 |
| s.dist | 0.403 |
| p.adjustANOVA | 2.41e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| OR2AT4 | 11604 |
| OR8A1 | 11448 |
| OR2M3 | 11395 |
| RTP4 | 11292 |
| OR10H5 | 10984 |
| OR6Y1 | 10944 |
| OR10G3 | 10629 |
| OR2C3 | 10611 |
| OR6K3 | 10427 |
| OR7C1 | 10226 |
| OR2A5 | 9979 |
| OR2T33 | 9961 |
| OR2I1P | 9910 |
| OR2G6 | 9516 |
| OR10A6 | 9513 |
| OR2L2 | 9392 |
| OR2V2 | 9225 |
| OR52K1 | 9191 |
| OR5A2 | 9048 |
| OR7A5 | 9014 |
| GeneID | Gene Rank |
|---|---|
| OR2AT4 | 11604 |
| OR8A1 | 11448 |
| OR2M3 | 11395 |
| RTP4 | 11292 |
| OR10H5 | 10984 |
| OR6Y1 | 10944 |
| OR10G3 | 10629 |
| OR2C3 | 10611 |
| OR6K3 | 10427 |
| OR7C1 | 10226 |
| OR2A5 | 9979 |
| OR2T33 | 9961 |
| OR2I1P | 9910 |
| OR2G6 | 9516 |
| OR10A6 | 9513 |
| OR2L2 | 9392 |
| OR2V2 | 9225 |
| OR52K1 | 9191 |
| OR5A2 | 9048 |
| OR7A5 | 9014 |
| REEP3 | 8840 |
| OR4E1 | 8769 |
| OR6C75 | 8698 |
| OR1I1 | 8672 |
| OR1D2 | 8419 |
| OR51L1 | 8101 |
| OR5AS1 | 8048 |
| RTP5 | 7976 |
| OR1C1 | 7818 |
| REEP1 | 7706 |
| OR56A1 | 7701 |
| OR7G2 | 7525 |
| OR2M4 | 7488 |
| OR2H2 | 7445 |
| OR52N4 | 6649 |
| OR14J1 | 6491 |
| OR4D9 | 6454 |
| OR5A1 | 5489 |
| REEP5 | 5355 |
| OR7D4 | 4655 |
| OR4D1 | 4519 |
| OR5AU1 | 3772 |
| OR5AN1 | 3574 |
| OR4K17 | 1760 |
| OR1M1 | 1175 |
| OR1A1 | 1065 |
| OR14L1P | 848 |
| REEP2 | 459 |
| OR2B11 | 252 |
| OR7A17 | -658 |
| OR52A1 | -2141 |
| OR2W3 | -2772 |
| OR10AC1 | -3145 |
| OR7D2 | -3238 |
| OR2A7 | -3414 |
| OR3A3 | -3468 |
| GNB1 | -5109 |
| GNAL | -6950 |
| REEP4 | -8128 |
| OR2A1 | -8172 |
| REEP6 | -10290 |
Homologous DNA Pairing and Strand Exchange
| 502 | |
|---|---|
| set | Homologous DNA Pairing and Strand Exchange |
| setSize | 42 |
| pANOVA | 6.3e-06 |
| s.dist | 0.403 |
| p.adjustANOVA | 0.000191 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RAD51B | 11348 |
| RBBP8 | 11241 |
| RMI1 | 11215 |
| RMI2 | 11085 |
| NBN | 10610 |
| RAD50 | 10371 |
| DNA2 | 9957 |
| RAD17 | 9946 |
| RFC4 | 9891 |
| BRCA2 | 9757 |
| RAD9B | 9234 |
| RAD51C | 9158 |
| HUS1 | 9132 |
| BARD1 | 9023 |
| TOPBP1 | 8826 |
| BRCA1 | 8138 |
| RFC3 | 7972 |
| RAD51AP1 | 7821 |
| CHEK1 | 7791 |
| BRIP1 | 6803 |
| GeneID | Gene Rank |
|---|---|
| RAD51B | 11348 |
| RBBP8 | 11241 |
| RMI1 | 11215 |
| RMI2 | 11085 |
| NBN | 10610 |
| RAD50 | 10371 |
| DNA2 | 9957 |
| RAD17 | 9946 |
| RFC4 | 9891 |
| BRCA2 | 9757 |
| RAD9B | 9234 |
| RAD51C | 9158 |
| HUS1 | 9132 |
| BARD1 | 9023 |
| TOPBP1 | 8826 |
| BRCA1 | 8138 |
| RFC3 | 7972 |
| RAD51AP1 | 7821 |
| CHEK1 | 7791 |
| BRIP1 | 6803 |
| RAD1 | 6800 |
| RAD51 | 6337 |
| RPA2 | 5538 |
| ATR | 4908 |
| BLM | 4120 |
| WRN | 4117 |
| PALB2 | 3783 |
| RHNO1 | 3076 |
| EXO1 | 2398 |
| RPA3 | 2293 |
| ATRIP | 2287 |
| MRE11 | 2275 |
| RFC5 | 919 |
| KAT5 | -301 |
| XRCC2 | -645 |
| RFC2 | -697 |
| ATM | -768 |
| RAD9A | -1761 |
| TOP3A | -2746 |
| RAD51D | -2821 |
| RPA1 | -4771 |
| XRCC3 | -8531 |
FOXO-mediated transcription of cell death genes
| 373 | |
|---|---|
| set | FOXO-mediated transcription of cell death genes |
| setSize | 16 |
| pANOVA | 0.00558 |
| s.dist | -0.4 |
| p.adjustANOVA | 0.0534 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| FOXO4 | -9911 |
| PINK1 | -9108 |
| STK11 | -8976 |
| CREBBP | -8918 |
| BBC3 | -8875 |
| FOXO1 | -8143 |
| FOXO3 | -7061 |
| CITED2 | -5315 |
| FASLG | -4042 |
| EP300 | -2667 |
| BCL6 | -2615 |
| NFYA | -556 |
| BCL2L11 | 196 |
| DDIT3 | 2994 |
| NFYC | 5216 |
| NFYB | 7833 |
| GeneID | Gene Rank |
|---|---|
| FOXO4 | -9911 |
| PINK1 | -9108 |
| STK11 | -8976 |
| CREBBP | -8918 |
| BBC3 | -8875 |
| FOXO1 | -8143 |
| FOXO3 | -7061 |
| CITED2 | -5315 |
| FASLG | -4042 |
| EP300 | -2667 |
| BCL6 | -2615 |
| NFYA | -556 |
| BCL2L11 | 196 |
| DDIT3 | 2994 |
| NFYC | 5216 |
| NFYB | 7833 |
A tetrasaccharide linker sequence is required for GAG synthesis
| 1 | |
|---|---|
| set | A tetrasaccharide linker sequence is required for GAG synthesis |
| setSize | 18 |
| pANOVA | 0.00339 |
| s.dist | -0.399 |
| p.adjustANOVA | 0.0392 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| B3GAT3 | -9818 |
| XYLT1 | -9723 |
| GPC4 | -9454 |
| B3GALT6 | -8920 |
| XYLT2 | -8645 |
| B4GALT7 | -8207 |
| GPC1 | -8099 |
| GPC2 | -7735 |
| HSPG2 | -5458 |
| CSPG4 | -4429 |
| B3GAT2 | -1900 |
| SDC4 | -1368 |
| B3GAT1 | 18 |
| SDC3 | 1680 |
| VCAN | 1854 |
| DCN | 2926 |
| SDC2 | 3889 |
| AGRN | 6202 |
| GeneID | Gene Rank |
|---|---|
| B3GAT3 | -9818 |
| XYLT1 | -9723 |
| GPC4 | -9454 |
| B3GALT6 | -8920 |
| XYLT2 | -8645 |
| B4GALT7 | -8207 |
| GPC1 | -8099 |
| GPC2 | -7735 |
| HSPG2 | -5458 |
| CSPG4 | -4429 |
| B3GAT2 | -1900 |
| SDC4 | -1368 |
| B3GAT1 | 18 |
| SDC3 | 1680 |
| VCAN | 1854 |
| DCN | 2926 |
| SDC2 | 3889 |
| AGRN | 6202 |
rRNA processing in the mitochondrion
| 1358 | |
|---|---|
| set | rRNA processing in the mitochondrion |
| setSize | 29 |
| pANOVA | 0.000227 |
| s.dist | -0.395 |
| p.adjustANOVA | 0.00468 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MT-ATP8 | -10332 |
| MT-ATP6 | -9606 |
| MT-ND4L | -9074 |
| MT-CO3 | -8680 |
| MT-ND3 | -8450 |
| MT-TV | -8443 |
| MT-TF | -8294 |
| MT-TL2 | -7298 |
| MT-CYB | -7017 |
| MT-TM | -6674 |
| MT-ND1 | -6593 |
| MT-ND5 | -6176 |
| MRM1 | -5820 |
| MTERF4 | -5707 |
| MT-CO2 | -5700 |
| MT-ND2 | -4966 |
| MT-TL1 | -3853 |
| MT-RNR2 | -3648 |
| MT-RNR1 | -3295 |
| HSD17B10 | -2865 |
| GeneID | Gene Rank |
|---|---|
| MT-ATP8 | -10332 |
| MT-ATP6 | -9606 |
| MT-ND4L | -9074 |
| MT-CO3 | -8680 |
| MT-ND3 | -8450 |
| MT-TV | -8443 |
| MT-TF | -8294 |
| MT-TL2 | -7298 |
| MT-CYB | -7017 |
| MT-TM | -6674 |
| MT-ND1 | -6593 |
| MT-ND5 | -6176 |
| MRM1 | -5820 |
| MTERF4 | -5707 |
| MT-CO2 | -5700 |
| MT-ND2 | -4966 |
| MT-TL1 | -3853 |
| MT-RNR2 | -3648 |
| MT-RNR1 | -3295 |
| HSD17B10 | -2865 |
| ELAC2 | -2324 |
| MRM3 | -2058 |
| MRM2 | -1116 |
| MT-CO1 | -685 |
| MT-ND4 | 3305 |
| NSUN4 | 4732 |
| PRORP | 6071 |
| TFB1M | 6776 |
| TRMT10C | 10717 |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
| 1192 | |
|---|---|
| set | TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) |
| setSize | 16 |
| pANOVA | 0.00639 |
| s.dist | -0.394 |
| p.adjustANOVA | 0.0583 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PARD6A | -9275 |
| RPS27A | -8388 |
| TGFB1 | -8091 |
| TGFBR2 | -8064 |
| PRKCZ | -7701 |
| UBA52 | -7375 |
| ARHGEF18 | -5836 |
| CGN | -5578 |
| UBB | -4944 |
| F11R | -4885 |
| UBC | -4177 |
| PARD3 | -2235 |
| SMURF1 | -1891 |
| TGFBR1 | 5352 |
| FKBP1A | 6665 |
| RHOA | 7611 |
| GeneID | Gene Rank |
|---|---|
| PARD6A | -9275 |
| RPS27A | -8388 |
| TGFB1 | -8091 |
| TGFBR2 | -8064 |
| PRKCZ | -7701 |
| UBA52 | -7375 |
| ARHGEF18 | -5836 |
| CGN | -5578 |
| UBB | -4944 |
| F11R | -4885 |
| UBC | -4177 |
| PARD3 | -2235 |
| SMURF1 | -1891 |
| TGFBR1 | 5352 |
| FKBP1A | 6665 |
| RHOA | 7611 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
| 50 | |
|---|---|
| set | Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S |
| setSize | 59 |
| pANOVA | 2.08e-07 |
| s.dist | -0.391 |
| p.adjustANOVA | 8.61e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| EIF3C | -9873 |
| EIF4H | -9779 |
| EIF3G | -9710 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| EIF3L | -9269 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPS28 | -8941 |
| RPS19 | -8814 |
| EIF3B | -8804 |
| GeneID | Gene Rank |
|---|---|
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| EIF3C | -9873 |
| EIF4H | -9779 |
| EIF3G | -9710 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| EIF3L | -9269 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPS28 | -8941 |
| RPS19 | -8814 |
| EIF3B | -8804 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPS14 | -8173 |
| EIF3I | -7931 |
| RPS15A | -7835 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPS6 | -7364 |
| EIF4G1 | -7029 |
| EIF4B | -6655 |
| RPS7 | -6568 |
| EIF3K | -6222 |
| RPS25 | -5670 |
| EIF3D | -5647 |
| RPS13 | -5170 |
| EIF4EBP1 | -4513 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| EIF3H | -1365 |
| RPS24 | -89 |
| EIF4A1 | 1541 |
| RPS4X | 1825 |
| EIF3A | 1969 |
| RPS3A | 3173 |
| PABPC1 | 4591 |
| RPSA | 5249 |
| EIF3E | 8272 |
| EIF3M | 8578 |
| EIF1AX | 8776 |
| EIF2S2 | 9317 |
| EIF2S1 | 9563 |
| RPS27L | 9625 |
| EIF3J | 9804 |
| EIF4A2 | 10043 |
| EIF2S3 | 10258 |
| EIF4E | 11624 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2
| 1327 | |
|---|---|
| set | WNT5A-dependent internalization of FZD2, FZD5 and ROR2 |
| setSize | 11 |
| pANOVA | 0.0249 |
| s.dist | -0.391 |
| p.adjustANOVA | 0.147 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AP2M1 | -8930 |
| CLTB | -8800 |
| AP2A2 | -7814 |
| FZD2 | -7097 |
| AP2A1 | -6826 |
| AP2S1 | -3863 |
| AP2B1 | -3395 |
| CLTA | 509 |
| CLTC | 1283 |
| FZD5 | 1477 |
| ROR1 | 3385 |
| GeneID | Gene Rank |
|---|---|
| AP2M1 | -8930 |
| CLTB | -8800 |
| AP2A2 | -7814 |
| FZD2 | -7097 |
| AP2A1 | -6826 |
| AP2S1 | -3863 |
| AP2B1 | -3395 |
| CLTA | 509 |
| CLTC | 1283 |
| FZD5 | 1477 |
| ROR1 | 3385 |
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
| 1177 | |
|---|---|
| set | Synthesis of Prostaglandins (PG) and Thromboxanes (TX) |
| setSize | 12 |
| pANOVA | 0.0193 |
| s.dist | -0.39 |
| p.adjustANOVA | 0.121 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PTGS2 | -10227 |
| PTGES2 | -9522 |
| PRXL2B | -9063 |
| AKR1C3 | -7972 |
| PTGDS | -6443 |
| PTGS1 | -6287 |
| PTGR2 | -5053 |
| CBR1 | -4667 |
| PTGES | 202 |
| TBXAS1 | 500 |
| HPGD | 4018 |
| PTGES3 | 10886 |
| GeneID | Gene Rank |
|---|---|
| PTGS2 | -10227 |
| PTGES2 | -9522 |
| PRXL2B | -9063 |
| AKR1C3 | -7972 |
| PTGDS | -6443 |
| PTGS1 | -6287 |
| PTGR2 | -5053 |
| CBR1 | -4667 |
| PTGES | 202 |
| TBXAS1 | 500 |
| HPGD | 4018 |
| PTGES3 | 10886 |
Pexophagy
| 816 | |
|---|---|
| set | Pexophagy |
| setSize | 11 |
| pANOVA | 0.0251 |
| s.dist | -0.39 |
| p.adjustANOVA | 0.147 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PEX5 | -8871 |
| RPS27A | -8388 |
| SQSTM1 | -7746 |
| UBA52 | -7375 |
| UBB | -4944 |
| UBC | -4177 |
| USP30 | -2323 |
| ATM | -768 |
| NBR1 | 483 |
| MAP1LC3B | 1057 |
| EPAS1 | 3063 |
| GeneID | Gene Rank |
|---|---|
| PEX5 | -8871 |
| RPS27A | -8388 |
| SQSTM1 | -7746 |
| UBA52 | -7375 |
| UBB | -4944 |
| UBC | -4177 |
| USP30 | -2323 |
| ATM | -768 |
| NBR1 | 483 |
| MAP1LC3B | 1057 |
| EPAS1 | 3063 |
Translation initiation complex formation
| 1272 | |
|---|---|
| set | Translation initiation complex formation |
| setSize | 58 |
| pANOVA | 2.9e-07 |
| s.dist | -0.389 |
| p.adjustANOVA | 1.17e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| EIF3C | -9873 |
| EIF4H | -9779 |
| EIF3G | -9710 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| EIF3L | -9269 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPS28 | -8941 |
| RPS19 | -8814 |
| EIF3B | -8804 |
| GeneID | Gene Rank |
|---|---|
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| EIF3C | -9873 |
| EIF4H | -9779 |
| EIF3G | -9710 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| EIF3L | -9269 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPS28 | -8941 |
| RPS19 | -8814 |
| EIF3B | -8804 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPS14 | -8173 |
| EIF3I | -7931 |
| RPS15A | -7835 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPS6 | -7364 |
| EIF4G1 | -7029 |
| EIF4B | -6655 |
| RPS7 | -6568 |
| EIF3K | -6222 |
| RPS25 | -5670 |
| EIF3D | -5647 |
| RPS13 | -5170 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| EIF3H | -1365 |
| RPS24 | -89 |
| EIF4A1 | 1541 |
| RPS4X | 1825 |
| EIF3A | 1969 |
| RPS3A | 3173 |
| PABPC1 | 4591 |
| RPSA | 5249 |
| EIF3E | 8272 |
| EIF3M | 8578 |
| EIF1AX | 8776 |
| EIF2S2 | 9317 |
| EIF2S1 | 9563 |
| RPS27L | 9625 |
| EIF3J | 9804 |
| EIF4A2 | 10043 |
| EIF2S3 | 10258 |
| EIF4E | 11624 |
Influenza Viral RNA Transcription and Replication
| 530 | |
|---|---|
| set | Influenza Viral RNA Transcription and Replication |
| setSize | 135 |
| pANOVA | 9.54e-15 |
| s.dist | -0.386 |
| p.adjustANOVA | 7.67e-13 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| POLR2L | -10282 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| POM121C | -9374 |
| GTF2F1 | -9355 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| GeneID | Gene Rank |
|---|---|
| RPL37 | -10308 |
| POLR2L | -10282 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| POM121C | -9374 |
| GTF2F1 | -9355 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| POLR2I | -9194 |
| POLR2F | -9158 |
| RPS5 | -9130 |
| NUP210 | -9099 |
| POLR2E | -9034 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| POM121 | -8910 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| RPL32 | -8070 |
| POLR2G | -8006 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| RPL19 | -6701 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| POLR2A | -6255 |
| POLR2J | -5993 |
| RPL36A | -5966 |
| NUP188 | -5843 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| RPL5 | -5445 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| PARP1 | -4864 |
| RPL10A | -4820 |
| POLR2H | -4752 |
| RPL23 | -4456 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| SEC13 | -3159 |
| NUP62 | -3119 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| POLR2C | -2998 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| IPO5 | -1917 |
| AAAS | -1609 |
| RPS24 | -89 |
| NDC1 | -77 |
| RPL23A | 138 |
| RPL6 | 1290 |
| RPS4X | 1825 |
| NUP214 | 2090 |
| NUP98 | 2149 |
| NUP93 | 3043 |
| NUP155 | 3103 |
| RPS3A | 3173 |
| NUP160 | 3296 |
| NUP205 | 3520 |
| NUP153 | 3654 |
| NUP37 | 3973 |
| GRSF1 | 4059 |
| NUP88 | 4512 |
| POLR2D | 4912 |
| TPR | 4956 |
| RPSA | 5249 |
| GTF2F2 | 5332 |
| NUP133 | 5417 |
| RANBP2 | 5691 |
| RAE1 | 6124 |
| NUP85 | 6578 |
| NUP58 | 6817 |
| NUP50 | 7082 |
| POLR2B | 7601 |
| DNAJC3 | 7755 |
| NUP107 | 7988 |
| RPL22L1 | 8317 |
| HSP90AA1 | 8431 |
| NUP35 | 8941 |
| RPL3L | 8978 |
| RPS27L | 9625 |
| SEH1L | 9849 |
| POLR2K | 9927 |
| NUP43 | 10569 |
| NUP42 | 10900 |
| NUP54 | 11540 |
MET activates RAP1 and RAC1
| 622 | |
|---|---|
| set | MET activates RAP1 and RAC1 |
| setSize | 10 |
| pANOVA | 0.0351 |
| s.dist | 0.385 |
| p.adjustANOVA | 0.183 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RAP1A | 11696 |
| RAC1 | 9649 |
| GAB1 | 8927 |
| CRK | 8347 |
| HGF | 8211 |
| RAP1B | 7493 |
| DOCK7 | 6267 |
| GRB2 | 75 |
| CRKL | -3376 |
| RAPGEF1 | -7965 |
| GeneID | Gene Rank |
|---|---|
| RAP1A | 11696 |
| RAC1 | 9649 |
| GAB1 | 8927 |
| CRK | 8347 |
| HGF | 8211 |
| RAP1B | 7493 |
| DOCK7 | 6267 |
| GRB2 | 75 |
| CRKL | -3376 |
| RAPGEF1 | -7965 |
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
| 1005 | |
|---|---|
| set | Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) |
| setSize | 26 |
| pANOVA | 0.000729 |
| s.dist | 0.383 |
| p.adjustANOVA | 0.0126 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RAD51B | 11348 |
| RBBP8 | 11241 |
| RMI1 | 11215 |
| RMI2 | 11085 |
| NBN | 10610 |
| RAD50 | 10371 |
| DNA2 | 9957 |
| BRCA2 | 9757 |
| RAD51C | 9158 |
| BARD1 | 9023 |
| BRCA1 | 8138 |
| RAD51AP1 | 7821 |
| BRIP1 | 6803 |
| RAD51 | 6337 |
| BLM | 4120 |
| WRN | 4117 |
| PALB2 | 3783 |
| EXO1 | 2398 |
| MRE11 | 2275 |
| KAT5 | -301 |
| GeneID | Gene Rank |
|---|---|
| RAD51B | 11348 |
| RBBP8 | 11241 |
| RMI1 | 11215 |
| RMI2 | 11085 |
| NBN | 10610 |
| RAD50 | 10371 |
| DNA2 | 9957 |
| BRCA2 | 9757 |
| RAD51C | 9158 |
| BARD1 | 9023 |
| BRCA1 | 8138 |
| RAD51AP1 | 7821 |
| BRIP1 | 6803 |
| RAD51 | 6337 |
| BLM | 4120 |
| WRN | 4117 |
| PALB2 | 3783 |
| EXO1 | 2398 |
| MRE11 | 2275 |
| KAT5 | -301 |
| XRCC2 | -645 |
| ATM | -768 |
| TOP3A | -2746 |
| RAD51D | -2821 |
| RTEL1 | -6202 |
| XRCC3 | -8531 |
Signaling by Leptin
| 1107 | |
|---|---|
| set | Signaling by Leptin |
| setSize | 10 |
| pANOVA | 0.037 |
| s.dist | -0.381 |
| p.adjustANOVA | 0.188 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SOCS3 | -10318 |
| IRS1 | -9921 |
| IRS2 | -9048 |
| STAT5A | -7264 |
| STAT5B | -6114 |
| SH2B1 | -4573 |
| LEPR | -1573 |
| PTPN11 | -619 |
| STAT3 | 2791 |
| JAK2 | 11299 |
| GeneID | Gene Rank |
|---|---|
| SOCS3 | -10318 |
| IRS1 | -9921 |
| IRS2 | -9048 |
| STAT5A | -7264 |
| STAT5B | -6114 |
| SH2B1 | -4573 |
| LEPR | -1573 |
| PTPN11 | -619 |
| STAT3 | 2791 |
| JAK2 | 11299 |
Ribosomal scanning and start codon recognition
| 1018 | |
|---|---|
| set | Ribosomal scanning and start codon recognition |
| setSize | 58 |
| pANOVA | 5.74e-07 |
| s.dist | -0.379 |
| p.adjustANOVA | 2.12e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| EIF3C | -9873 |
| EIF4H | -9779 |
| EIF3G | -9710 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| EIF3L | -9269 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPS28 | -8941 |
| RPS19 | -8814 |
| EIF3B | -8804 |
| GeneID | Gene Rank |
|---|---|
| EIF3F | -10244 |
| RPS2 | -10243 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| EIF3C | -9873 |
| EIF4H | -9779 |
| EIF3G | -9710 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| EIF3L | -9269 |
| RPS10 | -9222 |
| RPS5 | -9130 |
| RPS28 | -8941 |
| RPS19 | -8814 |
| EIF3B | -8804 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPS14 | -8173 |
| EIF3I | -7931 |
| RPS15A | -7835 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPS6 | -7364 |
| EIF4G1 | -7029 |
| EIF4B | -6655 |
| RPS7 | -6568 |
| EIF3K | -6222 |
| RPS25 | -5670 |
| EIF3D | -5647 |
| RPS13 | -5170 |
| RPS26 | -3701 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| EIF3H | -1365 |
| RPS24 | -89 |
| EIF4A1 | 1541 |
| RPS4X | 1825 |
| EIF3A | 1969 |
| RPS3A | 3173 |
| RPSA | 5249 |
| EIF3E | 8272 |
| EIF3M | 8578 |
| EIF1AX | 8776 |
| EIF2S2 | 9317 |
| EIF2S1 | 9563 |
| RPS27L | 9625 |
| EIF3J | 9804 |
| EIF4A2 | 10043 |
| EIF2S3 | 10258 |
| EIF5 | 10905 |
| EIF4E | 11624 |
Pausing and recovery of Tat-mediated HIV elongation
| 808 | |
|---|---|
| set | Pausing and recovery of Tat-mediated HIV elongation |
| setSize | 30 |
| pANOVA | 0.000324 |
| s.dist | -0.379 |
| p.adjustANOVA | 0.0059 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| POLR2L | -10282 |
| CDK9 | -10180 |
| CTDP1 | -9955 |
| NELFB | -9862 |
| GTF2F1 | -9355 |
| POLR2I | -9194 |
| POLR2F | -9158 |
| POLR2E | -9034 |
| ELL | -8355 |
| ELOB | -8164 |
| POLR2G | -8006 |
| SUPT5H | -7930 |
| POLR2A | -6255 |
| POLR2J | -5993 |
| SSRP1 | -5218 |
| NELFA | -5007 |
| POLR2H | -4752 |
| NELFCD | -4629 |
| CCNT1 | -3403 |
| POLR2C | -2998 |
| GeneID | Gene Rank |
|---|---|
| POLR2L | -10282 |
| CDK9 | -10180 |
| CTDP1 | -9955 |
| NELFB | -9862 |
| GTF2F1 | -9355 |
| POLR2I | -9194 |
| POLR2F | -9158 |
| POLR2E | -9034 |
| ELL | -8355 |
| ELOB | -8164 |
| POLR2G | -8006 |
| SUPT5H | -7930 |
| POLR2A | -6255 |
| POLR2J | -5993 |
| SSRP1 | -5218 |
| NELFA | -5007 |
| POLR2H | -4752 |
| NELFCD | -4629 |
| CCNT1 | -3403 |
| POLR2C | -2998 |
| NELFE | -2081 |
| ELOC | 1200 |
| SUPT4H1 | 1271 |
| SUPT16H | 2912 |
| ELOA | 2983 |
| POLR2D | 4912 |
| GTF2F2 | 5332 |
| POLR2B | 7601 |
| TCEA1 | 8287 |
| POLR2K | 9927 |
Tat-mediated HIV elongation arrest and recovery
| 1220 | |
|---|---|
| set | Tat-mediated HIV elongation arrest and recovery |
| setSize | 30 |
| pANOVA | 0.000324 |
| s.dist | -0.379 |
| p.adjustANOVA | 0.0059 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| POLR2L | -10282 |
| CDK9 | -10180 |
| CTDP1 | -9955 |
| NELFB | -9862 |
| GTF2F1 | -9355 |
| POLR2I | -9194 |
| POLR2F | -9158 |
| POLR2E | -9034 |
| ELL | -8355 |
| ELOB | -8164 |
| POLR2G | -8006 |
| SUPT5H | -7930 |
| POLR2A | -6255 |
| POLR2J | -5993 |
| SSRP1 | -5218 |
| NELFA | -5007 |
| POLR2H | -4752 |
| NELFCD | -4629 |
| CCNT1 | -3403 |
| POLR2C | -2998 |
| GeneID | Gene Rank |
|---|---|
| POLR2L | -10282 |
| CDK9 | -10180 |
| CTDP1 | -9955 |
| NELFB | -9862 |
| GTF2F1 | -9355 |
| POLR2I | -9194 |
| POLR2F | -9158 |
| POLR2E | -9034 |
| ELL | -8355 |
| ELOB | -8164 |
| POLR2G | -8006 |
| SUPT5H | -7930 |
| POLR2A | -6255 |
| POLR2J | -5993 |
| SSRP1 | -5218 |
| NELFA | -5007 |
| POLR2H | -4752 |
| NELFCD | -4629 |
| CCNT1 | -3403 |
| POLR2C | -2998 |
| NELFE | -2081 |
| ELOC | 1200 |
| SUPT4H1 | 1271 |
| SUPT16H | 2912 |
| ELOA | 2983 |
| POLR2D | 4912 |
| GTF2F2 | 5332 |
| POLR2B | 7601 |
| TCEA1 | 8287 |
| POLR2K | 9927 |
HS-GAG degradation
| 489 | |
|---|---|
| set | HS-GAG degradation |
| setSize | 16 |
| pANOVA | 0.00872 |
| s.dist | -0.379 |
| p.adjustANOVA | 0.071 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SGSH | -10002 |
| NAGLU | -9725 |
| GPC4 | -9454 |
| GPC1 | -8099 |
| GPC2 | -7735 |
| GUSB | -5871 |
| HSPG2 | -5458 |
| IDS | -5405 |
| IDUA | -4267 |
| HPSE | -2954 |
| SDC4 | -1368 |
| GLB1L | 62 |
| SDC3 | 1680 |
| GLB1 | 2354 |
| SDC2 | 3889 |
| AGRN | 6202 |
| GeneID | Gene Rank |
|---|---|
| SGSH | -10002 |
| NAGLU | -9725 |
| GPC4 | -9454 |
| GPC1 | -8099 |
| GPC2 | -7735 |
| GUSB | -5871 |
| HSPG2 | -5458 |
| IDS | -5405 |
| IDUA | -4267 |
| HPSE | -2954 |
| SDC4 | -1368 |
| GLB1L | 62 |
| SDC3 | 1680 |
| GLB1 | 2354 |
| SDC2 | 3889 |
| AGRN | 6202 |
Interleukin-2 signaling
| 563 | |
|---|---|
| set | Interleukin-2 signaling |
| setSize | 11 |
| pANOVA | 0.0316 |
| s.dist | -0.374 |
| p.adjustANOVA | 0.173 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IL2RB | -10303 |
| PTK2B | -8809 |
| JAK1 | -8196 |
| STAT5A | -7264 |
| STAT5B | -6114 |
| LCK | -4371 |
| JAK3 | -2805 |
| SHC1 | 137 |
| SYK | 2432 |
| IL2RA | 2703 |
| IL2RG | 4503 |
| GeneID | Gene Rank |
|---|---|
| IL2RB | -10303 |
| PTK2B | -8809 |
| JAK1 | -8196 |
| STAT5A | -7264 |
| STAT5B | -6114 |
| LCK | -4371 |
| JAK3 | -2805 |
| SHC1 | 137 |
| SYK | 2432 |
| IL2RA | 2703 |
| IL2RG | 4503 |
p75NTR signals via NF-kB
| 1354 | |
|---|---|
| set | p75NTR signals via NF-kB |
| setSize | 15 |
| pANOVA | 0.0127 |
| s.dist | -0.372 |
| p.adjustANOVA | 0.0887 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RELA | -9628 |
| IRAK1 | -9487 |
| RPS27A | -8388 |
| SQSTM1 | -7746 |
| UBA52 | -7375 |
| UBB | -4944 |
| NFKBIA | -4692 |
| IKBKB | -4462 |
| UBC | -4177 |
| NGFR | -2692 |
| RIPK2 | 156 |
| NFKB1 | 1266 |
| TRAF6 | 2326 |
| MYD88 | 4098 |
| PRKCI | 4288 |
| GeneID | Gene Rank |
|---|---|
| RELA | -9628 |
| IRAK1 | -9487 |
| RPS27A | -8388 |
| SQSTM1 | -7746 |
| UBA52 | -7375 |
| UBB | -4944 |
| NFKBIA | -4692 |
| IKBKB | -4462 |
| UBC | -4177 |
| NGFR | -2692 |
| RIPK2 | 156 |
| NFKB1 | 1266 |
| TRAF6 | 2326 |
| MYD88 | 4098 |
| PRKCI | 4288 |
Estrogen-dependent nuclear events downstream of ESR-membrane signaling
| 352 | |
|---|---|
| set | Estrogen-dependent nuclear events downstream of ESR-membrane signaling |
| setSize | 22 |
| pANOVA | 0.00255 |
| s.dist | -0.372 |
| p.adjustANOVA | 0.0329 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AKT2 | -10102 |
| MAPK3 | -10100 |
| FOS | -9975 |
| AKT1 | -9799 |
| HBEGF | -8469 |
| AREG | -8418 |
| ELK1 | -7817 |
| SRF | -7749 |
| EREG | -7409 |
| FOXO3 | -7061 |
| CCND1 | -5765 |
| TGFA | -5162 |
| PTK2 | -2003 |
| MAPK1 | -1844 |
| CDKN1B | -1307 |
| EGF | 514 |
| UHMK1 | 696 |
| BCL2 | 2357 |
| AKT3 | 2465 |
| EPGN | 3595 |
| GeneID | Gene Rank |
|---|---|
| AKT2 | -10102 |
| MAPK3 | -10100 |
| FOS | -9975 |
| AKT1 | -9799 |
| HBEGF | -8469 |
| AREG | -8418 |
| ELK1 | -7817 |
| SRF | -7749 |
| EREG | -7409 |
| FOXO3 | -7061 |
| CCND1 | -5765 |
| TGFA | -5162 |
| PTK2 | -2003 |
| MAPK1 | -1844 |
| CDKN1B | -1307 |
| EGF | 514 |
| UHMK1 | 696 |
| BCL2 | 2357 |
| AKT3 | 2465 |
| EPGN | 3595 |
| CREB1 | 6457 |
| XPO1 | 11455 |
Activation of Matrix Metalloproteinases
| 41 | |
|---|---|
| set | Activation of Matrix Metalloproteinases |
| setSize | 24 |
| pANOVA | 0.00164 |
| s.dist | -0.371 |
| p.adjustANOVA | 0.0247 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MMP9 | -10277 |
| FURIN | -10276 |
| TPSAB1 | -9796 |
| MMP14 | -8825 |
| CTSG | -7910 |
| MMP15 | -7494 |
| ELANE | -6634 |
| COL18A1 | -6216 |
| MMP8 | -6018 |
| TIMP2 | -5731 |
| MMP24 | -5305 |
| PRSS2 | -4636 |
| KLKB1 | -4063 |
| MMP7 | -2929 |
| MMP1 | -2757 |
| MMP25 | -2400 |
| PRSS1 | -1563 |
| CTSV | -759 |
| MMP11 | -513 |
| MMP17 | -8 |
| GeneID | Gene Rank |
|---|---|
| MMP9 | -10277 |
| FURIN | -10276 |
| TPSAB1 | -9796 |
| MMP14 | -8825 |
| CTSG | -7910 |
| MMP15 | -7494 |
| ELANE | -6634 |
| COL18A1 | -6216 |
| MMP8 | -6018 |
| TIMP2 | -5731 |
| MMP24 | -5305 |
| PRSS2 | -4636 |
| KLKB1 | -4063 |
| MMP7 | -2929 |
| MMP1 | -2757 |
| MMP25 | -2400 |
| PRSS1 | -1563 |
| CTSV | -759 |
| MMP11 | -513 |
| MMP17 | -8 |
| TIMP1 | 1642 |
| KLK2 | 4164 |
| CTSK | 7149 |
| PLG | 8929 |
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS)
| 267 | |
|---|---|
| set | Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) |
| setSize | 12 |
| pANOVA | 0.0271 |
| s.dist | -0.369 |
| p.adjustANOVA | 0.154 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| F12 | -9231 |
| VWF | -8805 |
| GP9 | -8734 |
| GP1BB | -7511 |
| GP1BA | -6740 |
| TPST2 | -6004 |
| KLKB1 | -4063 |
| GP5 | -3922 |
| TPST1 | -2552 |
| GGCX | -505 |
| F8 | 6093 |
| SERPING1 | 11201 |
| GeneID | Gene Rank |
|---|---|
| F12 | -9231 |
| VWF | -8805 |
| GP9 | -8734 |
| GP1BB | -7511 |
| GP1BA | -6740 |
| TPST2 | -6004 |
| KLKB1 | -4063 |
| GP5 | -3922 |
| TPST1 | -2552 |
| GGCX | -505 |
| F8 | 6093 |
| SERPING1 | 11201 |
Diseases of hemostasis
| 295 | |
|---|---|
| set | Diseases of hemostasis |
| setSize | 12 |
| pANOVA | 0.0271 |
| s.dist | -0.369 |
| p.adjustANOVA | 0.154 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| F12 | -9231 |
| VWF | -8805 |
| GP9 | -8734 |
| GP1BB | -7511 |
| GP1BA | -6740 |
| TPST2 | -6004 |
| KLKB1 | -4063 |
| GP5 | -3922 |
| TPST1 | -2552 |
| GGCX | -505 |
| F8 | 6093 |
| SERPING1 | 11201 |
| GeneID | Gene Rank |
|---|---|
| F12 | -9231 |
| VWF | -8805 |
| GP9 | -8734 |
| GP1BB | -7511 |
| GP1BA | -6740 |
| TPST2 | -6004 |
| KLKB1 | -4063 |
| GP5 | -3922 |
| TPST1 | -2552 |
| GGCX | -505 |
| F8 | 6093 |
| SERPING1 | 11201 |
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
| 176 | |
|---|---|
| set | Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex |
| setSize | 12 |
| pANOVA | 0.0312 |
| s.dist | 0.359 |
| p.adjustANOVA | 0.172 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| YWHAB | 11092 |
| YWHAZ | 9618 |
| CDK1 | 9135 |
| CHEK1 | 7791 |
| YWHAE | 6642 |
| CCNB1 | 5971 |
| CHEK2 | 5577 |
| WEE1 | 4830 |
| YWHAH | 3131 |
| YWHAQ | 2580 |
| YWHAG | -3999 |
| SFN | -6586 |
| GeneID | Gene Rank |
|---|---|
| YWHAB | 11092 |
| YWHAZ | 9618 |
| CDK1 | 9135 |
| CHEK1 | 7791 |
| YWHAE | 6642 |
| CCNB1 | 5971 |
| CHEK2 | 5577 |
| WEE1 | 4830 |
| YWHAH | 3131 |
| YWHAQ | 2580 |
| YWHAG | -3999 |
| SFN | -6586 |
Establishment of Sister Chromatid Cohesion
| 350 | |
|---|---|
| set | Establishment of Sister Chromatid Cohesion |
| setSize | 11 |
| pANOVA | 0.0399 |
| s.dist | 0.358 |
| p.adjustANOVA | 0.194 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ESCO1 | 11353 |
| SMC3 | 10955 |
| PDS5B | 7409 |
| RAD21 | 6566 |
| STAG2 | 6346 |
| ESCO2 | 4045 |
| PDS5A | 3914 |
| WAPL | 2842 |
| CDCA5 | 1040 |
| STAG1 | 71 |
| SMC1A | -3594 |
| GeneID | Gene Rank |
|---|---|
| ESCO1 | 11353 |
| SMC3 | 10955 |
| PDS5B | 7409 |
| RAD21 | 6566 |
| STAG2 | 6346 |
| ESCO2 | 4045 |
| PDS5A | 3914 |
| WAPL | 2842 |
| CDCA5 | 1040 |
| STAG1 | 71 |
| SMC1A | -3594 |
Pre-NOTCH Processing in Golgi
| 849 | |
|---|---|
| set | Pre-NOTCH Processing in Golgi |
| setSize | 18 |
| pANOVA | 0.00904 |
| s.dist | -0.355 |
| p.adjustANOVA | 0.0714 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MFNG | -10322 |
| FURIN | -10276 |
| ST3GAL4 | -9287 |
| ATP2A3 | -8695 |
| NOTCH1 | -8307 |
| RFNG | -7532 |
| ST3GAL3 | -6159 |
| B4GALT1 | -6125 |
| NOTCH3 | -5144 |
| NOTCH2 | -5057 |
| LFNG | -4880 |
| NOTCH4 | -3355 |
| ATP2A2 | -2559 |
| ATP2A1 | -2334 |
| SEL1L | 4617 |
| RAB6A | 8257 |
| ST3GAL6 | 9285 |
| TMED2 | 9346 |
| GeneID | Gene Rank |
|---|---|
| MFNG | -10322 |
| FURIN | -10276 |
| ST3GAL4 | -9287 |
| ATP2A3 | -8695 |
| NOTCH1 | -8307 |
| RFNG | -7532 |
| ST3GAL3 | -6159 |
| B4GALT1 | -6125 |
| NOTCH3 | -5144 |
| NOTCH2 | -5057 |
| LFNG | -4880 |
| NOTCH4 | -3355 |
| ATP2A2 | -2559 |
| ATP2A1 | -2334 |
| SEL1L | 4617 |
| RAB6A | 8257 |
| ST3GAL6 | 9285 |
| TMED2 | 9346 |
Constitutive Signaling by NOTCH1 HD Domain Mutants
| 211 | |
|---|---|
| set | Constitutive Signaling by NOTCH1 HD Domain Mutants |
| setSize | 14 |
| pANOVA | 0.0216 |
| s.dist | -0.355 |
| p.adjustANOVA | 0.131 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NEURL1B | -9789 |
| RPS27A | -8388 |
| NOTCH1 | -8307 |
| UBA52 | -7375 |
| DLL1 | -7224 |
| MIB2 | -6846 |
| JAG1 | -6208 |
| UBB | -4944 |
| UBC | -4177 |
| MIB1 | -2896 |
| JAG2 | 96 |
| NEURL1 | 3966 |
| ADAM10 | 7907 |
| ADAM17 | 8758 |
| GeneID | Gene Rank |
|---|---|
| NEURL1B | -9789 |
| RPS27A | -8388 |
| NOTCH1 | -8307 |
| UBA52 | -7375 |
| DLL1 | -7224 |
| MIB2 | -6846 |
| JAG1 | -6208 |
| UBB | -4944 |
| UBC | -4177 |
| MIB1 | -2896 |
| JAG2 | 96 |
| NEURL1 | 3966 |
| ADAM10 | 7907 |
| ADAM17 | 8758 |
Signaling by NOTCH1 HD Domain Mutants in Cancer
| 1113 | |
|---|---|
| set | Signaling by NOTCH1 HD Domain Mutants in Cancer |
| setSize | 14 |
| pANOVA | 0.0216 |
| s.dist | -0.355 |
| p.adjustANOVA | 0.131 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NEURL1B | -9789 |
| RPS27A | -8388 |
| NOTCH1 | -8307 |
| UBA52 | -7375 |
| DLL1 | -7224 |
| MIB2 | -6846 |
| JAG1 | -6208 |
| UBB | -4944 |
| UBC | -4177 |
| MIB1 | -2896 |
| JAG2 | 96 |
| NEURL1 | 3966 |
| ADAM10 | 7907 |
| ADAM17 | 8758 |
| GeneID | Gene Rank |
|---|---|
| NEURL1B | -9789 |
| RPS27A | -8388 |
| NOTCH1 | -8307 |
| UBA52 | -7375 |
| DLL1 | -7224 |
| MIB2 | -6846 |
| JAG1 | -6208 |
| UBB | -4944 |
| UBC | -4177 |
| MIB1 | -2896 |
| JAG2 | 96 |
| NEURL1 | 3966 |
| ADAM10 | 7907 |
| ADAM17 | 8758 |
HDR through Single Strand Annealing (SSA)
| 482 | |
|---|---|
| set | HDR through Single Strand Annealing (SSA) |
| setSize | 37 |
| pANOVA | 0.000189 |
| s.dist | 0.355 |
| p.adjustANOVA | 0.00403 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RBBP8 | 11241 |
| RMI1 | 11215 |
| RMI2 | 11085 |
| NBN | 10610 |
| RAD50 | 10371 |
| DNA2 | 9957 |
| RAD17 | 9946 |
| RFC4 | 9891 |
| RAD9B | 9234 |
| HUS1 | 9132 |
| BARD1 | 9023 |
| TOPBP1 | 8826 |
| BRCA1 | 8138 |
| RFC3 | 7972 |
| ERCC4 | 7215 |
| BRIP1 | 6803 |
| RAD1 | 6800 |
| RAD51 | 6337 |
| RPA2 | 5538 |
| ATR | 4908 |
| GeneID | Gene Rank |
|---|---|
| RBBP8 | 11241 |
| RMI1 | 11215 |
| RMI2 | 11085 |
| NBN | 10610 |
| RAD50 | 10371 |
| DNA2 | 9957 |
| RAD17 | 9946 |
| RFC4 | 9891 |
| RAD9B | 9234 |
| HUS1 | 9132 |
| BARD1 | 9023 |
| TOPBP1 | 8826 |
| BRCA1 | 8138 |
| RFC3 | 7972 |
| ERCC4 | 7215 |
| BRIP1 | 6803 |
| RAD1 | 6800 |
| RAD51 | 6337 |
| RPA2 | 5538 |
| ATR | 4908 |
| BLM | 4120 |
| WRN | 4117 |
| RHNO1 | 3076 |
| EXO1 | 2398 |
| RPA3 | 2293 |
| ATRIP | 2287 |
| MRE11 | 2275 |
| RAD52 | 2122 |
| RFC5 | 919 |
| KAT5 | -301 |
| RFC2 | -697 |
| ATM | -768 |
| RAD9A | -1761 |
| TOP3A | -2746 |
| RPA1 | -4771 |
| ABL1 | -7441 |
| ERCC1 | -9432 |
p75NTR recruits signalling complexes
| 1353 | |
|---|---|
| set | p75NTR recruits signalling complexes |
| setSize | 12 |
| pANOVA | 0.0354 |
| s.dist | -0.351 |
| p.adjustANOVA | 0.183 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IRAK1 | -9487 |
| RPS27A | -8388 |
| SQSTM1 | -7746 |
| UBA52 | -7375 |
| UBB | -4944 |
| IKBKB | -4462 |
| UBC | -4177 |
| NGFR | -2692 |
| RIPK2 | 156 |
| TRAF6 | 2326 |
| MYD88 | 4098 |
| PRKCI | 4288 |
| GeneID | Gene Rank |
|---|---|
| IRAK1 | -9487 |
| RPS27A | -8388 |
| SQSTM1 | -7746 |
| UBA52 | -7375 |
| UBB | -4944 |
| IKBKB | -4462 |
| UBC | -4177 |
| NGFR | -2692 |
| RIPK2 | 156 |
| TRAF6 | 2326 |
| MYD88 | 4098 |
| PRKCI | 4288 |
RMTs methylate histone arginines
| 899 | |
|---|---|
| set | RMTs methylate histone arginines |
| setSize | 37 |
| pANOVA | 0.000231 |
| s.dist | -0.35 |
| p.adjustANOVA | 0.00468 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS2 | -10243.0 |
| H2AZ1 | -8776.0 |
| DNMT3A | -8681.0 |
| PRMT7 | -8305.0 |
| SMARCA4 | -8195.0 |
| PRMT1 | -8163.0 |
| CARM1 | -8103.0 |
| H3C15 | -8038.5 |
| ARID1B | -7820.0 |
| H2AJ | -7536.0 |
| SMARCD2 | -6959.0 |
| PRMT6 | -6823.0 |
| SMARCA2 | -6736.0 |
| H2AW | -6266.0 |
| ARID1A | -5907.0 |
| CDK4 | -5841.0 |
| CCND1 | -5765.0 |
| WDR5 | -5526.0 |
| SMARCD3 | -5169.0 |
| H2AC6 | -4383.0 |
| GeneID | Gene Rank |
|---|---|
| RPS2 | -10243.0 |
| H2AZ1 | -8776.0 |
| DNMT3A | -8681.0 |
| PRMT7 | -8305.0 |
| SMARCA4 | -8195.0 |
| PRMT1 | -8163.0 |
| CARM1 | -8103.0 |
| H3C15 | -8038.5 |
| ARID1B | -7820.0 |
| H2AJ | -7536.0 |
| SMARCD2 | -6959.0 |
| PRMT6 | -6823.0 |
| SMARCA2 | -6736.0 |
| H2AW | -6266.0 |
| ARID1A | -5907.0 |
| CDK4 | -5841.0 |
| CCND1 | -5765.0 |
| WDR5 | -5526.0 |
| SMARCD3 | -5169.0 |
| H2AC6 | -4383.0 |
| SMARCE1 | -3958.0 |
| H2AC11 | -3957.0 |
| SMARCC2 | -3632.0 |
| SMARCC1 | -2907.0 |
| COPRS | -2686.0 |
| H2AZ2 | -2475.0 |
| SMARCD1 | -1501.0 |
| SMARCB1 | -1331.0 |
| PRMT5 | 1982.0 |
| ARID2 | 2546.0 |
| WDR77 | 2958.0 |
| H2AC20 | 3907.0 |
| PBRM1 | 4182.0 |
| RBBP7 | 4858.0 |
| ACTL6A | 5304.0 |
| PRMT3 | 10740.0 |
| JAK2 | 11299.0 |
Heparan sulfate/heparin (HS-GAG) metabolism
| 499 | |
|---|---|
| set | Heparan sulfate/heparin (HS-GAG) metabolism |
| setSize | 38 |
| pANOVA | 0.000232 |
| s.dist | -0.345 |
| p.adjustANOVA | 0.00468 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SGSH | -10002 |
| B3GAT3 | -9818 |
| NAGLU | -9725 |
| XYLT1 | -9723 |
| GPC4 | -9454 |
| B3GALT6 | -8920 |
| XYLT2 | -8645 |
| HS3ST3A1 | -8515 |
| HS6ST1 | -8243 |
| B4GALT7 | -8207 |
| GPC1 | -8099 |
| GPC2 | -7735 |
| GUSB | -5871 |
| NDST1 | -5681 |
| HSPG2 | -5458 |
| IDS | -5405 |
| NDST2 | -4937 |
| CSPG4 | -4429 |
| IDUA | -4267 |
| HPSE | -2954 |
| GeneID | Gene Rank |
|---|---|
| SGSH | -10002 |
| B3GAT3 | -9818 |
| NAGLU | -9725 |
| XYLT1 | -9723 |
| GPC4 | -9454 |
| B3GALT6 | -8920 |
| XYLT2 | -8645 |
| HS3ST3A1 | -8515 |
| HS6ST1 | -8243 |
| B4GALT7 | -8207 |
| GPC1 | -8099 |
| GPC2 | -7735 |
| GUSB | -5871 |
| NDST1 | -5681 |
| HSPG2 | -5458 |
| IDS | -5405 |
| NDST2 | -4937 |
| CSPG4 | -4429 |
| IDUA | -4267 |
| HPSE | -2954 |
| B3GAT2 | -1900 |
| HS3ST1 | -1780 |
| HS3ST3B1 | -1489 |
| EXT2 | -1446 |
| SDC4 | -1368 |
| B3GAT1 | 18 |
| GLB1L | 62 |
| HS2ST1 | 1340 |
| SDC3 | 1680 |
| VCAN | 1854 |
| GLB1 | 2354 |
| GLCE | 2404 |
| HS3ST2 | 2578 |
| DCN | 2926 |
| SDC2 | 3889 |
| SLC35D2 | 4601 |
| EXT1 | 5091 |
| AGRN | 6202 |
Regulation of IFNG signaling
| 958 | |
|---|---|
| set | Regulation of IFNG signaling |
| setSize | 14 |
| pANOVA | 0.0255 |
| s.dist | 0.345 |
| p.adjustANOVA | 0.147 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PIAS1 | 11651 |
| JAK2 | 11299 |
| IFNG | 11066 |
| SUMO1 | 10348 |
| STAT1 | 9925 |
| IFNGR1 | 9252 |
| SOCS1 | 8886 |
| IFNGR2 | 7797 |
| PTPN2 | 7592 |
| PTPN11 | -619 |
| PTPN6 | -2890 |
| PTPN1 | -2967 |
| JAK1 | -8196 |
| SOCS3 | -10318 |
| GeneID | Gene Rank |
|---|---|
| PIAS1 | 11651 |
| JAK2 | 11299 |
| IFNG | 11066 |
| SUMO1 | 10348 |
| STAT1 | 9925 |
| IFNGR1 | 9252 |
| SOCS1 | 8886 |
| IFNGR2 | 7797 |
| PTPN2 | 7592 |
| PTPN11 | -619 |
| PTPN6 | -2890 |
| PTPN1 | -2967 |
| JAK1 | -8196 |
| SOCS3 | -10318 |
Synthesis of PIPs at the late endosome membrane
| 1175 | |
|---|---|
| set | Synthesis of PIPs at the late endosome membrane |
| setSize | 11 |
| pANOVA | 0.0479 |
| s.dist | 0.344 |
| p.adjustANOVA | 0.219 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MTM1 | 11112 |
| FIG4 | 8956 |
| MTMR9 | 8405 |
| PIK3C2A | 8129 |
| PIK3C3 | 7079 |
| PIK3R4 | 5876 |
| MTMR7 | 5356 |
| MTMR2 | 3647 |
| PIKFYVE | 2542 |
| MTMR4 | -2215 |
| VAC14 | -9559 |
| GeneID | Gene Rank |
|---|---|
| MTM1 | 11112 |
| FIG4 | 8956 |
| MTMR9 | 8405 |
| PIK3C2A | 8129 |
| PIK3C3 | 7079 |
| PIK3R4 | 5876 |
| MTMR7 | 5356 |
| MTMR2 | 3647 |
| PIKFYVE | 2542 |
| MTMR4 | -2215 |
| VAC14 | -9559 |
Collagen chain trimerization
| 198 | |
|---|---|
| set | Collagen chain trimerization |
| setSize | 27 |
| pANOVA | 0.00198 |
| s.dist | -0.344 |
| p.adjustANOVA | 0.0276 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| COL13A1 | -10378 |
| COL5A1 | -10274 |
| COL8A2 | -9359 |
| COL26A1 | -9085 |
| COL7A1 | -8954 |
| COL27A1 | -8272 |
| COL5A3 | -7982 |
| COL24A1 | -7193 |
| COL6A1 | -7192 |
| COL11A2 | -6500 |
| COL18A1 | -6216 |
| COL5A2 | -5813 |
| COL6A2 | -5676 |
| COL28A1 | -4958 |
| COL10A1 | -4755 |
| COL15A1 | -4732 |
| COL17A1 | -3908 |
| COL19A1 | -3023 |
| COL23A1 | -1246 |
| COL4A2 | 917 |
| GeneID | Gene Rank |
|---|---|
| COL13A1 | -10378 |
| COL5A1 | -10274 |
| COL8A2 | -9359 |
| COL26A1 | -9085 |
| COL7A1 | -8954 |
| COL27A1 | -8272 |
| COL5A3 | -7982 |
| COL24A1 | -7193 |
| COL6A1 | -7192 |
| COL11A2 | -6500 |
| COL18A1 | -6216 |
| COL5A2 | -5813 |
| COL6A2 | -5676 |
| COL28A1 | -4958 |
| COL10A1 | -4755 |
| COL15A1 | -4732 |
| COL17A1 | -3908 |
| COL19A1 | -3023 |
| COL23A1 | -1246 |
| COL4A2 | 917 |
| COL4A3 | 1778 |
| COL4A4 | 3285 |
| COL9A3 | 3915 |
| COL9A2 | 4540 |
| COL8A1 | 8161 |
| COL1A2 | 8984 |
| COL6A3 | 9600 |
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
| 32 | |
|---|---|
| set | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 |
| setSize | 22 |
| pANOVA | 0.00533 |
| s.dist | -0.343 |
| p.adjustANOVA | 0.0516 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H2AZ1 | -8776.0 |
| H2BC12 | -8742.0 |
| PKN1 | -8565.0 |
| H2BC17 | -8346.0 |
| H3C15 | -8038.5 |
| H2BC4 | -7928.0 |
| H2AJ | -7536.0 |
| H2BC9 | -6894.0 |
| H2BC11 | -5751.0 |
| H2BC21 | -5415.0 |
| H2BC15 | -4416.0 |
| H2AC6 | -4383.0 |
| H2BC5 | -3070.0 |
| H2AZ2 | -2475.0 |
| AR | -366.0 |
| NCOA2 | 1439.0 |
| KDM1A | 2200.0 |
| KDM4C | 2529.0 |
| H2BU1 | 2721.0 |
| H2AC20 | 3907.0 |
| GeneID | Gene Rank |
|---|---|
| H2AZ1 | -8776.0 |
| H2BC12 | -8742.0 |
| PKN1 | -8565.0 |
| H2BC17 | -8346.0 |
| H3C15 | -8038.5 |
| H2BC4 | -7928.0 |
| H2AJ | -7536.0 |
| H2BC9 | -6894.0 |
| H2BC11 | -5751.0 |
| H2BC21 | -5415.0 |
| H2BC15 | -4416.0 |
| H2AC6 | -4383.0 |
| H2BC5 | -3070.0 |
| H2AZ2 | -2475.0 |
| AR | -366.0 |
| NCOA2 | 1439.0 |
| KDM1A | 2200.0 |
| KDM4C | 2529.0 |
| H2BU1 | 2721.0 |
| H2AC20 | 3907.0 |
| KLK2 | 4164.0 |
| H3-3A | 5193.0 |
Plasma lipoprotein clearance
| 827 | |
|---|---|
| set | Plasma lipoprotein clearance |
| setSize | 29 |
| pANOVA | 0.00147 |
| s.dist | -0.341 |
| p.adjustANOVA | 0.0234 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SCARB1 | -9861 |
| NR1H2 | -9025 |
| AP2M1 | -8930 |
| APOE | -8186 |
| APOBR | -7903 |
| AP2A2 | -7814 |
| AP2A1 | -6826 |
| LSR | -6787 |
| CES3 | -6277 |
| CUBN | -5579 |
| LIPC | -4960 |
| NR1H3 | -4903 |
| MYLIP | -4778 |
| AMN | -4299 |
| NPC1 | -4273 |
| VLDLR | -4257 |
| AP2S1 | -3863 |
| AP2B1 | -3395 |
| LIPA | -3104 |
| APOC4 | -2383 |
| GeneID | Gene Rank |
|---|---|
| SCARB1 | -9861 |
| NR1H2 | -9025 |
| AP2M1 | -8930 |
| APOE | -8186 |
| APOBR | -7903 |
| AP2A2 | -7814 |
| AP2A1 | -6826 |
| LSR | -6787 |
| CES3 | -6277 |
| CUBN | -5579 |
| LIPC | -4960 |
| NR1H3 | -4903 |
| MYLIP | -4778 |
| AMN | -4299 |
| NPC1 | -4273 |
| VLDLR | -4257 |
| AP2S1 | -3863 |
| AP2B1 | -3395 |
| LIPA | -3104 |
| APOC4 | -2383 |
| LDLRAP1 | -1661 |
| CLTA | 509 |
| CLTC | 1283 |
| HDLBP | 2104 |
| NCEH1 | 3162 |
| SOAT1 | 4111 |
| LDLR | 4250 |
| NPC2 | 6507 |
| SOAT2 | 7476 |
IRAK4 deficiency (TLR2/4)
| 515 | |
|---|---|
| set | IRAK4 deficiency (TLR2/4) |
| setSize | 10 |
| pANOVA | 0.0621 |
| s.dist | 0.341 |
| p.adjustANOVA | 0.256 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TLR2 | 10184 |
| CD36 | 9777 |
| BTK | 9179 |
| LY96 | 7947 |
| TLR1 | 7591 |
| MYD88 | 4098 |
| TLR6 | 3066 |
| TLR4 | 1481 |
| TIRAP | -3612 |
| CD14 | -5276 |
| GeneID | Gene Rank |
|---|---|
| TLR2 | 10184 |
| CD36 | 9777 |
| BTK | 9179 |
| LY96 | 7947 |
| TLR1 | 7591 |
| MYD88 | 4098 |
| TLR6 | 3066 |
| TLR4 | 1481 |
| TIRAP | -3612 |
| CD14 | -5276 |
MyD88 deficiency (TLR2/4)
| 688 | |
|---|---|
| set | MyD88 deficiency (TLR2/4) |
| setSize | 10 |
| pANOVA | 0.0621 |
| s.dist | 0.341 |
| p.adjustANOVA | 0.256 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TLR2 | 10184 |
| CD36 | 9777 |
| BTK | 9179 |
| LY96 | 7947 |
| TLR1 | 7591 |
| MYD88 | 4098 |
| TLR6 | 3066 |
| TLR4 | 1481 |
| TIRAP | -3612 |
| CD14 | -5276 |
| GeneID | Gene Rank |
|---|---|
| TLR2 | 10184 |
| CD36 | 9777 |
| BTK | 9179 |
| LY96 | 7947 |
| TLR1 | 7591 |
| MYD88 | 4098 |
| TLR6 | 3066 |
| TLR4 | 1481 |
| TIRAP | -3612 |
| CD14 | -5276 |
Constitutive Signaling by AKT1 E17K in Cancer
| 207 | |
|---|---|
| set | Constitutive Signaling by AKT1 E17K in Cancer |
| setSize | 26 |
| pANOVA | 0.0027 |
| s.dist | -0.34 |
| p.adjustANOVA | 0.0338 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AKT2 | -10102 |
| AKT1S1 | -10026 |
| FOXO4 | -9911 |
| AKT1 | -9799 |
| PRR5 | -9351 |
| BAD | -9119 |
| MTOR | -8632 |
| FOXO1 | -8143 |
| PDPK1 | -7616 |
| TSC2 | -7121 |
| FOXO3 | -7061 |
| FOXO6 | -6422 |
| MLST8 | -6381 |
| RPS6KB2 | -6218 |
| GSK3A | -5827 |
| CDKN1B | -1307 |
| GSK3B | -223 |
| CASP9 | 286 |
| NR4A1 | 2131 |
| AKT3 | 2465 |
| GeneID | Gene Rank |
|---|---|
| AKT2 | -10102 |
| AKT1S1 | -10026 |
| FOXO4 | -9911 |
| AKT1 | -9799 |
| PRR5 | -9351 |
| BAD | -9119 |
| MTOR | -8632 |
| FOXO1 | -8143 |
| PDPK1 | -7616 |
| TSC2 | -7121 |
| FOXO3 | -7061 |
| FOXO6 | -6422 |
| MLST8 | -6381 |
| RPS6KB2 | -6218 |
| GSK3A | -5827 |
| CDKN1B | -1307 |
| GSK3B | -223 |
| CASP9 | 286 |
| NR4A1 | 2131 |
| AKT3 | 2465 |
| MAPKAP1 | 3210 |
| CDKN1A | 3342 |
| CREB1 | 6457 |
| RICTOR | 6758 |
| CHUK | 7378 |
| MDM2 | 11204 |
Regulation of localization of FOXO transcription factors
| 989 | |
|---|---|
| set | Regulation of localization of FOXO transcription factors |
| setSize | 12 |
| pANOVA | 0.0448 |
| s.dist | -0.335 |
| p.adjustANOVA | 0.21 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AKT2 | -10102 |
| FOXO4 | -9911 |
| AKT1 | -9799 |
| FOXO1 | -8143 |
| FOXO3 | -7061 |
| SFN | -6586 |
| FOXO6 | -6422 |
| YWHAG | -3999 |
| AKT3 | 2465 |
| YWHAQ | 2580 |
| YWHAZ | 9618 |
| YWHAB | 11092 |
| GeneID | Gene Rank |
|---|---|
| AKT2 | -10102 |
| FOXO4 | -9911 |
| AKT1 | -9799 |
| FOXO1 | -8143 |
| FOXO3 | -7061 |
| SFN | -6586 |
| FOXO6 | -6422 |
| YWHAG | -3999 |
| AKT3 | 2465 |
| YWHAQ | 2580 |
| YWHAZ | 9618 |
| YWHAB | 11092 |
Retrograde neurotrophin signalling
| 1014 | |
|---|---|
| set | Retrograde neurotrophin signalling |
| setSize | 12 |
| pANOVA | 0.0465 |
| s.dist | -0.332 |
| p.adjustANOVA | 0.216 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| DNM2 | -9367 |
| DNAL4 | -9030 |
| AP2M1 | -8930 |
| AP2A2 | -7814 |
| AP2A1 | -6826 |
| AP2S1 | -3863 |
| AP2B1 | -3395 |
| DNM3 | -1395 |
| CLTA | 509 |
| CLTC | 1283 |
| NTRK1 | 5106 |
| DNM1 | 7802 |
| GeneID | Gene Rank |
|---|---|
| DNM2 | -9367 |
| DNAL4 | -9030 |
| AP2M1 | -8930 |
| AP2A2 | -7814 |
| AP2A1 | -6826 |
| AP2S1 | -3863 |
| AP2B1 | -3395 |
| DNM3 | -1395 |
| CLTA | 509 |
| CLTC | 1283 |
| NTRK1 | 5106 |
| DNM1 | 7802 |
Lewis blood group biosynthesis
| 602 | |
|---|---|
| set | Lewis blood group biosynthesis |
| setSize | 13 |
| pANOVA | 0.0389 |
| s.dist | -0.331 |
| p.adjustANOVA | 0.192 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| B3GALT2 | -10110 |
| FUT7 | -9983 |
| ST3GAL4 | -9287 |
| ST3GAL3 | -6159 |
| B3GALT4 | -5604 |
| B4GALNT2 | -5330 |
| FUT4 | -4894 |
| ST6GALNAC6 | -2666 |
| FUT2 | -252 |
| FUT10 | 1123 |
| FUT11 | 1230 |
| B3GALT1 | 3901 |
| ST3GAL6 | 9285 |
| GeneID | Gene Rank |
|---|---|
| B3GALT2 | -10110 |
| FUT7 | -9983 |
| ST3GAL4 | -9287 |
| ST3GAL3 | -6159 |
| B3GALT4 | -5604 |
| B4GALNT2 | -5330 |
| FUT4 | -4894 |
| ST6GALNAC6 | -2666 |
| FUT2 | -252 |
| FUT10 | 1123 |
| FUT11 | 1230 |
| B3GALT1 | 3901 |
| ST3GAL6 | 9285 |
Cleavage of the damaged purine
| 193 | |
|---|---|
| set | Cleavage of the damaged purine |
| setSize | 24 |
| pANOVA | 0.0052 |
| s.dist | -0.329 |
| p.adjustANOVA | 0.0512 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H2AZ1 | -8776 |
| H2BC12 | -8742 |
| H2BC17 | -8346 |
| MUTYH | -7969 |
| H2BC4 | -7928 |
| MPG | -7571 |
| H2AJ | -7536 |
| H2BC9 | -6894 |
| ACD | -6691 |
| H2BC11 | -5751 |
| H2BC21 | -5415 |
| TINF2 | -4662 |
| H2BC15 | -4416 |
| H2AC6 | -4383 |
| TERF2IP | -3454 |
| H2BC5 | -3070 |
| H2AZ2 | -2475 |
| OGG1 | -1535 |
| H2BU1 | 2721 |
| H2AC20 | 3907 |
| GeneID | Gene Rank |
|---|---|
| H2AZ1 | -8776 |
| H2BC12 | -8742 |
| H2BC17 | -8346 |
| MUTYH | -7969 |
| H2BC4 | -7928 |
| MPG | -7571 |
| H2AJ | -7536 |
| H2BC9 | -6894 |
| ACD | -6691 |
| H2BC11 | -5751 |
| H2BC21 | -5415 |
| TINF2 | -4662 |
| H2BC15 | -4416 |
| H2AC6 | -4383 |
| TERF2IP | -3454 |
| H2BC5 | -3070 |
| H2AZ2 | -2475 |
| OGG1 | -1535 |
| H2BU1 | 2721 |
| H2AC20 | 3907 |
| NEIL3 | 3946 |
| TERF2 | 4874 |
| TERF1 | 8885 |
| POT1 | 10140 |
Depurination
| 277 | |
|---|---|
| set | Depurination |
| setSize | 24 |
| pANOVA | 0.0052 |
| s.dist | -0.329 |
| p.adjustANOVA | 0.0512 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H2AZ1 | -8776 |
| H2BC12 | -8742 |
| H2BC17 | -8346 |
| MUTYH | -7969 |
| H2BC4 | -7928 |
| MPG | -7571 |
| H2AJ | -7536 |
| H2BC9 | -6894 |
| ACD | -6691 |
| H2BC11 | -5751 |
| H2BC21 | -5415 |
| TINF2 | -4662 |
| H2BC15 | -4416 |
| H2AC6 | -4383 |
| TERF2IP | -3454 |
| H2BC5 | -3070 |
| H2AZ2 | -2475 |
| OGG1 | -1535 |
| H2BU1 | 2721 |
| H2AC20 | 3907 |
| GeneID | Gene Rank |
|---|---|
| H2AZ1 | -8776 |
| H2BC12 | -8742 |
| H2BC17 | -8346 |
| MUTYH | -7969 |
| H2BC4 | -7928 |
| MPG | -7571 |
| H2AJ | -7536 |
| H2BC9 | -6894 |
| ACD | -6691 |
| H2BC11 | -5751 |
| H2BC21 | -5415 |
| TINF2 | -4662 |
| H2BC15 | -4416 |
| H2AC6 | -4383 |
| TERF2IP | -3454 |
| H2BC5 | -3070 |
| H2AZ2 | -2475 |
| OGG1 | -1535 |
| H2BU1 | 2721 |
| H2AC20 | 3907 |
| NEIL3 | 3946 |
| TERF2 | 4874 |
| TERF1 | 8885 |
| POT1 | 10140 |
Recognition and association of DNA glycosylase with site containing an affected purine
| 940 | |
|---|---|
| set | Recognition and association of DNA glycosylase with site containing an affected purine |
| setSize | 24 |
| pANOVA | 0.0052 |
| s.dist | -0.329 |
| p.adjustANOVA | 0.0512 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H2AZ1 | -8776 |
| H2BC12 | -8742 |
| H2BC17 | -8346 |
| MUTYH | -7969 |
| H2BC4 | -7928 |
| MPG | -7571 |
| H2AJ | -7536 |
| H2BC9 | -6894 |
| ACD | -6691 |
| H2BC11 | -5751 |
| H2BC21 | -5415 |
| TINF2 | -4662 |
| H2BC15 | -4416 |
| H2AC6 | -4383 |
| TERF2IP | -3454 |
| H2BC5 | -3070 |
| H2AZ2 | -2475 |
| OGG1 | -1535 |
| H2BU1 | 2721 |
| H2AC20 | 3907 |
| GeneID | Gene Rank |
|---|---|
| H2AZ1 | -8776 |
| H2BC12 | -8742 |
| H2BC17 | -8346 |
| MUTYH | -7969 |
| H2BC4 | -7928 |
| MPG | -7571 |
| H2AJ | -7536 |
| H2BC9 | -6894 |
| ACD | -6691 |
| H2BC11 | -5751 |
| H2BC21 | -5415 |
| TINF2 | -4662 |
| H2BC15 | -4416 |
| H2AC6 | -4383 |
| TERF2IP | -3454 |
| H2BC5 | -3070 |
| H2AZ2 | -2475 |
| OGG1 | -1535 |
| H2BU1 | 2721 |
| H2AC20 | 3907 |
| NEIL3 | 3946 |
| TERF2 | 4874 |
| TERF1 | 8885 |
| POT1 | 10140 |
NOTCH3 Activation and Transmission of Signal to the Nucleus
| 707 | |
|---|---|
| set | NOTCH3 Activation and Transmission of Signal to the Nucleus |
| setSize | 23 |
| pANOVA | 0.00629 |
| s.dist | -0.329 |
| p.adjustANOVA | 0.0577 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NEURL1B | -9789 |
| PSEN2 | -8735 |
| TACC3 | -8710 |
| RPS27A | -8388 |
| APH1A | -8076 |
| UBA52 | -7375 |
| DLL1 | -7224 |
| MIB2 | -6846 |
| JAG1 | -6208 |
| NOTCH3 | -5144 |
| UBB | -4944 |
| YBX1 | -4896 |
| WWP2 | -4221 |
| UBC | -4177 |
| MIB1 | -2896 |
| PSENEN | -1485 |
| JAG2 | 96 |
| EGF | 514 |
| NEURL1 | 3966 |
| NCSTN | 4145 |
| GeneID | Gene Rank |
|---|---|
| NEURL1B | -9789 |
| PSEN2 | -8735 |
| TACC3 | -8710 |
| RPS27A | -8388 |
| APH1A | -8076 |
| UBA52 | -7375 |
| DLL1 | -7224 |
| MIB2 | -6846 |
| JAG1 | -6208 |
| NOTCH3 | -5144 |
| UBB | -4944 |
| YBX1 | -4896 |
| WWP2 | -4221 |
| UBC | -4177 |
| MIB1 | -2896 |
| PSENEN | -1485 |
| JAG2 | 96 |
| EGF | 514 |
| NEURL1 | 3966 |
| NCSTN | 4145 |
| PSEN1 | 5605 |
| ADAM10 | 7907 |
| APH1B | 8804 |
Biosynthesis of DHA-derived SPMs
| 111 | |
|---|---|
| set | Biosynthesis of DHA-derived SPMs |
| setSize | 14 |
| pANOVA | 0.0336 |
| s.dist | -0.328 |
| p.adjustANOVA | 0.179 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PTGS2 | -10227 |
| ALOX15 | -10146 |
| CYP2D6 | -9540 |
| CYP2E1 | -8914 |
| LTC4S | -8566 |
| GSTM4 | -5489 |
| ALOX12 | -3352 |
| EPHX2 | -3039 |
| GPX4 | -2653 |
| CYP2C9 | -93 |
| ALOX5 | 932 |
| HPGD | 4018 |
| LTA4H | 5996 |
| CYP1A2 | 9770 |
| GeneID | Gene Rank |
|---|---|
| PTGS2 | -10227 |
| ALOX15 | -10146 |
| CYP2D6 | -9540 |
| CYP2E1 | -8914 |
| LTC4S | -8566 |
| GSTM4 | -5489 |
| ALOX12 | -3352 |
| EPHX2 | -3039 |
| GPX4 | -2653 |
| CYP2C9 | -93 |
| ALOX5 | 932 |
| HPGD | 4018 |
| LTA4H | 5996 |
| CYP1A2 | 9770 |
Chondroitin sulfate/dermatan sulfate metabolism
| 179 | |
|---|---|
| set | Chondroitin sulfate/dermatan sulfate metabolism |
| setSize | 39 |
| pANOVA | 0.000415 |
| s.dist | -0.327 |
| p.adjustANOVA | 0.00737 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| UST | -10325 |
| B3GAT3 | -9818 |
| XYLT1 | -9723 |
| GPC4 | -9454 |
| B3GALT6 | -8920 |
| CHST13 | -8851 |
| XYLT2 | -8645 |
| CHPF2 | -8533 |
| B4GALT7 | -8207 |
| GPC1 | -8099 |
| CHST14 | -7842 |
| GPC2 | -7735 |
| HYAL3 | -7583 |
| CHST7 | -7467 |
| CHPF | -7214 |
| CHST11 | -6832 |
| HSPG2 | -5458 |
| IDS | -5405 |
| CSPG4 | -4429 |
| IDUA | -4267 |
| GeneID | Gene Rank |
|---|---|
| UST | -10325 |
| B3GAT3 | -9818 |
| XYLT1 | -9723 |
| GPC4 | -9454 |
| B3GALT6 | -8920 |
| CHST13 | -8851 |
| XYLT2 | -8645 |
| CHPF2 | -8533 |
| B4GALT7 | -8207 |
| GPC1 | -8099 |
| CHST14 | -7842 |
| GPC2 | -7735 |
| HYAL3 | -7583 |
| CHST7 | -7467 |
| CHPF | -7214 |
| CHST11 | -6832 |
| HSPG2 | -5458 |
| IDS | -5405 |
| CSPG4 | -4429 |
| IDUA | -4267 |
| HEXA | -4137 |
| CHSY1 | -3078 |
| CSGALNACT1 | -2785 |
| B3GAT2 | -1900 |
| SDC4 | -1368 |
| CHST12 | -1069 |
| B3GAT1 | 18 |
| CHST15 | 1540 |
| SDC3 | 1680 |
| VCAN | 1854 |
| DCN | 2926 |
| DSE | 3281 |
| ARSB | 3778 |
| SDC2 | 3889 |
| HEXB | 4049 |
| AGRN | 6202 |
| HYAL1 | 6747 |
| DSEL | 8172 |
| CSGALNACT2 | 10728 |
Common Pathway of Fibrin Clot Formation
| 201 | |
|---|---|
| set | Common Pathway of Fibrin Clot Formation |
| setSize | 14 |
| pANOVA | 0.0359 |
| s.dist | -0.324 |
| p.adjustANOVA | 0.184 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PRTN3 | -10161 |
| CD177 | -9288 |
| PF4 | -8535 |
| PROCR | -7828 |
| F13A1 | -7712 |
| PF4V1 | -5752 |
| PROC | -5663 |
| THBD | -5008 |
| PROS1 | -2517 |
| SERPINE2 | 1211 |
| F2R | 1412 |
| F5 | 4372 |
| F8 | 6093 |
| SERPIND1 | 8734 |
| GeneID | Gene Rank |
|---|---|
| PRTN3 | -10161 |
| CD177 | -9288 |
| PF4 | -8535 |
| PROCR | -7828 |
| F13A1 | -7712 |
| PF4V1 | -5752 |
| PROC | -5663 |
| THBD | -5008 |
| PROS1 | -2517 |
| SERPINE2 | 1211 |
| F2R | 1412 |
| F5 | 4372 |
| F8 | 6093 |
| SERPIND1 | 8734 |
Packaging Of Telomere Ends
| 804 | |
|---|---|
| set | Packaging Of Telomere Ends |
| setSize | 20 |
| pANOVA | 0.0122 |
| s.dist | -0.324 |
| p.adjustANOVA | 0.0874 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H2AZ1 | -8776 |
| H2BC12 | -8742 |
| H2BC17 | -8346 |
| H2BC4 | -7928 |
| H2AJ | -7536 |
| H2BC9 | -6894 |
| ACD | -6691 |
| H2BC11 | -5751 |
| H2BC21 | -5415 |
| TINF2 | -4662 |
| H2BC15 | -4416 |
| H2AC6 | -4383 |
| TERF2IP | -3454 |
| H2BC5 | -3070 |
| H2AZ2 | -2475 |
| H2BU1 | 2721 |
| H2AC20 | 3907 |
| TERF2 | 4874 |
| TERF1 | 8885 |
| POT1 | 10140 |
| GeneID | Gene Rank |
|---|---|
| H2AZ1 | -8776 |
| H2BC12 | -8742 |
| H2BC17 | -8346 |
| H2BC4 | -7928 |
| H2AJ | -7536 |
| H2BC9 | -6894 |
| ACD | -6691 |
| H2BC11 | -5751 |
| H2BC21 | -5415 |
| TINF2 | -4662 |
| H2BC15 | -4416 |
| H2AC6 | -4383 |
| TERF2IP | -3454 |
| H2BC5 | -3070 |
| H2AZ2 | -2475 |
| H2BU1 | 2721 |
| H2AC20 | 3907 |
| TERF2 | 4874 |
| TERF1 | 8885 |
| POT1 | 10140 |
Downregulation of ERBB2:ERBB3 signaling
| 306 | |
|---|---|
| set | Downregulation of ERBB2:ERBB3 signaling |
| setSize | 12 |
| pANOVA | 0.0533 |
| s.dist | -0.322 |
| p.adjustANOVA | 0.235 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AKT2 | -10102 |
| AKT1 | -9799 |
| ERBB2 | -8564 |
| RPS27A | -8388 |
| UBA52 | -7375 |
| UBB | -4944 |
| UBC | -4177 |
| NRG1 | -1293 |
| RNF41 | -1156 |
| AKT3 | 2465 |
| ERBB3 | 7160 |
| USP8 | 11545 |
| GeneID | Gene Rank |
|---|---|
| AKT2 | -10102 |
| AKT1 | -9799 |
| ERBB2 | -8564 |
| RPS27A | -8388 |
| UBA52 | -7375 |
| UBB | -4944 |
| UBC | -4177 |
| NRG1 | -1293 |
| RNF41 | -1156 |
| AKT3 | 2465 |
| ERBB3 | 7160 |
| USP8 | 11545 |
HIV elongation arrest and recovery
| 487 | |
|---|---|
| set | HIV elongation arrest and recovery |
| setSize | 32 |
| pANOVA | 0.00164 |
| s.dist | -0.322 |
| p.adjustANOVA | 0.0247 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| POLR2L | -10282 |
| CDK9 | -10180 |
| CTDP1 | -9955 |
| NELFB | -9862 |
| GTF2F1 | -9355 |
| POLR2I | -9194 |
| POLR2F | -9158 |
| POLR2E | -9034 |
| ELL | -8355 |
| ELOB | -8164 |
| POLR2G | -8006 |
| SUPT5H | -7930 |
| POLR2A | -6255 |
| POLR2J | -5993 |
| SSRP1 | -5218 |
| NELFA | -5007 |
| POLR2H | -4752 |
| NELFCD | -4629 |
| CCNT1 | -3403 |
| POLR2C | -2998 |
| GeneID | Gene Rank |
|---|---|
| POLR2L | -10282 |
| CDK9 | -10180 |
| CTDP1 | -9955 |
| NELFB | -9862 |
| GTF2F1 | -9355 |
| POLR2I | -9194 |
| POLR2F | -9158 |
| POLR2E | -9034 |
| ELL | -8355 |
| ELOB | -8164 |
| POLR2G | -8006 |
| SUPT5H | -7930 |
| POLR2A | -6255 |
| POLR2J | -5993 |
| SSRP1 | -5218 |
| NELFA | -5007 |
| POLR2H | -4752 |
| NELFCD | -4629 |
| CCNT1 | -3403 |
| POLR2C | -2998 |
| NELFE | -2081 |
| ELOC | 1200 |
| SUPT4H1 | 1271 |
| SUPT16H | 2912 |
| ELOA | 2983 |
| POLR2D | 4912 |
| CCNK | 5104 |
| GTF2F2 | 5332 |
| POLR2B | 7601 |
| CCNT2 | 8285 |
| TCEA1 | 8287 |
| POLR2K | 9927 |
Pausing and recovery of HIV elongation
| 807 | |
|---|---|
| set | Pausing and recovery of HIV elongation |
| setSize | 32 |
| pANOVA | 0.00164 |
| s.dist | -0.322 |
| p.adjustANOVA | 0.0247 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| POLR2L | -10282 |
| CDK9 | -10180 |
| CTDP1 | -9955 |
| NELFB | -9862 |
| GTF2F1 | -9355 |
| POLR2I | -9194 |
| POLR2F | -9158 |
| POLR2E | -9034 |
| ELL | -8355 |
| ELOB | -8164 |
| POLR2G | -8006 |
| SUPT5H | -7930 |
| POLR2A | -6255 |
| POLR2J | -5993 |
| SSRP1 | -5218 |
| NELFA | -5007 |
| POLR2H | -4752 |
| NELFCD | -4629 |
| CCNT1 | -3403 |
| POLR2C | -2998 |
| GeneID | Gene Rank |
|---|---|
| POLR2L | -10282 |
| CDK9 | -10180 |
| CTDP1 | -9955 |
| NELFB | -9862 |
| GTF2F1 | -9355 |
| POLR2I | -9194 |
| POLR2F | -9158 |
| POLR2E | -9034 |
| ELL | -8355 |
| ELOB | -8164 |
| POLR2G | -8006 |
| SUPT5H | -7930 |
| POLR2A | -6255 |
| POLR2J | -5993 |
| SSRP1 | -5218 |
| NELFA | -5007 |
| POLR2H | -4752 |
| NELFCD | -4629 |
| CCNT1 | -3403 |
| POLR2C | -2998 |
| NELFE | -2081 |
| ELOC | 1200 |
| SUPT4H1 | 1271 |
| SUPT16H | 2912 |
| ELOA | 2983 |
| POLR2D | 4912 |
| CCNK | 5104 |
| GTF2F2 | 5332 |
| POLR2B | 7601 |
| CCNT2 | 8285 |
| TCEA1 | 8287 |
| POLR2K | 9927 |
NOTCH2 Activation and Transmission of Signal to the Nucleus
| 705 | |
|---|---|
| set | NOTCH2 Activation and Transmission of Signal to the Nucleus |
| setSize | 20 |
| pANOVA | 0.0133 |
| s.dist | -0.32 |
| p.adjustANOVA | 0.0912 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NEURL1B | -9789 |
| PSEN2 | -8735 |
| RPS27A | -8388 |
| APH1A | -8076 |
| UBA52 | -7375 |
| DLL1 | -7224 |
| MIB2 | -6846 |
| MDK | -6468 |
| JAG1 | -6208 |
| NOTCH2 | -5057 |
| UBB | -4944 |
| UBC | -4177 |
| MIB1 | -2896 |
| PSENEN | -1485 |
| JAG2 | 96 |
| NEURL1 | 3966 |
| NCSTN | 4145 |
| PSEN1 | 5605 |
| ADAM10 | 7907 |
| APH1B | 8804 |
| GeneID | Gene Rank |
|---|---|
| NEURL1B | -9789 |
| PSEN2 | -8735 |
| RPS27A | -8388 |
| APH1A | -8076 |
| UBA52 | -7375 |
| DLL1 | -7224 |
| MIB2 | -6846 |
| MDK | -6468 |
| JAG1 | -6208 |
| NOTCH2 | -5057 |
| UBB | -4944 |
| UBC | -4177 |
| MIB1 | -2896 |
| PSENEN | -1485 |
| JAG2 | 96 |
| NEURL1 | 3966 |
| NCSTN | 4145 |
| PSEN1 | 5605 |
| ADAM10 | 7907 |
| APH1B | 8804 |
NGF-stimulated transcription
| 701 | |
|---|---|
| set | NGF-stimulated transcription |
| setSize | 33 |
| pANOVA | 0.00149 |
| s.dist | -0.32 |
| p.adjustANOVA | 0.0234 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| FOSB | -10380 |
| EGR2 | -10349 |
| EGR1 | -10288 |
| SGK1 | -10263 |
| FOS | -9975 |
| JUND | -9967 |
| ID1 | -9733 |
| MEF2D | -9627 |
| JUNB | -9564 |
| DNM2 | -9367 |
| TRIB1 | -8748 |
| EGR3 | -8231 |
| ELK1 | -7817 |
| SRF | -7749 |
| CDK5R1 | -5195 |
| LYL1 | -5089 |
| ARC | -5010 |
| CHD4 | -4423 |
| RRAD | -3005 |
| EP300 | -2667 |
| GeneID | Gene Rank |
|---|---|
| FOSB | -10380 |
| EGR2 | -10349 |
| EGR1 | -10288 |
| SGK1 | -10263 |
| FOS | -9975 |
| JUND | -9967 |
| ID1 | -9733 |
| MEF2D | -9627 |
| JUNB | -9564 |
| DNM2 | -9367 |
| TRIB1 | -8748 |
| EGR3 | -8231 |
| ELK1 | -7817 |
| SRF | -7749 |
| CDK5R1 | -5195 |
| LYL1 | -5089 |
| ARC | -5010 |
| CHD4 | -4423 |
| RRAD | -3005 |
| EP300 | -2667 |
| NAB2 | -2510 |
| TCF12 | -482 |
| CDK5 | -342 |
| ID3 | 2031 |
| FOSL1 | 3109 |
| TF | 3982 |
| REST | 5083 |
| CREB1 | 6457 |
| ID2 | 6591 |
| TPH1 | 7055 |
| NAB1 | 9587 |
| ATF2 | 11312 |
| ATF1 | 11420 |
EGFR downregulation
| 321 | |
|---|---|
| set | EGFR downregulation |
| setSize | 27 |
| pANOVA | 0.00423 |
| s.dist | -0.318 |
| p.adjustANOVA | 0.0463 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ARHGEF7 | -10122 |
| EPN1 | -8948 |
| PTPRK | -8514 |
| HBEGF | -8469 |
| SH3GL1 | -8459 |
| AREG | -8418 |
| RPS27A | -8388 |
| SPRY1 | -7724 |
| EREG | -7409 |
| UBA52 | -7375 |
| EPS15L1 | -6954 |
| SPRY2 | -6106 |
| PTPN3 | -5217 |
| TGFA | -5162 |
| UBB | -4944 |
| UBC | -4177 |
| CBL | -2683 |
| HGS | -1976 |
| GRB2 | 75 |
| EGF | 514 |
| GeneID | Gene Rank |
|---|---|
| ARHGEF7 | -10122 |
| EPN1 | -8948 |
| PTPRK | -8514 |
| HBEGF | -8469 |
| SH3GL1 | -8459 |
| AREG | -8418 |
| RPS27A | -8388 |
| SPRY1 | -7724 |
| EREG | -7409 |
| UBA52 | -7375 |
| EPS15L1 | -6954 |
| SPRY2 | -6106 |
| PTPN3 | -5217 |
| TGFA | -5162 |
| UBB | -4944 |
| UBC | -4177 |
| CBL | -2683 |
| HGS | -1976 |
| GRB2 | 75 |
| EGF | 514 |
| PTPN12 | 1657 |
| SH3KBP1 | 3420 |
| EPGN | 3595 |
| STAM | 3859 |
| CDC42 | 9019 |
| STAM2 | 10760 |
| EPS15 | 11556 |
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
| 332 | |
|---|---|
| set | ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression |
| setSize | 32 |
| pANOVA | 0.00194 |
| s.dist | -0.317 |
| p.adjustANOVA | 0.0273 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| EHMT2 | -9644.0 |
| MBD3 | -9418.0 |
| MTA1 | -9323.0 |
| CHD3 | -8886.0 |
| H2AZ1 | -8776.0 |
| H2BC12 | -8742.0 |
| H2BC17 | -8346.0 |
| GATAD2A | -8189.0 |
| H3C15 | -8038.5 |
| H2BC4 | -7928.0 |
| ERCC6 | -7792.0 |
| H2AJ | -7536.0 |
| H2BC9 | -6894.0 |
| H2BC11 | -5751.0 |
| H2BC21 | -5415.0 |
| CHD4 | -4423.0 |
| H2BC15 | -4416.0 |
| H2AC6 | -4383.0 |
| MTA2 | -4303.0 |
| MTA3 | -3076.0 |
| GeneID | Gene Rank |
|---|---|
| EHMT2 | -9644.0 |
| MBD3 | -9418.0 |
| MTA1 | -9323.0 |
| CHD3 | -8886.0 |
| H2AZ1 | -8776.0 |
| H2BC12 | -8742.0 |
| H2BC17 | -8346.0 |
| GATAD2A | -8189.0 |
| H3C15 | -8038.5 |
| H2BC4 | -7928.0 |
| ERCC6 | -7792.0 |
| H2AJ | -7536.0 |
| H2BC9 | -6894.0 |
| H2BC11 | -5751.0 |
| H2BC21 | -5415.0 |
| CHD4 | -4423.0 |
| H2BC15 | -4416.0 |
| H2AC6 | -4383.0 |
| MTA2 | -4303.0 |
| MTA3 | -3076.0 |
| H2BC5 | -3070.0 |
| H2AZ2 | -2475.0 |
| GATAD2B | 1694.0 |
| H2BU1 | 2721.0 |
| H2AC20 | 3907.0 |
| HDAC1 | 4414.0 |
| RBBP7 | 4858.0 |
| H3-3A | 5193.0 |
| RBBP4 | 6165.0 |
| HDAC2 | 6675.0 |
| TTF1 | 10139.0 |
| CBX3 | 10802.0 |
Cyclin A/B1/B2 associated events during G2/M transition
| 222 | |
|---|---|
| set | Cyclin A/B1/B2 associated events during G2/M transition |
| setSize | 24 |
| pANOVA | 0.00749 |
| s.dist | 0.315 |
| p.adjustANOVA | 0.064 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CCNA1 | 11725 |
| PPP2R2A | 11691 |
| XPO1 | 11455 |
| CCNH | 11324 |
| CDK7 | 10265 |
| CDK1 | 9135 |
| PPP2CB | 8622 |
| FOXM1 | 6055 |
| CCNB1 | 5971 |
| PPP2CA | 5682 |
| CCNB2 | 5588 |
| MNAT1 | 5358 |
| CCNA2 | 4976 |
| WEE1 | 4830 |
| PPP2R1B | 3643 |
| CDK2 | 2315 |
| PPME1 | 2078 |
| LCMT1 | 1586 |
| PKMYT1 | 927 |
| CDC25B | -11 |
| GeneID | Gene Rank |
|---|---|
| CCNA1 | 11725 |
| PPP2R2A | 11691 |
| XPO1 | 11455 |
| CCNH | 11324 |
| CDK7 | 10265 |
| CDK1 | 9135 |
| PPP2CB | 8622 |
| FOXM1 | 6055 |
| CCNB1 | 5971 |
| PPP2CA | 5682 |
| CCNB2 | 5588 |
| MNAT1 | 5358 |
| CCNA2 | 4976 |
| WEE1 | 4830 |
| PPP2R1B | 3643 |
| CDK2 | 2315 |
| PPME1 | 2078 |
| LCMT1 | 1586 |
| PKMYT1 | 927 |
| CDC25B | -11 |
| PLK1 | -2414 |
| CDC25A | -3555 |
| PPP2R1A | -7631 |
| PPP2R3B | -9759 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
| 718 | |
|---|---|
| set | Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters |
| setSize | 21 |
| pANOVA | 0.013 |
| s.dist | -0.313 |
| p.adjustANOVA | 0.0895 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AP1M1 | -9320 |
| HLA-A | -9057 |
| AP2M1 | -8930 |
| AP1B1 | -8263 |
| ARF1 | -8086 |
| AP2A2 | -7814 |
| CD28 | -7250 |
| PACS1 | -7044 |
| AP1M2 | -6981 |
| AP2A1 | -6826 |
| LCK | -4371 |
| AP2S1 | -3863 |
| AP2B1 | -3395 |
| CD4 | -1298 |
| AP1S1 | -931 |
| AP1S3 | 2474 |
| CD8B | 3054 |
| AP1G1 | 4301 |
| ATP6V1H | 5572 |
| B2M | 9465 |
| GeneID | Gene Rank |
|---|---|
| AP1M1 | -9320 |
| HLA-A | -9057 |
| AP2M1 | -8930 |
| AP1B1 | -8263 |
| ARF1 | -8086 |
| AP2A2 | -7814 |
| CD28 | -7250 |
| PACS1 | -7044 |
| AP1M2 | -6981 |
| AP2A1 | -6826 |
| LCK | -4371 |
| AP2S1 | -3863 |
| AP2B1 | -3395 |
| CD4 | -1298 |
| AP1S1 | -931 |
| AP1S3 | 2474 |
| CD8B | 3054 |
| AP1G1 | 4301 |
| ATP6V1H | 5572 |
| B2M | 9465 |
| AP1S2 | 10082 |
Formation of ATP by chemiosmotic coupling
| 387 | |
|---|---|
| set | Formation of ATP by chemiosmotic coupling |
| setSize | 18 |
| pANOVA | 0.0216 |
| s.dist | -0.313 |
| p.adjustANOVA | 0.131 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MT-ATP8 | -10332 |
| ATP5ME | -9874 |
| MT-ATP6 | -9606 |
| ATP5F1D | -9424 |
| ATP5MG | -8771 |
| ATP5MF | -8024 |
| ATP5MC2 | -7490 |
| ATP5MC3 | -4398 |
| ATP5F1A | -4172 |
| ATP5F1E | -3220 |
| ATP5F1B | -2212 |
| ATP5PB | 704 |
| ATP5MC1 | 1413 |
| ATP5PF | 2504 |
| ATP5PO | 3036 |
| ATP5PD | 5191 |
| ATP5F1C | 5198 |
| DMAC2L | 9430 |
| GeneID | Gene Rank |
|---|---|
| MT-ATP8 | -10332 |
| ATP5ME | -9874 |
| MT-ATP6 | -9606 |
| ATP5F1D | -9424 |
| ATP5MG | -8771 |
| ATP5MF | -8024 |
| ATP5MC2 | -7490 |
| ATP5MC3 | -4398 |
| ATP5F1A | -4172 |
| ATP5F1E | -3220 |
| ATP5F1B | -2212 |
| ATP5PB | 704 |
| ATP5MC1 | 1413 |
| ATP5PF | 2504 |
| ATP5PO | 3036 |
| ATP5PD | 5191 |
| ATP5F1C | 5198 |
| DMAC2L | 9430 |
Influenza Infection
| 529 | |
|---|---|
| set | Influenza Infection |
| setSize | 154 |
| pANOVA | 2.27e-11 |
| s.dist | -0.312 |
| p.adjustANOVA | 1.41e-09 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SLC25A6 | -10385 |
| RPL37 | -10308 |
| POLR2L | -10282 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| POM121C | -9374 |
| GTF2F1 | -9355 |
| FAU | -9334 |
| RPS18 | -9321 |
| GeneID | Gene Rank |
|---|---|
| SLC25A6 | -10385 |
| RPL37 | -10308 |
| POLR2L | -10282 |
| RPS2 | -10243 |
| RPLP2 | -10185 |
| RPS29 | -10049 |
| RPS17 | -9962 |
| RPL36 | -9899 |
| RPL3 | -9867 |
| RPL8 | -9738 |
| RPL38 | -9692 |
| RPS16 | -9633 |
| RPS21 | -9530 |
| RPLP1 | -9501 |
| RPS4Y1 | -9458 |
| RPS12 | -9407 |
| POM121C | -9374 |
| GTF2F1 | -9355 |
| FAU | -9334 |
| RPS18 | -9321 |
| RPS27 | -9308 |
| RPL36AL | -9271 |
| RPS10 | -9222 |
| POLR2I | -9194 |
| POLR2F | -9158 |
| RPS5 | -9130 |
| NUP210 | -9099 |
| POLR2E | -9034 |
| RPLP0 | -9032 |
| RPL27A | -9016 |
| RPL7A | -8955 |
| RPS28 | -8941 |
| POM121 | -8910 |
| RPL35 | -8896 |
| RPL29 | -8882 |
| RPL37A | -8844 |
| RPS19 | -8814 |
| RPL18A | -8789 |
| RPL10 | -8752 |
| RPL27 | -8691 |
| RPS11 | -8677 |
| RPS3 | -8434 |
| RPS27A | -8388 |
| RPL39 | -8259 |
| RPL31 | -8234 |
| RPL41 | -8197 |
| RPS14 | -8173 |
| TGFB1 | -8091 |
| RPL32 | -8070 |
| CPSF4 | -8008 |
| POLR2G | -8006 |
| HSPA1A | -7940 |
| RPS15A | -7835 |
| RPL30 | -7798 |
| RPL18 | -7720 |
| RPS23 | -7714 |
| RPS9 | -7668 |
| RPS15 | -7663 |
| RPL12 | -7427 |
| UBA52 | -7375 |
| RPS6 | -7364 |
| RPL17 | -7051 |
| RPL35A | -6977 |
| RPL15 | -6926 |
| RPL19 | -6701 |
| RPL7 | -6643 |
| RPL22 | -6602 |
| RPS7 | -6568 |
| RPL14 | -6402 |
| RPL21 | -6288 |
| POLR2A | -6255 |
| POLR2J | -5993 |
| RPL36A | -5966 |
| NUP188 | -5843 |
| RPL39L | -5829 |
| RPL4 | -5814 |
| RPL13 | -5675 |
| RPS25 | -5670 |
| RPL5 | -5445 |
| RPL26 | -5374 |
| RPL28 | -5271 |
| RPL13A | -5249 |
| RPL11 | -5206 |
| RPS13 | -5170 |
| PARP1 | -4864 |
| RPL10A | -4820 |
| PABPN1 | -4813 |
| POLR2H | -4752 |
| RPL23 | -4456 |
| RPL24 | -3939 |
| RPS26 | -3701 |
| SEC13 | -3159 |
| NUP62 | -3119 |
| RPS8 | -3073 |
| RPS20 | -3024 |
| POLR2C | -2998 |
| RPL9 | -2451 |
| RPL26L1 | -2412 |
| RPL34 | -2254 |
| IPO5 | -1917 |
| AAAS | -1609 |
| RPS24 | -89 |
| NDC1 | -77 |
| RPL23A | 138 |
| CLTA | 509 |
| CLTC | 1283 |
| RPL6 | 1290 |
| RPS4X | 1825 |
| NUP214 | 2090 |
| NUP98 | 2149 |
| NUP93 | 3043 |
| CALR | 3069 |
| NUP155 | 3103 |
| RPS3A | 3173 |
| NUP160 | 3296 |
| CANX | 3437 |
| NUP205 | 3520 |
| NUP153 | 3654 |
| NUP37 | 3973 |
| GRSF1 | 4059 |
| NUP88 | 4512 |
| POLR2D | 4912 |
| TPR | 4956 |
| RAN | 5082 |
| RPSA | 5249 |
| GTF2F2 | 5332 |
| NUP133 | 5417 |
| RANBP2 | 5691 |
| RAE1 | 6124 |
| KPNA2 | 6216 |
| NUP85 | 6578 |
| NUP58 | 6817 |
| NUP50 | 7082 |
| KPNB1 | 7251 |
| POLR2B | 7601 |
| DNAJC3 | 7755 |
| NUP107 | 7988 |
| KPNA1 | 8096 |
| RPL22L1 | 8317 |
| HSP90AA1 | 8431 |
| NUP35 | 8941 |
| RPL3L | 8978 |
| KPNA3 | 9027 |
| RPS27L | 9625 |
| ISG15 | 9822 |
| SEH1L | 9849 |
| KPNA4 | 9875 |
| POLR2K | 9927 |
| KPNA5 | 9958 |
| NUP43 | 10569 |
| NUP42 | 10900 |
| XPO1 | 11455 |
| NUP54 | 11540 |
| EIF2AK2 | 11688 |
Here is the session info with all the versions of packages used.
sessionInfo()
## R version 4.0.3 (2020-10-10)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 20.04.2 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.9.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.9.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] parallel stats4 stats graphics grDevices utils datasets
## [8] methods base
##
## other attached packages:
## [1] pkgload_1.2.0 GGally_2.1.1
## [3] beeswarm_0.3.1 gtools_3.8.2
## [5] echarts4r_0.4.0 topconfects_1.6.0
## [7] limma_3.46.0 eulerr_6.1.0
## [9] mitch_1.2.2 MASS_7.3-53.1
## [11] fgsea_1.16.0 gplots_3.1.1
## [13] DESeq2_1.30.0 SummarizedExperiment_1.20.0
## [15] Biobase_2.50.0 MatrixGenerics_1.2.0
## [17] matrixStats_0.58.0 GenomicRanges_1.42.0
## [19] GenomeInfoDb_1.26.0 IRanges_2.24.0
## [21] S4Vectors_0.28.0 BiocGenerics_0.36.0
## [23] reshape2_1.4.4 forcats_0.5.1
## [25] stringr_1.4.0 dplyr_1.0.5
## [27] purrr_0.3.4 readr_1.4.0
## [29] tidyr_1.1.3 tibble_3.1.0
## [31] ggplot2_3.3.3 tidyverse_1.3.0
## [33] zoo_1.8-9
##
## loaded via a namespace (and not attached):
## [1] colorspace_2.0-0 ellipsis_0.3.1 rprojroot_2.0.2
## [4] XVector_0.30.0 fs_1.5.0 rstudioapi_0.13
## [7] farver_2.1.0 bit64_4.0.5 AnnotationDbi_1.52.0
## [10] fansi_0.4.2 lubridate_1.7.10 xml2_1.3.2
## [13] splines_4.0.3 cachem_1.0.4 geneplotter_1.68.0
## [16] knitr_1.31 polyclip_1.10-0 jsonlite_1.7.2
## [19] broom_0.7.5 annotate_1.68.0 dbplyr_2.1.0
## [22] shiny_1.6.0 compiler_4.0.3 httr_1.4.2
## [25] backports_1.2.1 assertthat_0.2.1 Matrix_1.3-2
## [28] fastmap_1.1.0 cli_2.3.1 later_1.1.0.1
## [31] htmltools_0.5.1.1 tools_4.0.3 gtable_0.3.0
## [34] glue_1.4.2 GenomeInfoDbData_1.2.4 fastmatch_1.1-0
## [37] Rcpp_1.0.6 cellranger_1.1.0 jquerylib_0.1.3
## [40] vctrs_0.3.6 polylabelr_0.2.0 xfun_0.22
## [43] ps_1.6.0 testthat_3.0.2 rvest_1.0.0
## [46] mime_0.10 lifecycle_1.0.0 XML_3.99-0.6
## [49] zlibbioc_1.36.0 scales_1.1.1 promises_1.2.0.1
## [52] hms_1.0.0 RColorBrewer_1.1-2 yaml_2.2.1
## [55] memoise_2.0.0 gridExtra_2.3 sass_0.3.1
## [58] reshape_0.8.8 stringi_1.5.3 RSQLite_2.2.4
## [61] highr_0.8 genefilter_1.72.0 desc_1.3.0
## [64] caTools_1.18.1 BiocParallel_1.24.1 rlang_0.4.10
## [67] pkgconfig_2.0.3 bitops_1.0-6 evaluate_0.14
## [70] lattice_0.20-41 labeling_0.4.2 htmlwidgets_1.5.3
## [73] bit_4.0.4 tidyselect_1.1.0 plyr_1.8.6
## [76] magrittr_2.0.1 R6_2.5.0 generics_0.1.0
## [79] DelayedArray_0.16.0 DBI_1.1.1 pillar_1.5.1
## [82] haven_2.3.1 withr_2.4.1 survival_3.2-10
## [85] RCurl_1.98-1.3 modelr_0.1.8 crayon_1.4.1
## [88] KernSmooth_2.23-18 utf8_1.2.1 rmarkdown_2.7
## [91] locfit_1.5-9.4 grid_4.0.3 readxl_1.3.1
## [94] data.table_1.14.0 blob_1.2.1 reprex_1.0.0
## [97] digest_0.6.27 xtable_1.8-4 httpuv_1.5.5
## [100] munsell_0.5.0 bslib_0.2.4
END of report